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ABSTRACT 
Mitochondria contain their own genome (mtDNA), which encodes 13 polypeptides 
essential for oxidative phosphorylation. Dysfunctional mitochondria have been 
associated with disease and the ageing process. Expression of mtDNA requires import 
of many nuclear-encoded polypeptides that are synthesised in the cytosol and imported 
into the mitochondrion. As many as 300 nuclear-encoded mitochondrial proteins are 
estimated to be unidentified or their functions remain unknown. The importance of 
understanding the nuances of human mitochondrial gene expression machinery has been 
highlighted by the predisposition of paediatric mitochondrial patients with nuclear gene 
mutations that manifest as mitochondrial translation defects.  
The aim of this research was to further the understanding of mitochondrial gene 
expression by characterising the protein AURKAIP1, which was identified during a 
screen of 224 candidate proteins as being likely to have a role in mitochondrial gene 
expression.  
By mitochondrial sub-fractionation techniques I was able to show that AURKAIP1 is a 
mitochondrial matrix protein. I have shown that AURKAIP1 is involved in 
mitochondrial gene expression since depletion of AURKAIP1 severely depletes the 
levels of mitochondrial-encoded proteins ND1, COXI and COXII. In addition, the 
overexpression of AURKAIP1 in mammalian cell lines causes a dramatic decrease in 
the de novo synthesis of mitochondrial polypeptides, which was studied by labelling 
nascent peptides with [35S] labelled methionine. The overexpression of AURKAIP1 also 
reduces the steady state levels of many mitoribosomal proteins, suggesting the reduced 
level of mitochondrial gene expression is due to a reduction in the number of functional 
mitoribosomes. I have also demonstrated a novel interaction between AURKAIP1 and 
the mitochondrial protein, p32, which is essential for mitochondrial translation. A 
paediatric patient with severe mitochondrial disease was found to have mutations in 
p32, which highlights the importance of mitochondrial gene expression and the need for 
further study into the factors involved. 
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CHAPTER 1: INTRODUCTION 
1.1 MITOCHONDRIA: BRIEF INTRODUCTION 
Mitochondria are dynamic organelles that are essential to almost all eukaryotic cells, the 
exceptions being some non-nucleated cells such as mature erythrocytes. A major role of 
mitochondria is ATP production via oxidative phosphorylation (OXPHOS). 
Approximately 90% of the energy requirement of the cell is met by hydrolysing the 
ATP produced by OXPHOS in mitochondria. However, mitochondria also have 
important roles in iron sulphur cluster formation (Lill, 2009), the citric acid cycle 
(Rustin et al., 1997), regulation of apoptosis (Chipuk et al., 2006) and calcium 
homeostasis, in conjunction with the endoplasmic reticulum (ER) (de Brito and 
Scorrano, 2010). As a result of these various functions, dysfunctional mitochondria can 
cause a wide variety of diseases ranging from neurodegenerative disorders (Knott and 
Bossy-Wetzel, 2008), to cancer (Dang, 2012) and other multifactorial diseases such as 
diabetes (Højlund et al., 2008) among others. Mitochondria are also implicated to play a 
role in the ageing process (Lesnefsky and Hoppel, 2006). However, the term 
‘mitochondrial disorder’ is often used to refer to defects in the OXPHOS system, which 
frequently affects multiple tissues and can be lethal early in life (Goldstein et al., 2013). 
The incidence of mitochondrial disease may be as high as 1 in 5000 (Schaefer et al., 
2004), but the clinical manifestations and underlying pathology vary drastically. 
Mitochondria contain their own genome, which only encodes a small number of 
components of the OXPHOS system (discussed later). All other mitochondrial proteins, 
approximately 1500 in number (Lopez et al., 2000; Taylor et al., 2003a; Taylor et al., 
2003b), are nuclear-encoded. Therefore, mutations in the mitochondrial genome, in any 
nuclear gene that encodes a protein required for the expression of mitochondrially 
encoded proteins or a protein involved in any key mitochondrial function can lead to 
mitochondrial disease (reviewed in Boesch et al., 2008).  
This introductory chapter will focus mainly on current knowledge of the various aspects 
of mitochondrial gene expression. The structure and functions of mitochondria will also 
be discussed, but I will start by addressing the origins of the organelle. 
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1.2 MITOCHONDRIAL EVOLUTION 
The serial endosymbiosis theory of mitochondrial evolution was proposed by Margulis 
(Margulis, 1971) and is now widely accepted (Gray et al., 1999; Kurland and 
Andersson, 2000). Simply put, this states that an ancestral α-proteobacteria was 
endocytosed by the common cellular ancestor of eukaryotes and formed a symbiotic 
relationship. This endosymbiosis event is predicted to have occurred approximately 1.5 
billion years ago (Brocks et al., 1999) and since that time, the α-proteobacteria has 
evolved into the modern mitochondrion. Evidence for this comes from phylogenetic 
linkage analysis, which suggests a common ancestor for α-proteobacteria and 
mitochondria, and that mitochondria arose only once in evolution (Gray et al., 1999). 
Furthermore, the genome of the modern proteobacteria, Rickettsia prowazekii, has been 
shown to be highly similar to the mitochondrial genome (Andersson et al., 1998).  
Although phylogenetic evidence strongly suggests an endosymbiotic origin of 
mitochondria, a single event may be an over-simplification. Indeed, several major 
components of the mitochondrial transcription and replication machinery, including the 
DNA and RNA polymerases, are derived from the T-odd lineage of bacteriophage 
(Shutt and Gray, 2006). The T-odd lineage include T3 and T7 bacteriophages and their 
close relatives and are known to infect γ-proteobacteria, it has therefore been proposed 
that some mitochondrial genes were acquired from an ancestral T-odd phage. Whether 
these genes were acquired by the ancestral α-proteobacteria prior to the endosymbiosis 
event or in the early evolution of the eukaryotic cell is still a matter of debate (Shutt and 
Gray, 2006). In the same manner, the timing of the mitochondrial endosymbiosis event 
in relation to the evolution of the nucleus is also uncertain. Initially it was proposed that 
the α-proteobacteria was endocytosed by a nucleus-containing amitochondriate 
eukaryotic cell, whereas more recently it was proposed that mitochondria and the 
nucleus evolved simultaneously after fusion of an archaebacterium and an α-
proteobacterium (reviewed in Gray et al., 1999; Lang et al., 1999), effectively being the 
origin of eukarya.  
Since all nucleated eukaryotic cells (with limited exceptions) contain mitochondria, and 
the acquisition of mitochondria appears to have been a singular occurrence in evolution, 
it is reasonable to assume that the endosymbiotic relationship provided an advantage 
against a strong selection pressure. Initially it was thought that the aerobic respiration of 
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the α-proteobacteria provided the host with ATP and that the symbiont received organic 
substrates in return. However, only two parasitic bacteria are known to have an ATP 
transporter, and in both cases these act as ATP importers (Kurland and Andersson, 
2000). On this basis it is difficult to see the immediate benefit of the symbiont to the 
host if ATP was not made available. One possibility is that the aerobic α-proteobacteria 
detoxified the cytosol of the host by consuming oxygen (OX-Tox model). The OX-Tox 
theory is supported by the fact that atmospheric oxygen levels rose dramatically over 
200 million years approximately 2 billion years ago (Holland et al., 1994), which would 
have increased the oxidative stress on anaerobic bacteria. The endosymbiosis event is 
also predicted to have occurred between 1.5 and 2 billion years ago, which lends 
credence to the OX-Tox model (Kurland and Andersson, 2000; Gray et al., 1999). 
The initial observations in favour of the endosymbiosis hypothesis included the double 
membrane structure of mitochondria, which could have been formed by endocytosis, 
and the presence of mitochondrial DNA (mtDNA), which resembled bacterial DNA 
(Margulis, 1971). Since that time mtDNA has been shown to vary widely in size, genes 
encoded and form (circular or linear) between species and even more so between more 
distant taxons. The size of the mitochondrial genome ranges from <6kpb in Plasmodium 
falciparum (Gray et al., 1999) to approximately 16kbp in mammals (Bibb et al., 1981; 
Anderson et al., 1981), approximately 100kbp in fungi (Trametes cingulata) (Haridas 
and Gantt, 2010) and over 500kbp in the case of several plants (Kitazaki and Kubo, 
2010), reaching 2400kbp in muskmelon (Ward et al., 1981). Further, the number of 
mitochondrially encoded proteins range from 3 (P. falciparum) to 67 (Reclinomonas 
americana) in known species, and the mtDNA encoding of tRNAs and 5S rRNA is also 
not universal (Gray et al., 1999).  
Generally, mitochondrial genomes are smaller than the genome of the closest modern 
relative, the α-proteobacteria R. prowazekii (1,111,523bp), which in turn is predicted to 
be smaller than the ancestral α-proteobacteria (Gray et al., 1999). Most metazoan 
mitochondrial genomes are very compact, with few non-coding regions. This is in 
contrast to many plant mitochondria, including angiosperms, which have larger 
mitochondrial genomes with many non-coding, repeated regions (Kitazaki and Kubo, 
2010). However, even in the case of angiosperms, there are far fewer protein coding 
genes in the mitochondrial genome compared to free living bacteria (Gray et al., 1999; 
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Kitazaki and Kubo, 2010). This is thought to be a consequence of loss of redundant 
genes or relocation of genes to the nuclear genome of the host from the original α-
proteobacteria. This reduction in genome size has occurred to varying degrees in 
different species (reviewed in Adams and Palmer, 2003).  
Due to this variety in the mitochondrial genome and the fact that all of my research has 
focused on human mitochondria, for clarity, this report will only refer to features of 
human mitochondria from this point onwards, unless otherwise specified. 
1.3 MITOCHONDRIAL STRUCTURE 
Mitochondria have two membranes and have at least four distinct compartments; the 
outer mitochondrial membrane (OMM), inner mitochondrial membrane (IMM), inter-
membrane space (IMS) and the matrix (Figure 1.1).  
 
Figure 1.1: Mitochondrial Structure. (A) Diagram depicting the intra-organellar compartments of the 
mitochondrion: the outer mitochondrial membrane (OMM, green), the inter-membrane space (IMS, 
purple), the inner mitochondrial membrane (IMM, black line) and mitochondrial matrix (beige). The 
IMM folds, forming structures called cristae. The cristae (or intracristal space) can be considered as a 
fifth compartment as the protein composition can differ between the IMS and intracristal space. (B) 
Image of a single mitochondrion captured using electron microscopy. Scale bar = 500nm (image courtesy 
of Rawaa AliZahid). (C) An image illustrating the mitochondrial network of a U2OS cell. Mitochondria 
were stained with 5nm TMRM and visualised by fluorescent microscopy Scale bar = 10µm (own image). 
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The OMM is permeable to small molecules and ions of up to approximately 5000Da 
(Benz, 1994; Mannella, 1992), allowing them to pass into the IMS. This permeability is 
mediated primarily by the presence of porins (also known as voltage dependent anion 
channels, VDAC), which are transmembrane, 19 stranded β-barrel structured pores that 
mediate trafficking of ions and interact with members of the Bcl-2 family to prevent the 
release of apoptogenic proteins into the cytosol (Hiller et al., 2008). 
The IMM is more selective and is not as permeable as the OMM, a feature that is 
essential for maintaining the mitochondrial membrane potential (Ψm). The maintenance 
of Ψm is vital to allow the proton gradient to drive ATP synthesis by the OXPHOS 
system, which consists of five multi-protein complexes situated in the IMM. The 
difference in permeability between the IMM and the OMM is due to the different 
protein content, but also to the phospholipid content of each membrane. The IMM has a 
much higher proportion of cardiolipin. Indeed, it is debated whether the OMM has any 
cardiolipin at all (de Kroon et al., 1997; Gerbert et al., 2009) and recent data suggests 
translocation of cardiolipin to the OMM acts as a signal of mitochondrial damage and 
targets defective mitochondria for elimination by mitophagy (Chu et al., 2013). 
Cardiolipin is a predominantly IMM specific phospholipid and is implicated in a wide 
range of functions (reviewed in Osman et al., 2010).  
The permeability of each mitochondrial membrane is not an entirely fixed value. For 
example, the pore size of porin (VDAC1) is variable depending on the voltage across 
the OMM and can exist in open or closed forms (Mannella, 1992; Benz, 1994). 
Additionally, porin overexpression can increase the permeability of the IMM 
(Tomasello et al., 2009). This results in reduced Ψm, swelling of the matrix via osmosis 
and rupture of the OMM, permitting the release of cytochrome c into the cytosol, which 
is a major mechanism for inducing apoptosis.   
The IMM forms folds called cristae to allow a larger surface area for reactions to take 
place. It is only more recently that the cristae (or intracristal space) have been seen as a 
separate compartment from the IMS. The relative protein composition can differ 
between the cristae and the IMS due to the presence of cristae junctions (CJs) (Jourdain 
and Martinou, 2009). CJs effectively form a collar-like structure at the base of the 
cristae, which limits the passage of proteins between the cristae and the IMS. OPA1 
(optic atrophy 1), mitofilin and the recently characterised ChChd3 (coiled-coil-helix-
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coiled-coil-helix domain containing 3) have been shown to be present at CJs and 
regulate their opening (Darshi et al., 2011). Cytochrome c content differs between the 
IMS and the cristae. There is a minor pool of cytochrome c in the IMS, but the major 
pool is located in the cristae. Increased permeability of the OMM will allow cytochrome 
c release, but as long as the CJs remain closed then only the minor pool can enter the 
cytosol. In this case, the concentration of cytochrome c in the cytosol is too low to 
activate the apoptotic cascade (Jourdain and Martinou, 2009). This is one line of 
evidence for viewing the IMS and cristae as separate compartments. 
The mitochondrial matrix is enclosed by the IMM and is the site for most of the 
reactions that take place in mitochondria including, but not limited to, the citric acid 
cycle, β-oxidation of fatty acids and iron-sulphur cluster formation. The matrix also 
houses the mtDNA and all of the replication, transcription and translation machinery. 
Due to the lack of permeability of the IMM, all required proteins and small molecules 
are imported through an array of membrane proteins. The import of mitochondrial 
proteins is primarily carried out by the TOM and TIM complexes (translocase of the 
outer membrane and translocase of the inner membrane respectively), but there are 
several other mechanisms of import, which I will discuss later. 
In addition to transport proteins and OXPHOS subunits the mitochondrial membranes 
also contain the fission and fusion machinery, which will now be discussed further.  
1.4 MITOCHONDRIAL DYNAMICS 
Mitochondria are not individual static organelles as depicted in many textbooks; they 
form dynamic networks that undergo fission and fusion. The classical cross sectional 
images (as in Figure 1.1A and B) show mitochondria as individual oval shaped 
organelles simply because they were first identified by electron microscopy on cross 
sections of cells. Although electron microscopy images are useful for visualising the 
intra-organellar sub-compartments of mitochondria, they are not representative of 
mitochondria throughout the cell. Fission and fusion events form fluid, tubular networks 
of mitochondria throughout healthy cells (Huang et al., 2011) as shown in Figures 1.1C 
and 1.2. Evidence indicates that mitochondria are also dynamic in that they can move 
around the cell in response to energy requirements (Nekrasova et al., 2011). The 
cytoskeleton is important for this mitochondrial motility. Vimentin intermediate fibres 
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and microtubules have both been shown to associate with mitochondria (Liu et al., 
2009; Tang et al., 2008) and depletion of vimentin results in mitochondrial 
fragmentation (Tang et al., 2008).  
 
 
Figure 1.2: Mitochondrial Dynamics. Diagram depicting the dynamic nature of mitochondria in 
neurons. Drp1 and Fis1 are involved in mitochondrial fission. OPA1 and mitofusins (Mfn) are important 
for mitochondrial fusion. OPA1 is also involved in cristae formation. Activation of calcineurin by Ca2+ 
promotes dephosphorylation of Drp1 causing translocation to the mitochondria, where it promotes fission 
and cristae disruption, which can lead to cytochrome c release and activate apoptosis. (Image adopted 
from Oliveira and Lightowlers, 2010). 
 
Two proteins playing crucial roles in mitochondrial fusion are mitofusin 1 and 
mitofusin 2 (Mfn1 and Mfn2). These are characterised as large GTPases that are present 
in the OMM and act in concert with OPA1. The latter has at least eight splice variants 
resulting in various protein isoforms that can be either long (l-OPA1) or short (s-OPA1) 
(Delettre et al., 2001). OPA1 is found in the IMS but due to the additional hydrophobic 
domain, l-OPA1 isoforms can also integrate into the IMM (Ishihara et al., 2006). It has 
been shown that l-OPA1 and s-OPA1 functionally complement each other and have 
minimal fusion activity alone (Song et al., 2007). Due to the location in the IMM and 
IMS, OPA1 co-ordinates IMM fusion, whereas the mitofusins are responsible for the 
fusion of the OMM. Recently it has been shown that mitochondria undergo both 
transient and complete fusion (Liu et al., 2009). Transient fusion only allows exchange 
of soluble proteins between two mitochondria in close proximity, whereas complete 
fusion allows the combining of membrane proteins and mixing of mtDNA populations 
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(Liu et al., 2009). This allows exchange of proteins and mtDNA between mitochondria 
when coupled with subsequent fission events. The cytoskeleton partly determines which 
form of fusion occurs, as two motile mitochondria on separate microtubules can 
undergo transient fusion, but only those on the same microtubule can undergo complete 
fusion (Liu et al., 2009). The same machinery governs both transient and complete 
fusion, but transient fusion can take place when OPA1 levels are either too high or too 
low to permit complete fusion (Liu et al., 2009). 
Dynamin related protein 1 (Drp1) is also a large GTPase located in the OMM, which 
contrastingly plays an important role in mitochondrial fission. Mitochondrial fission 
factor (Mff) also regulates fission, and was originally thought to work independently of 
the other known fission proteins (Gandre-Babbe and van der Bliek, 2008) in the IMM. 
However recent evidence suggests that Mff is essential for Drp1 recruitment (Otera et 
al., 2010) and is tail anchored in the OMM (Huang et al., 2011). MTP18 (mitochondrial 
protein 18kDa) also promotes mitochondrial fragmentation in the OMM, and is also 
required for fission homologue 1 (Fis1) mediated fission (Tondera et al., 2005). 
Mitochondrial dynamics are essential to healthy cell function. This is highlighted by 
their association with the intrinsic apoptosis system (reviewed in Landes and Martinou, 
2011) and the fact that mutations in genes that are known to be involved in fission or 
fusion can cause disease (reviewed in Knott and Bossy-Wetzel, 2008). For example 
OPA1 mutations lead to a form of dominant optic atrophy (Alexander et al., 2000) and 
Mfn2 mutations are the primary cause of Charcot-Marie-Tooth subtype 2A (CMT2A), 
which is a peripheral neuropathy (Züchner et al., 2004). These examples clearly show 
that dysfunctional mitochondrial dynamics can lead to disease.  
Mitochondrial dysfunction is also commonly seen in the early stages of many 
neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Huntington’s disease (HD), stroke and epilepsy (Knott and Bossy-Wetzel, 2008). 
Both amyloid beta (Aβ) (which accumulates in AD) and rotenone (which causes PD-
like symptoms in mice) have been shown to induce mitochondrial fragmentation, which 
indicates that the mitochondrial fragmentation could be a secondary effect rather than 
being causative of these diseases. However, the link between neurodegenerative 
disorders and dysfunctional mitochondrial dynamics remains interesting, particularly in 
the case of AD. A recent study showed that the expression of mitochondrial fusion 
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proteins (OPA1, Mfn1 and Mfn2) is reduced, whilst expression of fission proteins 
(Drp1 and Fis1) is increased in AD patients (Manczak et al., 2011). Furthermore, this 
study demonstrated co-localisation of Aβ with Drp1, thus suggesting a strong link 
between dysfunctional mitochondrial dynamics and AD (Manczak et al., 2011).   
1.5 MITOCHONDRIAL FUNCTIONS 
The origins and structure of mitochondria have been discussed. I will now outline a 
number of the functional roles of the organelle including, the regulation of apoptosis, 
the citric acid cycle and iron-sulphur cluster (Fe-S) cluster formation. A key role of 
mitochondria is the production of ATP via the OXPHOS system, as this provides 
approximately 90% of the usable energy to cells (Harris and Das, 1991). 
1.5.1 OXIDATIVE PHOSPHORYLATION 
The OXPHOS system consists of 5 multi-subunit complexes embedded in the IMM, 
namely NADH:ubiquinone oxidoreductase (Complex I), succinate:ubiquinone 
oxidoreductase (Complex II), ubiquinol:cytochrome c oxidoreductase (Complex III), 
cytochrome c oxidase (Complex IV) and FOF1 ATP synthase (Complex V).  
Put simply, Complexes I and II transfer electrons from reduced cofactors (NADH and 
FADH2 respectively) to ubiquinone (Q), causing its reduction to ubiquinol (QH2), which 
is delivered to Complex III. Complex III then oxidises QH2 to Q and reduces 
cytochrome c, effectively passing electrons from one to the other. Complex IV oxidises 
cytochrome c and reduces ½ O2 to H2O. Transfer of electrons by complex I, III and IV 
cause protons to by pumped into the IMS from the matrix, and together, Complexes I-
IV constitute the electron transport chain (ETC). The proton gradient generated by the 
ETC provides an electrochemical force and it is this proton motive force (driven by 
chemiosmosis) that is utilised by Complex V to produce ATP (Mitchell, 1961). 
The basic components of the OXPHOS system are illustrated in Figure 1.3; however, 
the organisation of the complexes and the movement of electrons and protons through 
the ETC is far more complicated than depicted by this figure. The organisation of the 
respiratory complexes within the IMM has long been debated, particularly whether the 
complexes are tightly associated with each other (forming supercomplexes), or whether 
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the respective complexes are independent units linked only by the fluid movement of 
coenzyme Q and cytochrome c (reviewed in Acin-Perez and Enriquez, 2014). 
Figure 1.3: The OXPHOS System. Illustration of the major components of the OXPHOS system in the 
IMM: Complex I (red), Complex II, (light blue), Complex III (green), Complex IV (purple) and Complex 
V (yellow). The co-factors coenzyme Q (labelled ‘Q’, dark blue) and cytochrome c (labelled ‘C’, orange) 
as well as the protons (labelled H+, dark red) are depicted as spheres. The flow of electrons is shown as 
blue arrows and the direction of the translocation of protons shown by white arrows. Chemical reactions 
are shown below the respective complexes in the mitochondrial matrix. Abbreviations: 
NAD=nicotinamide-adenine dinucleotide, FAD=flavin-adenine dinucleotide, ADP=adenosine 
diphosphate, ATP=adenosine triphosphate, Pi (inorganic phosphate).   
 
 
Mammalian Complex I is an approximately 980kDa multi-protein complex that was 
found to consist of 45 subunits, as analysed by tandem mass spectrometry (Carroll et al., 
2006; Hirst et al., 2003). Seven of these subunits are encoded by mtDNA (Chomyn et 
al., 1985; Chomyn, 2001). NADH is bound and oxidised to form NAD+ plus 2 free 
electrons by Complex I via non-covalently bound flavin mononucleotide (FMN) 
(Sazanov, 2006; Vogel et al., 2007; Hirst, 2005). These electrons are passed through a 
cascade of up to 9 Fe-S clusters before reducing Q to QH2 (Sazanov, 2006; Papa et al., 
2012; Vogel et al., 2007). Complex I uses the redox energy to pump protons from the 
matrix into the IMS at a stoichiometry of 4 protons per NADH oxidised (Galkin et al., 
2006). 
Complex II (also known as succinate dehydrogenase (SDH)) is the only respiratory 
complex that comprises solely nuclear-encoded components. The four subunits of 
Complex II are SDHA, SDHB, SDHC and SDHD. The catalytic core of Complex II is 
made up of SDHA and SDHB, which are hydrophilic and extend into the mitochondrial 
matrix (Rutter et al., 2010). The complex is anchored into the inner membrane by 
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SDHC and SDHD. SDHA oxidises succinate to fumarate and transfers the electrons to 
the covalently bound flavin adenine dinucleotide (FAD), thus reducing FAD to form 
FADH2. Complex II then re-oxidises FADH2 and passes electrons through 3 Fe-S 
clusters in SDHB, before the SHDC/SDHD subunits transfer electrons to Q, thus 
reducing Q to QH2 (Rutter et al., 2010). Unlike Complex I, Complex II mediated 
reduction of Q is not coupled to proton transfer across the IMM (Rutter et al., 2010).  
Complex III is approximately 480kDa in size and consists of 11 different subunits, only 
one of which, cytochrome b, is mtDNA-encoded (Saraste, 1999). Complex III dimerises 
and has a catalytic core comprising cytochrome b, cytochrome c and the Rieske Fe-S 
cluster protein (Mulkidjanian, 2010). The net transfer of electrons through Complex III 
is from QH2 (forming Q) to the electron carrier, cytochrome c, thus reducing it via a 
process called the Q cycle (Mitchell, 1975; Cramer et al., 2011). The transport of each 
electron through Complex III is coupled to the translocation of 2 protons across the 
IMM (Mulkidjanian, 2010). 
The terminal oxidase of the ETC is Complex IV, which oxidises the reduced 
cytochrome c from the Q cycle in Complex III (Capaldi, 1990). The electrons are 
passed through heme a and copper centres before reducing oxygen to water in a process 
that pumps 4 protons from the matrix to the IMS for each O2 reduced (Papa et al., 
2012). Mammalian Complex IV was thought to have 13 different protein subunits based 
on SDS-PAGE separation (Kadenbach et al., 1983) and crystal structure data (Tsukihara 
et al., 1996). However, recent data suggests that NDUFA4 is a structural subunit of 
Complex IV rather than Complex I, as previously thought (Balsa et al., 2012). 
Therefore, current knowledge indicates that there are 14 subunits of Complex IV and 44 
subunits of Complex I (Balsa et al., 2012). Complex IV forms a dimer where two 
monomers are connected by a cardiolipin molecule, and is considered the active form of 
the enzyme (Tsukihara et al., 1996; Fontanesi et al., 2006). Only 3 subunits of Complex 
IV are encoded by mtDNA, namely COXI, COXII and COXIII (Capaldi, 1990; Papa et 
al., 2012). 
Complex V, the ATP synthase, consists of two main subunits, FO and F1, each of which 
comprise multiple proteins (reviewed in Yoshida et al., 2001). The electrochemical 
gradient across the IMM, produced by the proton pumping action of Complex I, II and 
IV, drives protons through the FO subunit of Complex V causing it to rotate (Noji et al., 
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1997). The F1 subunit rotates in the opposite direction and this intricate rotary 
mechanism ultimately allows production of ATP from ADP and Pi (reviewed in 
Kinosita, 2012).  
1.5.2 CITRIC ACID CYCLE 
The citric acid cycle is another important mitochondrial function. The ETC is coupled 
to the citric acid cycle. The initial sources of electrons at the start of the ETC are in the 
form of reduced cofactors (NADH and FADH2, Figure 1.3). These co-factors are partly 
provided by the actions of the citric acid cycle.  
Pyruvate, derived from sugars in the cytosol via glycolysis, is imported into the 
mitochondrial matrix. Here, it is subjected to oxidative decarboxylation by the pyruvate 
dehydrogenase complex to form acetyl-CoA (acetyl coenzyme A). This provides the 
starting point for the citric acid cycle, which produces three NADH molecules and one 
FADH2 molecule per each complete oxidation of acetyl-CoA (reviewed in Ochoa, 
2006).  
1.5.3 IRON-SULPHUR CLUSTER FORMATION 
The mitochondrion is also responsible for the production of Fe-S clusters. This is a vital 
function as these clusters are present in numerous metalloproteins that are used in many 
fundamental pathways. Examples include: subunits of Complex I, II and III of the ETC, 
aconitase that is essential to the citric acid cycle, DNA polymerases and ferredoxins 
(Reviewed in Rawat and Stemmler, 2011; Lill, 2009). One of the most biologically 
advantageous features of Fe-S clusters is their ability to accept or donate electrons 
(Sheftel et al., 2010). It has been suggested that Fe-S cluster formation is the principle 
function of the mitochondrion based on the evolutionary conservation of the process. 
Fe-S cluster synthesis is retained even in the most rudimentary mitochondria-like 
organelles, such as Giardia mitosomes and Trichomonas hydrogenosomes, whereas 
OXPHOS is not, suggesting that Fe-S cluster formation is the most vital function of 
mitochondria (reviewed in Embley and Martin, 2006; Lill and Mühlenhoff, 2005).  
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1.5.4 APOPTOSIS 
Apoptosis can be induced by a variety of factors including oxidative stress from ROS, 
decrease in Ψm, growth factor withdrawal or DNA damage (Landes and Martinou, 
2011). There are two major apoptotic pathways, of which mitochondria are involved in 
the intrinsic pathway that involves Bax and Bak, two pro-apoptotic members of the B-
cell lymphoma 2 (Bcl2) family (Jourdain and Martinou, 2009). When activated, the 
mitochondrial permeability transition pore (mtPTP) can open, causing a collapse of Ψm 
and swelling of the matrix (Kinnally et al., 2011). This ruptures of the OMM, releasing 
IMS proteins into the cytosol. The IMS protein cytochrome c activates the caspase 
cascade to degrade proteins, whilst the IMS proteins endonuclease G and apoptosis 
inducing factor (AIF) are thought to be translocated to the nucleus where they condense 
and degrade chromatin DNA (Li et al., 2001; Lindenboim et al., 2011). There are other 
mitochondrial apoptotic factors such as Smac/Diablo (second mitochondrial activator of 
caspases/direct IAP binding protein with low pI) and HtrA2/Omi (reviewed in Vaux, 
2011). OPA1 can also affect the apoptotic process through its regulation of CJ opening. 
As mentioned earlier, the major pool of cytochrome c is sequestered in the cristae, but 
the minor pool is present in the IMS. During apoptosis the OMM is broken down 
releasing the minor pool of cytochrome c, which is not always sufficient to activate the 
caspase cascade. Over expression of OPA1 is protective against apoptosis because it 
keeps the CJs tightly closed, thus preventing the release of the major pool of 
cytochrome c into the cytosol after OMM rupture (Frezza et al., 2006). In contrast, 
siRNA depletion of OPA1 causes leaky CJs, resulting in higher levels of cytochrome c 
release and increases the likelihood of activating the caspase cascade and inducing 
apoptosis (Olichon et al., 2003). 
From the topics discussed above, it is clear that mitochondria have a role in many vital 
processes within the cell and that a comprehensive review of all of these processes is 
beyond the scope of this introduction. My studies were concerned with mitochondrial 
gene expression, so that is what I will now discuss, starting on the topic of the 
mitochondrial genome itself. 
 
 
  14 
1.6 MITOCHONDRIAL DNA 
In humans, mtDNA (Figure 1.4) is a double-stranded circular genome of 16,569bp that 
is supercoiled and encodes only 13 polypeptides, 22 tRNAs and 2 ribosomal RNAs 
(rRNAs) (Anderson et al., 1981; Ojala et al., 1981; Falkenberg et al., 2007). The two 
strands of mtDNA are designated heavy (H-strand) and light (L-strand) because of the 
H-strands higher intrinsic buoyant density in alkaline caesium chloride gradients owing 
to its greater guanine nucleotide content. The H-strand is also the location of the 
majority of mitochondrial genes, with only MT-ND6 and 8 of the tRNA genes encoded 
on the L-strand (Anderson et al., 1981).  
As mentioned previously (section 1.2) the mitochondrial genome has greatly reduced in 
size and number of genes compared to the ancestral α-proteobacteria, though mtDNA 
of different species varies wildly (Gray et al., 1999). In humans, the only proteins 
encoded by mtDNA are 13 hydrophobic components of the OXPHOS system. All other 
genes that were present in the ancestral α-proteobacteria, allowing life as an 
independent organism, have either been lost or translocated to the nuclear genome. 
During the estimated 1500 million years of mitochondrial evolution (Sicheritz-Ponten 
1998), human mtDNA has become incredibly compact with very few non-coding 
regions, no introns and only a few base pairs separating many of the genes. Indeed, 
there are two cases of overlapping genes, namely MT-ND4/MT-ND4L and MT-
ATP6/MT-ATP8. The only non-coding region of significant size (approximately 
1100bp) contains the displacement loop (D-loop), which houses regulatory sequences 
for controlling both replication and transcription (described later) and has a triple-
stranded structure.  
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Figure 1.4: The Human Mitochondrial Genome. Genes are labelled and are colour coded to identify 
genes encoding subunits of Complex I (red), Complex III (green), Complex IV (purple) and Complex V 
(yellow). The rRNA genes are shown in blue and the tRNA genes are depicted as black hexagons with 
their respective single letter code. The origins of replication (OH and OL) and transcriptional promoters 
(HSP and LSP) are labelled with arrows depicting their position and direction.  
 
There are many copies of mtDNA in each cell. However the copy number varies 
dramatically between cell types. For example, HeLa cells have been described as having 
approximately 8000 copies of mtDNA per cell (Bogenhagen and Clayton, 1974) 
compared to cultured mouse cell lines that have approximately 1300 (Nass, 1969; 
Bogenhagen and Clayton, 1974), though the average mtDNA copy number varies 
between tissues (Veltri et al., 1990). In humans, mature oocytes contain over 150,000 
copies of mtDNA (Wai et al., 2010), but the copy number is very variable, with reports 
of over 1,500,000 copies in a single oocyte (Greggains et al., 2014). Fibroblasts on the 
other hand, average approximately 1600 copies of mtDNA per cell, which is over 2 
orders of magnitude fewer than the average for oocytes (Greggains et al., 2014). 
The mechanism of inheritance of mtDNA differs from nuclear DNA in that it is 
generally solely maternally inherited, though a very rare instance of paternal inheritance 
has been documented (Schwartz and Vissing, 2002). Cells can be homoplasmic, where 
all mtDNA molecules are identical. However, mutations in mtDNA can cause 
heteroplasmy, where two variant populations of mtDNA exist within one cell. A 
number of mutations are pathogenic and can lead to mitochondrial dysfunction, causing 
disease (Holt et al., 1989; Wallace, 1989; Saneto and Sedensky, 2013). The 
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heteroplasmic level of the pathogenic mutated mtDNA can vary i) between 
mitochondria, as mtDNA is exchanged during fusion and fission; or ii) between cells as, 
during mitosis, mitochondria are randomly segregated into the daughter cells. The 
higher severity of clinical presentation correlates with higher ratios of mutant to wild-
type mtDNA (Chinnery et al., 1997), thus the presence of a mutation alone is not 
enough to predict a clinically pathological condition as low levels of mutated mtDNA 
may not cause disease. The particular mutation has a bearing on the severity of disease 
for example large deletions or mutations in tRNA genes will affect mitochondrial gene 
expression more than a single point mutation in one of the protein encoding genes. The 
levels of mutant heteroplasmy must generally reach a high percentage to manifest 
clinically. This is termed the threshold effect. The threshold effect of most mtDNA 
mutations is approximately 70-90% (Rossignol et al., 2003), though can vary between 
tissues (Rossignol et al., 1999). However, a functionally dominant mutation in the 
tRNATrp gene has been described that manifested clinically at <25% mutant 
heteroplasmy (Sacconi et al., 2008). 
The mtDNA is housed in the mitochondrial matrix, but it is not naked, it is protected by 
DNA-binding proteins that package the mtDNA into structures called nucleoids. The 
composition of mitochondrial nucleoids is a hotly contested topic, with the distinction 
between a nucleoid-associated protein and a bona fide nucleoid component being 
difficult to demonstrate (Bogenhagen, 2012; Bogenhagen et al., 2014). It is clear 
however that the major, if not only, essential component of the nucleoid is TFAM 
(mitochondrial transcription factor A) (Kukat and Larsson, 2013), which can bind and 
bend mtDNA without sequence specificity (Fisher et al., 1992). Nucleoids are not static 
packages of DNA, they are dynamic and allow access to the DNA replication and 
transcription machinery (Spelbrink, 2010). Therefore, studies that have isolated 
mammalian mtDNA and identified associated proteins as components of nucleoids may 
only be seeing peripheral proteins that themselves are not integral to nucleoid formation 
(see Bogenhagen, 2012 for a review). 
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1.7 MITOCHONDRIAL GENE EXPRESSION 
Mitochondrial gene expression involves many processes that include, but are not limited 
to the replication and maintenance of mtDNA, the transcription and subsequent 
processing, maturation and degradation of mitochondrial mRNA, mitochondrial protein 
synthesis, assembly of the mtDNA-encoded proteins into their respective respiratory 
complexes and even protein import of all of the nuclear-encoded mitochondrial proteins 
involved in these processes. Each of these can exert control over mitochondrial gene 
expression and I will therefore briefly outline these processes below. 
1.7.1 MITOCHONDRIAL DNA REPLICATION 
The process of mtDNA replication is still a matter of debate. The original model of 
strand-displacement (Robberson and Clayton, 1972; Berk and Clayton, 1974; Clayton, 
1982) is still favoured, however it is possible that replication occurs in more than one 
distinct way. More recently proposed models of mtDNA replication are the strand-
coupled bidirectional model (Bowmaker et al., 2003) and the RITOLS (ribonucleotide 
incorporation throughout the lagging strand) model (also referred to as the bootlace 
model) (Holt and Reyes, 2012; Reyes et al., 2013).  
The major replication machinery is common to all models and includes the 
mitochondrial DNA polymerase γ (POLγ), the mitochondrial helicase TWINKLE and 
the mitochondrial single-strand binding protein (mtSSB). The mitochondrial RNA 
polymerase (POLRMT) is also required to synthesise the RNA primers to initiate DNA 
synthesis (Xu, 1996; Wanrooij et al., 2008). POLγ functions as a heterotrimer that 
consists of the POLγA catalytic subunit and two POLγB accessory subunits. TWINKLE 
is a 5’ to 3’ DNA helicase and is found as a stable hexamer or heptamer (Ziebarth et al., 
2010; Makowska-Grzyska et al., 2010). The role of mtSSB is to bind, protect and 
stabilise ssDNA during the course of mtDNA replication and enhances the helicase 
activity of TWINKLE (Korhonen et al., 2003). 
DNA replication using only mitochondrial components has been successfully 
reconstituted in vitro. This work showed that 2kb of ssDNA could be produced using 
only POLγ and TWINKLE proteins in addition to the basic substrates (Korhonen et al., 
2004). The synthesis of over 16kb was possible with the addition of mtSSB (Korhonen 
et al., 2004), which covers the length of the mitochondrial genome, showing that these 
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three proteins are the minimum required for full mtDNA replication. However, as 
mentioned, POLRMT would also be required in vivo to produce the required primers 
(Wanrooij and Falkenberg, 2010).   
The strand-displacement (or strand-asynchronous) model states that replication is 
initiated at OH and elongation proceeds uni-directionally. After 700bp, POLγ often stalls 
at the cis-acting TAS site forming a D-loop where the DNA becomes triplex 
(Falkenberg et al., 2007). The function of the triplex D-loop is still unknown (Wanrooij 
and Falkenberg, 2010; Nicholls and Minczuk, 2014). If the polymerase continues 
beyond the TAS site, it proceeds about two thirds of the way around the mtDNA 
molecule until it reaches the region termed OL where the lagging strand forms a stem 
loop structure that prevents mtSSB binding (Shadel and Clayton 1997). This stem loop 
structure allows initiation of L-strand replication in the opposite direction (Wanrooij 
and Falkenberg, 2010). Both strands are then fully synthesised before each of their 
respective 5’ and 3’ ends are ligated to form closed circles (Falkenberg et al., 2007). 
One of the alternative hypotheses is that the mitochondria replicate their DNA 
symmetrically in a more conventional system, where the leading and lagging strand are 
synthesised simultaneously from bi-directional origins of replication within the 
noncoding region (strand-coupled model) (Holt et al., 2000). There is evidence for both 
models and it is possible that both mechanisms occur under different physiological 
conditions (Holt et al., 2000). More recent data, however, further reinforces the strength 
of the strand-displacement model as mutations in OL were selected against in an 
mtDNA mutator mouse model compared to mutations in tRNA genes, COXI 
(cytochrome c oxidase gene I) and non-coding regions (Wanrooij et al., 2012). The 
mutator mouse is a knock-in mouse that expresses a catalytic subunit of POLγ that has 
deficient proof-reading ability, causing mtDNA mutations and deletions to occur with 
3-5 fold higher frequency than wild-type mice (Trifunovic et al., 2004). If the strand-
coupled model was the principle mechanism of mtDNA replication then OL would not 
be important and it would be expected that mutations in the OL would be tolerated in 
these mice. Therefore, the fact that OL mutations are not tolerated strongly suggests that 
OL is critically needed for mtDNA replication as would be hypothesised by the strand-
displacement model.  
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A third proposed model is the RITOLS or bootlace model, which proposes that mtSSB 
is a minimal influence in replication and that much if not all of the single-stranded 
lagging strand is bound instead by RNA (reviewed in Holt and Reyes, 2012). 
Although the exact mechanism of lagging strand mtDNA replication is still debated, it 
is clear that leading strand synthesis is initiated at OH. The RNA primer for the initiation 
of mtDNA replication at OH is produced via transcription initiated at the light strand 
promoter (LSP), which is also situated in the D-loop region (Falkenberg et al., 2007; 
Clayton, 1982). This involvement of the mitochondrial transcription machinery in 
mtDNA replication highlights that different aspects of mitochondrial gene expression, 
as displayed in this report, are not necessarily separate entities.  
1.7.2 MITOCHONDRIAL TRANSCRIPTION 
The single subunit RNA polymerase, POLRMT, is responsible for mitochondrial 
transcription. However, POLRMT cannot initiate transcription from mitochondrial 
promoters alone, transcription factors TFAM and either TFB1M or TFB2M 
(mitochondrial transcription factor B 1 and 2 respectively) are required for 
mitochondrial transcription in vitro (Falkenberg et al., 2002). This study also showed 
that TFB2M is an order of magnitude more active than TFB1M at activating 
transcription (Falkenberg et al., 2002). Therefore the contribution of TFB1M to 
transcription initiation in vivo becomes questionable. Indeed, in vivo experiments in 
mice (Metodiev et al., 2009) and drosophila (Matsushima et al., 2005) suggest TFB1M 
does not play a role in mitochondrial transcription, unlike TFB2M (Matsushima et al., 
2004). More recent in vitro experiments failed to observe any transcription activation 
activity of TFB1M (Litonin et al., 2010). Loss of TFB1M has been shown to affect 
mitochondrial translation (Matsushima et al., 2005; Metodiev et al., 2009). Both 
TFB1M and TFB2M have been identified as similar to RNA methyltransferases (Seidel-
Rogol et al., 2003) and subsequent indirect evidence suggest that they function as such, 
although TFB1M is believed to be far more active than TFB2M (Seidel-Rogol et al., 
2003; Cotney and Shadel, 2006). Furthermore, TFB1M was recently implicated in the 
methylation of two highly conserved adenines towards the 3’ end of the 12S rRNA 
(Metodiev et al., 2009). Methylation of these adenine residues was found to be 
important for the stability of mitochondrial ribosomes (mitoribosomes), and therefore 
translation (Metodiev et al., 2009). Current evidence therefore suggests that TFB1M is 
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not acting as a transcription factor in mitochondria and that POLRMT, TFAM and 
TFB2M comprise the essential machinery of mitochondrial transcription initiation 
(Figure 1.5).  
Transcription is initiated independently at the respective LSP and heavy strand promoter 
(HSP) (Figure 1.5). There are two HSP initiation sites, HSP1 and the somewhat 
controversial HSP2 situated less than 100 bases apart in the D-loop (Micol et al., 1997). 
Transcription initiated at HSP1 starts 5’ to the phenylalanine mt-tRNA gene and 
terminates at the 3’ end of the 16S rRNA gene and has been suggested to only 
transcribe 2 tRNAs and the 2 rRNAs. Transcription initiated at HSP2 on the other hand 
is postulated to produce a long polycistronic transcript that begins at the 5’ end of the 
12S rRNA gene and includes all of the rRNA, tRNA and mRNA encoded by the H-
strand. Similarly transcription from the LSP produces a polycistronic transcript 
corresponding to the genes on the L-strand. The LSP is also situated in the D-loop, but 
transcribes in the opposite direction to the HSP. In HeLa cells, the transcription of the 
rRNA genes was found to be 50 to 100 times more common than transcription of the 
mRNAs (Gelfand and Attardi, 1981), indicating the HSP1 promoter is more active than 
HSP2. Recently the activity of the HSP2 promoter has been questioned since, in vitro, 
no HSP2 specific transcripts were observed, nor could POLRMT transcribe from pre-
melted promoter templates of HSP2 despite being able to transcribe from HSP1 or LSP 
(Litonin et al., 2010). However, recent work has now demonstrated transcription form 
HSP2 in vitro using recombinant POLRMT and TFB2M, but found that it is strongly 
inhibited by addition of TFAM (Lodeiro et al., 2012). The discovery of a potential 
transcriptional activator and repressor role of TFAM when using different promoters, 
further complicates the current understanding of mitochondrial transcription and 
highlights the difficulty in elucidating the in vivo situation.   
  21 
 
Figure 1.5: The Mitochondrial Transcription Machinery. Transcription initiation requires the 
recruitment of TFAM TFB2M and POLRMT. MTERF 1-3 also bind the promoter region and modulate 
transcription. Initiation at HSP1 results in transcription of tRNAPhe, tRNAVal and the two rRNAs 12S and 
16S, before terminating at the tRNALeu gene bound to MTERF1. Initiation form HSP2 however continues 
to transcribe the full length of the H-strand. Similarly initiation at LSP transcribes the full-length mtDNA, 
but in the opposite direction. Additionally transcription from LSP can be terminated shortly after 
initiation and the short RNA is used as a primer for H-strand DNA replication from OH (origin of H-
strand replication). Image adopted from Peralta et al., 2012. 
  
The specific method of transcription initiation in mitochondria is uncertain, but 
evidence suggests that TFAM binds to the promoter region, upstream of the initiation 
site and bends the DNA to a greater degree than non promoter DNA (Malarkey et al., 
2012) and that this is required for initiation. This is the case for HSP1 and LSP, but 
TFAM is inhibitory to transcription from HSP2 (Lodeiro et al., 2012), thus 
complicating the mechanism of initiation. Recent structural and biochemical 
observations suggest that, of the components of transcription initiation, only TFAM and 
POLRMT can interact, albeit weakly, in the absence of DNA (Yakubovskaya et al., 
2014). The same study shows that the addition of promoter DNA allows formation of a 
dense initiation complex, in which TFAM, POLRMT and TFB2M come into close 
proximity and may interact via protein-protein interactions, although the DNA is the 
clear anchoring point (Yakubovskaya et al., 2014). After initiation, POLRMT proceeds 
to transcribe almost the entire mtDNA molecule, forming large polycistronic mRNAs 
from HSP2 and LSP Transcription must be terminated, but the mechanism is poorly 
understood and only the HSP1 initiated transcript has a proven termination site located 
at the first tRNALeu gene (between the 16s rRNA gene and MT-ND1) (Figure 1.5).  
Since the transcription of mitochondrial genes generates polycistronic units, the unit 
will require post-transcriptional processing before its constituents can be translated into 
protein. The tRNA punctuation model suggests that the polycistronic transcript is 
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processed following folding and cleavage of the tRNAs that are encoded between the 
mRNAs (Ojala et al., 1981). Since full-length polycistronic RNAs are not usually 
observed in vivo it is likely that this processing takes place during or shortly after 
transcription. Most mRNAs have at least one tRNA between them. The tRNA portions 
of the polycistronic RNA form a secondary structure that allows 5’ cleavage by the 
endoribonuclease mitochondrial RNase P (Ojala et al 1981, Holtzmann et al 2008) and 
3’ cleavage by ELAC2, which functions as the mitochondrial RNase Z (Brzezniak et al., 
2011; Rossmanith, 2011; Vogel et al., 2005). This model will account for most of the 
separating of the tRNAs and mRNAs, but cannot be the sole system as there is not a 
tRNA gene between every protein encoding gene, for example MT-ATP6 and MT-CO3 
(Anderson et al., 1981, reviewed in Temperley et al., 2010a).  
Generally, mitochondrial mRNA transcripts differ from nuclear transcripts in that they 
have no introns, have very short (<3 nucleotides) or absent 5’ untranslated regions 
(UTRs) and no 5’ 7-methylguanylate cap. Furthermore, the majority do not have 3’ 
UTRs. In fact, in the case of 7 open reading frames the ‘stop’ codon is incomplete and 
therefore 3’ polyadenylation is required to complete the termination codons. All 
mitochondrial mRNAs and tRNAs undergo maturation. Polyadenylation of mRNAs is 
performed by the mitochondrial poly(A) polymerase (mtPAP) (Gallerani et al., 1976; 
Tomecki et al., 2004), resulting in frayed polyadenylation of approximately 50 
nucleotides. The tRNAs are matured by a post-transcriptional addition of a CCA motif 
by the ATP(CTP):tRNA nucleotidyltransferase (Nagaike et al., 2001). 
1.7.3 MITOCHONDRIAL TRANSLATION 
Translation is the process of protein synthesis through conversion of the mRNA code 
into polypeptides. As is the case in eubacteria and the cytosol, protein synthesis begins 
with methionine encoded by AUG, however, human mitochondria can also recognise 
AUA and AUU as initiating methionines (Rustin et al., 1997; Anderson et al., 1981). 
This is an example of one of the differences between the ‘universal’ and the 
mitochondrial code used for protein synthesis; in the cytosol AUA and AUU would 
encode isoleucine. Additionally, several other codons differ from their ‘universal’ code. 
The conventional ‘stop’ codon UGA is re-coded to be recognised as tryptophan and the 
two ‘universal’ arginine codons AGG and AGA were assumed to act as ‘stop’ codons 
(Anderson et al., 1981). Recent data, however, has indicated that they are not ‘stop’ 
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codons, but simply unassigned codons that promote a -1nt frameshift that results in a 
standard UAG termination codon becoming positioned in the A site (Temperley, et al., 
2010b). 
In mitochondria, protein synthesis takes place on mitoribosomes. Mitoribosomes are 
more closely related to eubacterial ribosomes than eukaryotic cytosolic ribosomes 
(Desmond et al., 2011), but the evolution of mitoribosomes has been dynamic and the 
composition has changed drastically from its α-proteobacterial origin. Approximately 
50% of MRPs have eubacterial orthologs and are evolving at 10 times the rate of the 
cytosolic ribosome proteins (O'Brien, 2002). Most ribosomes have a composition of 
approximately 70% RNA and 30% protein by mass. This is completely reversed in 
mammalian mitoribosomes to approximately 30% RNA and 70% protein (Koc and 
Haque, 2010). Mitoribosomes have a greater mass than their eubacterial counterparts 
but are far less dense, due to numerous parts of the rRNAs not being replaced by 
protein. A number of mitoribosomal proteins (MRPs) have functionally replaced some 
rRNAs that have been lost relative to their prokaryotic origin.  
The increase in protein content, more porous and less dense nature of mitoribosomes 
causes a change in sedimentation with respect to other ribosomes. Thus, the mammalian 
mitoribosome is a 55S particle compared to the 80S or 70S particles of eukaryotic 
cytosolic or bacterial ribosomes respectively. The 55S mitoribosomes consist of a 28S 
small subunit (SSU) and a 39S large subunit (LSU). As with most ribosomes, there is an 
A-site (aminoacyl-tRNA site) and a P-site (peptidyl-tRNA site) (Schmeing and 
Ramakrishnan, 2009). Eubacterial and cytosolic eukaryotic ribosomes also have an E-
site (exit site), but mounting evidence suggests this is either weak or absent from 
mitoribosomes (Sharma et al., 2003) or at least considerably altered, probably to aid in 
the insertion of the nascent peptides into the IMM (Greber et al., 2014). Indeed, in 
mitochondria, translation is sensitive to IMM integrity and it has been demonstrated that 
that approximately 50% of mitoribosomes are tightly associated with the IMM (Liu and 
Spremulli, 2000). Recent data suggests that MRPL45 may act as an anchor to align the 
nascent polypeptide exit tunnel with the membrane insertion machinery (Greber et al., 
2014). Mature MRPL32 is also tightly associated with the IMM and the maturation of 
MRPL32 by the m-AAA protease is required for mitochondrial protein synthesis 
(Nolden et al., 2005).  
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There are only 22 mitochondrial tRNAs encoded by mtDNA (Anderson et al., 1981) 
and there is no import of nuclear-encoded tRNAs (Kolesnikova, 2004). Thus, there are 
fewer tRNA species in mitochondria than the 31 predicted by Crick to be necessary for 
translation. This is possible because mitochondria use slight variations to the rules of 
translation, due to the loss of discrimination with the wobble base (Barrell et al., 1980). 
Modifications to the base in the wobble position are required for certain tRNAs, for 
example tRNALys has a modified uridine (5-taurinomethyl-2-thiouridine) at the wobble 
position of its anticodon (Umeda et al., 2005). The 2-thio modification is carried out by 
MTU1 (mitochondrial tRNA-specific 2-thiouridylase 1) in yeast and is essential for 
mitochondrial protein synthesis (Umeda et al., 2005). In addition to tRNALys, 5-
taurinomethyluridine is also present in tRNALeu, tRNAGlu and tRNAGln and is important 
for mitochondrial protein synthesis (Schaffer et al., 2014). Indeed, mutations that 
interfere with the formation of 5-taurinomethyluridine can lead to mitochondrial disease 
(MELAS and MERRF) (Schaffer et al., 2014). Another difference between the tRNA 
content in mitochondria compared to the cytosol is that there is only one tRNAMet for 
both initiation and elongation in animal mitochondria, whereas there are two distinct 
tRNAMets in the cytosol (Mikelsaar, 1983). Formylation of the methionine tRNA 
(tRNAfMet) is still required for initiation of translation in mitochondria, as in numerous 
other systems (Bianchetti et al., 1971). Mitochondrial tRNAfMet binds initiation factor 2 
(IF2) to initiate translation (Spencer and Spremulli, 2004). The unformylated tRNAMet 
is used in translation elongation. Mitochondrial methionyl-tRNA formyltransferase 
(mtFMT) is responsible for the formylation of tRNAMet to tRNAfMet (Takeuchi et al., 
2001).  
Translation has four distinct stages: initiation, elongation, termination and ribosome 
recycling (Figure 1.6). Most mitochondrial translation factors have been named to 
correspond to their eubacterial homologues, but despite the eubacterial origins of 
mitochondria and their presence in the eukaryotic cytosol, there are differences between 
these translation systems, some of which are outlined below.  
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Figure 1.6. Mitochondrial Translation. Diagram of the stages of mitochondrial translation including 
initiation (green), elongation (purple) and termination (red). The factors involved in each stage are 
depicted (more detailed information in text) including the stages that require GTP (yellow) hydrolysis to 
GDP (beige). Image adopted from Smits et al., 2010. 
 
Initiation: In prokaryotes, initiation requires IF1, IF2 and IF3. Of these, IF1 and IF2 are 
considered universal and essential, as IF3 is not found in the eukaryotic cytosol 
(Marintchev and Wagner, 2004). Mitochondrial translation differs because only IF2 and 
IF3 homologues have been found, but mtIF2 was shown to functionally replace both 
bacterial IF1 and IF2 (Gaur et al., 2008). This appears to be due to the insertion of a 
conserved 37aa sequence in mtIF2 (Ma et al., 1995), which allows binding to the 
mitoribosome, therefore assuming the role of IF1 (Gaur et al., 2008). In mitochondria, 
the initiation of translation is partially mediated by mtIF3, which binds to the 28S SSU, 
preventing and/or disrupting formation of the 55S (Koc and Spremulli, 2002; Christian 
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and Spremulli, 2009). This allows the subsequent binding of mtIF2, tRNAfMet and the 
mRNA. Since the mitochondrial mRNAs essentially have no 5’UTR (up to 3 
nucleotides) it is assumed that translation begins at the start codon at the 5’ terminus. 
Supporting this is data where mRNAs with longer 5’ UTRs were not translated as 
efficiently and the formation of the initiation complex was favoured at a terminal AUG 
rather than an internal AUG (Christian and Spremulli, 2010). A stable initiation 
complex is only generated when GTP-bound mtIF2 binds tRNAfMet, the SSU and 
mRNA start codon. Without the start codon and/or tRNAfMet the mRNA continues to 
pass through the SSU and eventually dissociates (Christian and Spremulli, 2010). If 
tRNAfMet binds the 5’ AUG start codon, the LSU is recruited, forming the monosome. 
The GTP bound to mtIF2 is hydrolysed to GDP and the initiation factors are released. 
The 55S initiation complex can then proceed to the elongation phase. 
Elongation: All three prokaryotic elongation factors namely EFTu, EFTs and EFG have 
homologues in mitochondria (Xin et al., 1995; Lang et al., 1999; Hammarsund et al., 
2001). However, there are two mtEFGs (mtEFG1 and mtEFG2) (Hammarsund et al., 
2001). Only mtEFG1 is functional in elongation and is needed for translocation of the 
mRNA through the ribosome (Bhargava et al., 2004), while mtEFG2 seems to be 
primarily involved in ribosome recycling (Tsuboi et al., 2009). The elongation process 
begins with GTP-bound mtEFTu, which is active and can bind an aminoacylated tRNA 
and allow it to enter the A-site of the mitoribosome. If the anticodon of the tRNA 
correctly matches the codon on the mRNA, then GTP is hydrolysed and mtEFTu-GDP 
is released. A peptide bond is formed between the aminoacylated tRNA in the A site 
and the amino acid at the end of the nascent polypeptide chain in the P-site. This is 
catalysed by the peptidyl-transferase centre of the LSU and results in the deacylation of 
the tRNA in the P-site. The new peptidyl tRNA (with the peptide one amino acid 
longer) in the A-site is then translocated to the P-site, which is driven by GTP 
hydrolysis from mtEFG1-GTP to mtEFG1-GDP, and results in the displacement of the 
deacylated tRNA from the P-site. Finally mtEFTs acts as a guanine exchange factor that 
facilitates the activation of mtEFTu-GDP to mtEFTu-GTP to allow another cycle of 
elongation to occur. The process described above is based on current knowledge of 
mitochondrial translation elongation (as reviewed in Christian and Spremulli, 2012). 
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Termination and ribosome recycling: termination occurs when a ‘stop’ codon enters the 
A-site and elongation cannot proceed. Only two triplets are used as stop codons in 
human mitochondria, UAA and UAG, and there is only one release factor (mtRF1a) that 
recognises both of these stop codons (Soleimanpour-Lichaei et al., 2007). The 
recognition of the stop codon by mtRF1a catalyses the cleavage of the ester bond 
between the terminal amino acid of the nascent polypeptide and the tRNA in the P site 
in a process that requires GTP hydrolysis (Smits et al., 2010; Christian and Spremulli, 
2012). After release of the completed polypeptide, mitochondrial ribosome recycling 
factor (mtRRF) (Rorbach et al., 2008) and mtEFG2 (also known as mtRRF2) (Tsuboi et 
al., 2009) bind the A-site and cause the release of the mRNA and deacylated tRNA as 
well as dissociation of the SSU and LSU (Christian and Spremulli, 2012). This then 
allows another round of translation to initiate, with the binding of mtIF3 preventing 
reassembly of the monosome until the initiation complex is reformed (Christian and 
Spremulli, 2009).  
There are still aspects of mitochondrial translation that remain enigmatic. For example, 
very little is known about the regulation of translation in human mitochondria. In yeast 
there are translational activators for each mRNA that usually bind the 5’ UTR of the 
transcripts (Herrmann et al., 2013). However, human mitochondria do not have 5’ 
UTRs and only one translational activator, TACO1, has been described, which activates 
synthesis of COXI (Weraarpachai et al., 2009). It is possible that there could be a family 
of translation activators yet to be identified that may further elucidate the control of 
mitochondrial protein synthesis.  
1.8 MITOCHONDRIAL PROTEIN IMPORT 
Approximately 1500 proteins are estimated to be necessary to generate functional 
mitochondria. Nuclear-encoded proteins account for 99% of these mitochondrial 
proteins and are synthesised in the cytosol before being imported into the mitochondria 
by a variety of mechanisms (reviewed in Endo et al., 2011). Therefore, mitochondrial 
import is vitally important for all of the mitochondrial processes. There is complex 
machinery in the mitochondria dedicated to protein sorting and import. Important 
components of this machinery are the translocases of the outer membrane (TOM) and 
inner membrane (TIM). Almost all imported proteins are translocated through the outer 
membrane by the TOM complex, which is made up of various TOM proteins (including 
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Tom20, 70, 71, 5, 6, 7, 22, 40) (reviewed in Chacinska et al., 2009). The essential pore 
forming member of the TOM complex is Tom40 (Ahting et al., 2001).  
Most imported proteins have an N-terminal mitochondrial targeting sequence, 
particularly those that are sub-localised to the matrix or IMM. Such targeting sequences 
generally do not share sequence homology, but form positively charged amphipathic α-
helices (Roise and Schatz, 1988). After import through the TOM complex the TIM23 
complex sorts and allows import of the N-terminally targeted matrix proteins (Endo et 
al., 2011). This type of targeting sequence is usually cleaved off after import by the 
mitochondrial processing peptidase (MPP) in the matrix (Ou et al., 1989; Taylor et al., 
2001). In contrast, the N-terminal mitochondrial targeting sequence of MRPL32 is 
cleaved by the m-AAA protease after translocation across the membrane rather than 
being cleaved during import by the MPP (Bonn et al., 2011). This highlights one 
exception to the classical import pathway. 
There are other import pathways in mitochondria, and many IMM proteins, soluble IMS 
proteins and OMM proteins do not have N-terminal cleavable pre-sequences, but 
contain targeting sequences more centrally within the protein (see Chacinska et al., 
2009 for a review). The main pathways in addition to the TOM and TIM complexes are 
the SAM (Sorting and Assembly Machinery of the Outer Mitochondrial Membrane) 
complex that allows integration of β-barrel containing OMM proteins and the MIA 
(Mitochondrial Intermembrane Space Import and Assembly) pathway that allows 
import of IMS proteins that have cysteine-containing signals (Chacinska et al., 2009). 
1.9 MITOCHONDRIAL DISEASE 
As previously mentioned, mitochondrial disease can be caused by mutations in the 
mitochondrial genome (reviewed in Taylor and Turnbull, 2005, Pinto and Moraes, 
2014). Mutations in the protein encoding mitochondrial genes typically manifest as 
isolated complex deficiencies. However, mitochondrial diseases are a heterogeneous 
group of disorders and there are many instances of multiple respiratory complex 
deficiencies (Kemp et al., 2011). These combined complex deficiencies can be due to 
mtDNA mutations, for example tRNA mutations leading to generalised mitochondrial 
translation defects (Pinto and Moraes, 2014), or can be due to mutations in nuclear 
genes encoding any factors involved in mitochondrial gene expression (reviewed in 
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Smits et al., 2010). There are many examples of mutations in nuclear genes products 
leading to mitochondrial disease, including factors involved in mitochondrial translation 
such as the elongation factors, mtEFTs (Smeitink et al., 2006), mtEFTu and mtEFG1 
(Vallente et al., 2007) or mitoribosomal proteins, MRPS16 (Miller et al., 2004) and 
MRPS22 (Saada et al., 2007) among others. 
Due to the heterogeneity of mitochondrial disorders, the molecular aetiology remains 
unknown in many patients with mitochondrial disease. Recent developments in next 
generation sequencing, including exome sequencing have allowed identification of 
mutations in some of these patients (Calvo et al., 2012). In some cases exome 
sequencing of patients with mitochondrial disease has allowed identification of novel 
gene products important for mitochondrial function. For example several patients with 
isolated Complex III deficiency have been shown to have causative mutations in TTC19 
(Ghezzi et al., 2011, Morino et al., 2014). Identification of TTC19 mutations in patients 
with mitochondrial disease allowed for characterisation of the protein as a Complex III 
assembly factor (Ghezzi et al., 2011). In this way, patients with mitochondrial disease 
can provide further information as to the factors and mechanisms involved in 
mitochondrial gene expression. For instance, mutations in mtFMT were found in two 
patients with Leigh syndrome, which showed that formylation of tRNAMet was 
important for mitochondrial translation in humans (Tucker et al., 2011), despite mtFMT 
not being essential for translation in yeast mitochondria (Hughes et al., 2000).  
There remain many patients without a genetic diagnosis of mitochondrial disease and by 
elucidating novel factors involved in mitochondrial gene expression we may be able to 
further elucidate the processes at work, perhaps leading to potential treatments. 
1.9 IDENTIFICATION OF NUCLEAR-ENCODED 
MITOCHONDRIAL PROTEINS 
It is thought that around 15% of the predicted 1500 nuclear-encoded mitochondrial 
proteins are yet to be identified (Calvo, 2010). Several methods are used to identify 
such proteins, including algorithms to predict the likelihood of classic N-terminal 
mitochondrial targeting sequences, such as TargetP (Emanuelsson et al., 2007; 2000), 
MitoProt II (Claros and Vincens, 1996) or Predator (Small et al., 2004). However, as 
discussed earlier, there are several mechanisms by which mitochondria import proteins, 
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hence finding N-terminal pre-sequences will not uncover all of the mitochondria-
destined proteins. Another method used is mass spectrometry, which has also identified 
mitochondrial proteins, where purified mitochondrial proteins were separated using 2D 
gels and then peptide mass fingerprinting was used to identify particular proteins 
(Rabilloud et al., 1998; Scheffler et al., 2001). This approach requires very sophisticated 
machinery and still has a tendency to include contaminant proteins that are not 
necessarily mitochondrial (Calvo, 2010). There are other methods of identifying 
mitochondrial proteins, but the most reliable and accurate is to use a combined approach 
that takes data from all of these sources and scores them to allow predictions of how 
likely certain proteins are to be mitochondrial.  
MitoCarta is a database that uses an integrated approach (Pagliarini et al., 2008) 
(www.broadinstitute.org/pubs/MitoCarta/human.mitocarta.html). To generate the 
MitoCarta inventory, mass spectrometry was performed on mitochondria isolated from 
14 different mouse tissues and mitochondrial localisation was assessed on a large scale 
by GFP-tagging and fluorescent microscopy (Pagliarini et al., 2008). The results from 
these experiments were integrated with bioinformatics approaches including; i) Target P 
predictions (Emanuelsson et al., 2007), ii) BlastP searches to identify mammalian 
homologues of known yeast mitochondrial proteins, iii) BlastP searches to identify 
homologues of R. prowazekii proteins, iv) identification of proteins with mitochondrial-
specific Pfam domain and v) evidence from literature. Maestro scores are also included 
on the MitoCarta inventory. Maestro uses a similar Bayesian integrated approach to 
predict mitochondrial localisation (Calvo et al., 2006). These approaches were compiled 
into a list of 1098 mouse genes, which are likely to encode mitochondrial proteins 
(Pagliarini et al., 2008). A human MitoCarta inventory was then produced by 
identifying human HomoloGene homologues to the mouse MitoCarta collection 
(Pagliarini et al., 2008). 
The data from the human MitoCarta database was used by my host laboratory to 
identify a list of 224 proteins that are both likely to be mitochondrial and potentially had 
a role in mitochondrial gene expression, but were largely of undefined function 
(compiled by Prof R. N. Lightowlers). A screen of these candidate proteins was 
performed using three different siRNAs targeted to each gene. Depletion (via siRNA) of 
the transcripts encoding each candidate protein was performed in both HeLa cells and 
Rho0 cells. Rho0 cells lack mtDNA (King and Attardi, 1989) and can therefore grow in 
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the absence of factors uniquely involved in maintaining or transcribing mtDNA, 
translating the resultant mRNA or proteins modifying rRNA/tRNAs. If depletion of a 
particular protein, with at least two of the three siRNAs, caused significant growth or 
morphology changes in HeLa cells, but not in Rho0 cells, then that protein was 
classified as one of those most likely to be both mitochondrial and involved in 
mitochondrial gene expression (initial siRNA screen performed by Dr J. Rorbach). 
Thirty-three candidate proteins fulfilled these criteria and were selected for further study 
(Figure 1.7A). 
One optimal siRNA sequence was chosen for each of the 33 genes on the basis of a 
significant growth defect in Hela cells with no or little growth defect in Rho0 cells. To 
give an indication at what stage a defect in mitochondrial gene expression maybe 
occurring, the levels of mtDNA (as described in 2.3.11) were assessed by qPCR (Figure 
1.7). Transcription of mtDNA was estimated by measuring MT-CO1 mRNA levels 
using qPCR (Figure 1.7). To investigate translation, [35S]-labelled methionine 
([35S]met) was used. Cells were pulse labelled for 1 hour with [35S]met in the presence 
of emetine, which inhibits cytosolic translation. As translation occurs the [35S]met was 
incorporated into newly synthesised proteins. Following a three-hour chase with 
unlabelled methionine, proteinaceous material was precipitated with trichloroacetic acid 
(TCA) and incorporated radioactivity was measured by scintillation counting as a crude 
indictor of mitochondrial translation (Figure 1.7). Lower levels of [35S]met 
incorporation in siRNA treated samples may indicate a role in translation or post 
transcriptional processing for that candidate protein. O2 consumption of the cells was 
measured using Seahorse XF analyser, in order to assess the function of the OXPHOS 
system (Figure 1.7).  
These preliminary data were generated by Dr P. M. Smith and indicated that 
AURKAIP1 depleted cells show increased mtDNA copy number, but reduced mRNA 
levels, [35S]met incorporation and O2 consumption. SLMO2 depleted cells show normal 
levels of mtDNA and mRNA, but reduced [35S]met incorporation and O2 consumption. 
Of the 33 candidate proteins studied further, siRNA-mediated depletion of AURKAIP1 
and SLMO2 (also known as c20orf45), caused particularly severe phenotypes in HeLa 
cells (Figure 1.7B), without any effects on Rho0 cells, For these reasons, my thesis 
aimed to focus on these two proteins, each of which will be discussed briefly below. 
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1.10 SLMO2 
SLMO2 is a homologue of the SLMO protein in Drosophila (Dee and Moffat, 2005) 
and is a PRELI domain containing protein. Although the PRELI domain itself is of 
unknown function, it is highly conserved across species, including a family of yeast 
proteins called Ups (Sesaki, 2006). Ups proteins have been shown to be important in 
maintaining the phospholipid content of mitochondria with Ups1 being significant in 
maintaining normal cardiolipin (CL) levels (Potting et al., 2010).  
 
 
A 
B 
Figure 1.7: Effect on Mitochondrial Metabolism 
Following Depletion of 33 Mitochondrial Candidate 
Proteins. A) siRNA depletion of each candidate protein was 
performed in HeLa cells, after which, mtDNA copy number 
(red), mRNA levels (dark blue), [S35]met incorporation 
(light blue) and O2 consumption (white) were measured. 
The proteins to be studied in this project, AURKAIP1 and 
SLMO2 (c20orf45), are highlighted in red boxes. B) 
Enlarged depliction of AURKAIP1 and SLMO2, for ease of 
viewing. 
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INVOLVEMENT IN REGULATION OF CARDIOLIPIN? 
CL is an essential phospholipid that is mainly located in the inner membrane of 
mitochondria (Chang et al., 1998a). CL is thought to be important in diverse functions 
such as protein import (Gerbert et al., 2009), mitophagy (Chu et al., 2013) and 
cytochrome c oxidase function (Hoffmann et al., 1994; Tsukihara et al., 1996; Fontanesi 
et al., 2006). CL is synthesised from phosphatidic acid via CDP-diacylglycerol, PGP 
(phosphatidylglycerolphosphate) and PG (phosphatidylglycerol). There are many 
enzymes involved in the synthesis of CL, of which most yeast and bacterial homologs 
are known (Chang et al., 1998b; Osman et al., 2010; 2011).  
In yeast, the PRELI domain-containing Ups proteins seem to regulate the phospholipid 
content of the mitochondria. Cells lacking Ups1 (Δups1) have much less CL whereas 
Δups2 cells have more CL but less phosphatidylethanolamine (PE) (Osman et al., 2009; 
Tamura et al., 2009). Recently, Mdm35 has been shown to aid in the import of Ups 
proteins and binds them stably in the IMS (Tamura et al., 2010; Potting et al., 2010).  
EVIDENCE FOR MITOCHONDRIAL LOCALISATION 
SLMO2 is one of at least 4 PRELI domain-containing proteins encoded by the human 
genome (Herrmann, 2010). PRELI domain-containing proteins in yeast are known to be 
mitochondrial proteins; therefore it is likely that SLMO2 is also mitochondrial. 
Furthermore, SLMO2 is included in the human MitoCarta database based on the yeast 
homologues and microscopy of GFP-tagged protein (Pagliarini et al., 2008). Data from 
the siRNA screen showed SLMO2 depleted cells still have normal levels of mtDNA and 
mRNA, but less [35S]met incorporation indicating a possible defect in protein synthesis. 
These data suggest a role for SLMO2 in mitochondrial gene expression (Figure 1.7). 
During the course of my studies, it became apparent that SLMO2 was a protein being 
investigated by another group. This, coupled with problems in generating soluble 
protein expression, and expression cell lines led me to focus my thesis primarily on 
AURKAIP1.   
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1.11 AURKAIP1 
AURKAIP1 (Aurora Kinase A Interacting Protein) has previously been described as a 
nuclear protein involved in targeting Aurora-A kinase for degradation via a proteasome 
dependent - ubiquitin independent pathway (Lim et al., 2007). However, there is a 
report to the contrary that suggests AURKAIP1 actually promotes stability of Aurora-A 
kinase (Katayama et al., 2007). These data also suggest nuclear localisation of 
AURKAIP1, but these observations were derived from a FLAG-tagged construct of 
AURKAIP1 where the FLAG-tag was added at the N-terminus (Lim et al., 2007). As 
mentioned previously, many mitochondrial proteins have cleavable N-terminal pre-
sequences that direct subcellular localisation. By altering the N-terminus of the protein 
it is likely that AURKAIP1 had been aberrantly targeted and mitochondrial localisation 
has been disrupted.  
Bioinformatics approaches, including Target P, have identified AURKAIP1 as being 
likely to contain an N-terminal mitochondrial targeting sequence (Emanuelsson et al., 
2007). AURKAIP1 is also one of the 1013 proteins in the human MitoCarta database, 
which lists proteins with strong evidence of mitochondrial localisation based on various 
analytical criteria including analysis of pre-sequence, and subcellular localisation by 
GFP-tagging and fluorescence microscopy (Pagliarini et al., 2008). Furthermore, 
preliminary data generated in my host laboratory prior to my investigations, inferred 
that AURKAIP1 depletion had no effect on mtDNA copy number, but led to a decrease 
in mRNA (qPCR on MT-CO1), de novo mitochondrial protein synthesis and O2 
consumption. These data are suggestive of a protein involved in mitochondrial gene 
expression. 
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1.12 AIMS 
As illustrated throughout this introductory chapter, there are many facets of 
mitochondrial gene expression that remain to be elucidated. The siRNA screen 
performed in my host laboratory was used to identify proteins that were likely to be 
involved in mitochondrial gene expression, with a view to furthering our understanding 
of gene expression in human mitochondria. As discussed earlier, AURKAIP1 was a 
strong candidate for further study based on preliminary data and my thesis will focus on 
the characterisation of AURKAIP1 and its potential role in mitochondrial gene 
expression. 
More specifically, the aims of these studies were as follows: 
• To express and purify recombinant AURKAIP1 to use as an antigen for antibody 
production 
 
• To produce stable human cell lines capable of expressing C-terminal FLAG-
tagged AURKAIP1  
 
• To use these tools to determine whether AURKAIP1 is mitochondrial, and if so, 
the sub-mitochondrial localisation 
 
• To characterise the phenotype of AURKAIP1 depletion, with a view to 
identifying any critical role of AURKAIP1 in mitochondrial gene expression 
 
• To identify binding partners of AURKAIP1 via immunoprecipitation to elucidate 
potential functions of AURKAIP1.  
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CHAPTER 2: GENERAL MATERIALS AND 
METHODS 
2.1 CELL CULTURE 
2.1.1 MAMMALIAN CELL LINES 
Flp-InTM TRExTM 293 Cell Line: Human Embryonic Kidney (HEK) cell line 
commercially available from Life Technologies. This cell line constitutively expresses 
the Tet repressor and has an integrated Flp Recombinase target (FRT) site to allow 
specific Flp Recombinase mediated integration of a gene of interest into the host 
genome (Further details on the Flp-InTM TRExTM sytem are discussed in Section 3.1 and 
the method of generating stable overexpressing cell lines outlined in Section 4.2.1). For 
the rest of the text these cells will be referred to simply as HEK293 cells as no other 
HEK293 cell line variant was used in experiments detailed in this report.   
Flp-InTM TRExTM U2OS Cell Line:  A Flp-InTM TRExTM cell line derived in the same 
way as the HEK293 cells. However the host cells were of U2OS origin, which is an 
osteosarcoma cell line. This cell line was kindly donated by Dr Nick Watkins. These 
cells will be referred to simply as U2OS cells throughout the remaining text. 
HeLa Cell Line: Cell line derived from Henrietta Lacks cervical cancer cells. 
143B Cell Line: A human osteosarcoma cell line.   
143B.206 Rho0 Cell Line: 143B cells were depleted of mtDNA via ethidium bromide 
treatment. This line was produced as described in (King and Attardi, 1989) and will be 
referred in the text as Rho0 cells. 
2.1.2 GENERAL CELL CULTURE AND MAINTENANCE 
All cell culture work was carried out in a class II Microflow cabinet with reagents from 
Sigma Aldrich unless otherwise indicated. Cells were monitored daily using the 
Axiovert25 microscope (Zeiss).  
All cells were propagated at 37°C and in a humidified 5% CO2 atmosphere. Cells were 
cultured in monolayers in vented tissue culture flasks (TPP or Corning) or 6-well plates 
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(Cellstar, Greiner Bio One or TPP). HeLa cells were cultured in Eagle’s Minimal 
Essential Media with Earle’s salts containing 2mM L-glutamine (EMEM, M4655) 
supplemented with 10% foetal calf serum (FCS, F7524) and 1x non-essential amino 
acids (NEAA, M7145). All other cell types were cultured in Dulbecco’s modified 
Eagle’s medium containing 1mM pyruvate, 2mM L-glutamine and 4500mg/L glucose 
(DMEM, D6540) and was supplemented with 10% FCS, 1x NEAA and 50µg/ml 
uridine. BlasticidinS (Melford Laboratories, B1105) was routinely added to all Flp-
InTMTRExTM cell lines every third feed at a final concentration of 10µg/ml. Media was 
changed approximately every 3 days or as required. Generally 1-2ml media was used 
per well for culture in 6 well plates, 5ml for culture in 25cm2 flasks, 15ml for culture in 
75cm2 flasks and 50-75ml for culture in 300cm2 flasks.  
When cells reached high levels of confluency (80-100%), they were passaged by 
harvesting in PBS/1mM EDTA (for HEK293, HeLa and Rho0 cells) or 1x trypsin/ 
EDTA (PBS used to dilute 10x stock, T4174) for 143B and U2OS cells, adding an 
equal volume of media and pelleting in a universal at 230g for 4 minutes. The cell pellet 
was resuspended in fresh media and a portion of cells was seeded into new flask(s). The 
degree of splitting and the flask type used depended on the intended application and the 
type of cells. 
2.1.3 CELL COUNTS 
Cells were harvested as above, the cell pellet was resuspended in 1ml fresh media and 
10µl was added to each chamber of a Neubauer improved haemocytometer. The cells in 
the 4 large squares of each chamber were counted and an average was calculated. The 
average number of cells per square was multiplied by 104 to obtain the cell count per 
ml. If there were too many cells to count accurately a 1 in 10 dilution was made and the 
average count multiplied by 105 to obtain the cell count per ml. 
2.1.4 FREEZING AND STORAGE 
For long-term storage, cells were harvested and the cell pellet resuspended in 0.5ml 
FCS with 10% DMSO and transferred to cryostorage vials. The cryostorage vials were 
then placed in the Nalgene® Mr. Frosty container stored at -80°C. This allowed a 
cooling rate of 1° per minute and after at least 24 hours, the vials were transferred into a 
liquid nitrogen storage tank for long-term storage.  
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To thaw cells, they were placed briefly at 37˚C and pre-warmed medium was slowly 
added to a final volume of 10ml. Cells were then pelleted as above, resuspended in 
medium and transferred to a culture flask of the same size as the cells were grown in 
before they were frozen. 
2.1.5 MYCOPLASMA TESTING 
Approximately every 3 months or as required, a 1ml aliquot of media from flasks with 
cells growing for at least 24 hours was taken to test for the presence of mycoplasma. 
The aliquot of conditioned media was subjected to centrifugation at 230g for 4 minutes 
to pellet any cells that may be present. The supernatant was then transferred to a 
microcentrifuge tube and stored at 4°C until mycoplasma testing was performed. 
The MycoAlertTM mycoplasma testing kit from (Lonza, LT07-118) was used to carry 
out the analysis as per manufacturer’s guidelines. If mycoplasma was detected cells 
were discarded and replaced with cells from an earlier passage that had tested negative 
for mycoplasma before being stored in liquid nitrogen (2.1.4).  
2.1.6 TRANSFECTING CELLS WITH SIRNA 
Depletions were usually performed by ‘reverse’ transfection of cells with siRNA in 6 
well plates, which I will describe now. For each depletion, a transfection mix of 250µl 
Optimem+GlutaMAX® (Gibco, 51985-026), 2µl lipofectamine RNAiMAX 
(Invitrogen, 13778150) and the appropriate volume of siRNA (see Table 2.1 for final 
concentrations of each siRNA used) were mixed gently in a microcentrifuge tube and 
incubated at room temperature for 15 minutes. During the incubation, cells that had 
been grown in a 75cm2 flask were harvested and counted to allow a concentration of 
60,000 cells per ml of media to be produced. Each transfection mix was gently mixed 
and transferred to a 9.6cm2 well before adding 1ml of the cell mix to each well. The 
plates were then gently rocked to mix and incubated for 3 days. 
After 3 days the cells were either harvested or re-transfected. Re-transfection was 
carried out by standard (or ‘forward’) transfection of cells whilst bound to plates. The 
same volumes were used to make up the transfection mix as above, but during the 
incubation, the old media was removed from the wells and the cells were washed once 
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with PBS before adding the transfection mix and 1ml of media to the cells in an 
adherent state, and incubating for a further 3 days.  
When larger amounts of material were required, then 25cm2 or 75cm2 flasks were used 
to perform the siRNA depletions. The procedure was the same but the volumes were 
adapted. For 25cm2 knockdowns 1ml of Optimem and 10µl of lipofectamine was used 
in the transfection mix with the appropriate amount of siRNA. For knockdowns in 
75cm2 flasks, 1.5ml Optimem and 12µl lipofectamine were used. A total of 300,000 
cells were seeded for depletion in 25cm2 flasks (in 4ml media) and 1,000,000 cells 
seeded for depletions in 75cm2 flasks (in 7.5ml media).  
Table 2.1: Details of siRNA Duplexes Used for Transfection of Cell Lines 
Name Sequences (5’ - 3’) Final Concentration  
AURKAIP1 
siRNA1 
5’-GUA CUU GUG GUG GUU CAU C dTdT 
5’-GAU GAA CCA CCA CAA GUA C dTdT 
33nM/ml 
AURKAIP1 
siRNA2 
5’-CUU CAC CAG CUU CCG GUA C dTdT 
5’-GUA CCG GAA GCU GCU GAA G dTdT 
33nM/ml 
AURKAIP1 
siRNA3 
5’-CUU CCG GUA CUU GUG GUG G dTdT 
5’-CCA CCA CAA GUA CCG GAA G dTdT 
33nM/ml 
p32  
siRNA2 
5’-AAG GAA AUC CAU UAG GUG G dTdT 
5’-CCA CCU AAU GGA UUU CCU U dTdT 
50nM/ml 
Non-
targeting 
siRNA non-targeting negative control duplex OR-
0030-NEG05 
Same as for the 
targeted siRNA used 
All siRNAs were synthesised by Eurogentech and stored as 20µM or 100µM stocks in 
RNase-free water at -20°C.  
NCBI Reference Sequences: AURKAIP1 = NM_001127229.1, p32 = NM_001212.3 
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2.2 BACTERIAL MANIPULATIONS 
2.2.1 BACTERIAL CULTURE AND STORAGE 
All bacteria were grown in LB media (Luria-Bertani: 5g NaCl, 5g bacto-tryptone, 2.5g 
yeast extract made up to 500ml with dH2O and autoclaved) either in liquid broth or on 
2% agar containing plates with appropriate antibiotics. Ampicillin (100µg/ml final 
concentration, Formedium, AMP25) and/or chloramphenicol (50µg/ml final 
concentration, Melford, C0113) were added to LB media or agar plates and bacteria 
were incubated overnight at 37˚C (with aeration for bacteria grown in suspension). For 
long-term storage, bacteria were frozen in LB media containing 18% glycerol at -80˚C. 
2.2.2 BACTERIAL TRANSFORMATION  
Aliquots of Bioline α-select chemically competent cells (40µl per transformation, BIO-
85025) were thawed on ice. Up to 4µl DNA was added and incubated on ice for 30 
minutes before being heat shocked at 42˚C for 45 seconds. Cells were again placed on 
ice for 2 minutes before adding 900µl pre-warmed SOC media (2% bacto-tryptone, 
0.5% yeast extract, 0.05% NaCl, 2.5mM KCl, 10mM MgCl2 and 20mM Glucose) and 
incubated at 37˚C, with agitation for one hour. Cells were then pelleted and resuspended 
in 50µl fresh SOC media, plated out on LB agar with appropriate antibiotics and 
incubated, inverted overnight at 37˚C. 
For antibody production using recombinant protein as the antigen, relevant open reading 
frames were cloned into pGEX-6P-1. The validated construct as used to transform α-
select cells for amplification of the desired plasmid, was subsequently used to transfect 
RosettaTM DE3 cells (Novagen) or TunerTM cells using the same protocol as for α-select 
cells (see Table 2.2 for details on bacterial strains). These bacterial cell lines allow 
overexpression of recombinant protein in bacteria. 
 
 
 
 
  41 
Table 2.2: Bacterial Strains 
Strain Genotype Application Antibiotic Resistance 
α-select 
Bronze 
Efficiency 
(Bioline) 
F- deoR endA1 recA1 relA1 gyrA96 
hsdR17(rk-, mm+) supE44 thi-1 phoA 
Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ- 
Transfection 
with plasmids none 
RosettaTM 
(DE3) 
(Novagen) 
F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE 
(CamR) 
Expression of 
recombinant 
eukaryotic 
proteins with 
rare E.coli 
codons 
Chloramphenicol 
TunerTM 
(Novagen) F
– ompT hsdSB (rB– mB–) gal dcm lacY1 
As for Rosetta, 
but allows 
titratable IPTG 
induction 
none 
 
2.2.3 EXPRESSION OF RECOMBINANT PROTEIN FROM BACTERIA  
The final protocol for the expression and purification of recombinant mature 
AURKAIP1 is presented here, but many iterations of the protocol were tested to allow 
maximum expression of soluble protein, described in detail in 3.2.2. 
Tuner cells transformed with pGEX-6P-1/mature AURKAIP1 were grown in 5ml 
LB+amp (LB supplemented with 100µg/ml ampicillin) at 37°C with aeration overnight. 
Two 5ml cultures were used to inoculate 500ml LB+amp and incubated at 37°C with 
aeration for several hours. Every 20-30 minutes 1ml aliquots were taken from the large 
cultures and the optical density at a wavelength of 600nm (OD600) measured. When an 
OD600 of 0.2 was achieved, the cultures were induced by adding 250µM IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) and incubated at 37°C for 4 hours with 
aeration. Cells were pelleted by centrifugation at 5000rpm (Sorvall GSA centrifuge, 
rotor code 10) for 15 minutes at 4°C before being incubated at -80°C for at least 2 hours 
to aid in cell breakage. The cell pellet was then thawed and resuspended by vortexing in 
10ml PBS supplemented with 1x EDTA-free protease inhibitor cocktail (Pierce, 88666), 
1mM PMSF and 250U Benzonase (Novagen, 70746-3) and incubated on ice for 20 
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minutes. The suspension was sonicated on ice 15 times for 10 seconds with an 18-
micron amplitude with 10 second intervals. The suspension was then centrifuged at 
30,000g for 30 minutes at 4°C to pellet the insoluble fraction and unbroken cells. The 
supernatant was saved and passed through a 45µm filter before proceeding to the 
purification step (3.2.2).   
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2.3 DNA MANIPULATION 
2.3.1 ISOLATION OF PLASMID DNA 
To amplify plasmid copy number, bacterial cultures (5ml LB + appropriate antibiotics) 
were inoculated with single colonies and incubated overnight as described above. Cells 
were pelleted in a microcentrifuge tube and the plasmid DNA was isolated using the 
GeneJET® plasmid miniprep kit (Thermo, K0503) according to manufacturer’s 
instructions. The isolated DNA was then eluted in 50µl dH2O and the DNA quality 
assessed by gel electrophoresis (2.3.8) and concentration measured using the Nano-drop 
(2.3.4). 
2.3.2 POLYMERASE CHAIN REACTION (PCR) 
PCR was used to amplify the defined DNA regions required for cloning. Primers were 
designed to initiate amplification of the open reading frame of AURKAIP1 (Further 
details and Primer sequences given in 3.2.1 and Table 3.1). Thin walled 0.5ml 
microcentrifuge tubes and a final volume of 50µl were used in all cases.  
Generic Proof Reading Polymerase Reaction Mix: 
o 1µM Forward Primer 
o 1µM Reverse Primer 
o 0.08mM dNTPs 
o 1.5mM MgSO4 
o 1x Buffer for KOD Hot Start Polymerase 
o 20-100ng DNA Template 
o 1 U KOD Hot Start DNA polymerase 
Generic PCR Cycling Conditions: 
Initial Denaturation 95˚C 4 minutes 
Denaturation 95˚C 1 minute 
Annealing  50˚C 1 minute           30 Cycles 
Extension 72˚C 4 minutes 
Final Extension 
Hold 
72˚C 
4°C  
7 minutes 
Indefinitely 
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The annealing temperature of the primers was measured by entering the sequence into 
OligoCalc (Kibbe, 2007) and using the salt corrected values. The initial annealing 
temperature used for PCR was approximately 5˚C below the lowest annealing 
temperature of the two primers used in a particular reaction. 
PCR products then underwent agarose gel electrophoresis and were visualised using a 
UV transilluminator. The PCR product was then cut out of the gel using a scalpel and 
cleaned up using the QIAquick® Gel Extraction Kit (QIAGEN, 28706) according to 
manufacturer’s guidelines. 
2.3.3 PHENOL/CHLOROFORM EXTRACTION AND ETHANOL 
PRECIPITATION OF DNA 
Typically for plasmid DNA or PCR products, DNA was diluted in 50µl dH2O and an 
equal volume (in this case 50µl) of phenol (Sigma, P-4557) was added. The samples 
were then vortexed for 30 seconds and centrifuged for 1 minute at 14,000g. The upper 
aqueous phase was carefully removed and placed into a fresh microcentrifuge tube 
before adding half of the original volume (i.e. 25µl) of phenol and half of the original 
volume (i.e. 25µl) of chloroform. The samples were again vortexed and centrifuged as 
described, before removing the top aqueous layer into a new tube. The same process 
was then repeated after adding an equal volume (50µl) of chloroform.  
A tenth of the volume (5µl) of 3M sodium acetate was added to the final aqueous layer 
before two times the volume (110µl) of 100% ethanol was added. The samples were 
then incubated at -80°C for at least 1 hour before pelleting the DNA by centrifugation at 
20,000g for 30 minutes at 4°C and resuspending the pellet in 10µl of sterile dH2O. 
If retaining the maximum amount of DNA was of great importance, the samples were 
initially diluted in a greater volume and volumes of phenol and chloroform were 
amended accordingly so that the relative proportion of aqueous phase, and thus, DNA 
retained was maximised.      
2.3.4 MEASUREMENT OF NUCLEIC ACID CONCENTRATION 
All single stranded, double-stranded DNA or RNA concentrations were obtained with 
the Nano-drop (Spectrophotometer ND-1000) with absorption at 260nm with 1 A260 
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unit (1cm light path) equivalent to 50µg/ml (double-stranded DNA), 40µg/ml (double-
stranded RNA) or 33mg/ml (oligodeoxynucleotide).  
2.3.5 RESTRICTION ENDONUCLEASE DIGESTS OF DNA 
Different restriction enzymes were used to cut the PCR products and vectors at the 
relevant restriction sites that had been engineered into the respective primers (Table 
3.1). For particular constructs double digests were used, requiring a combination of 
EcoR1 (Roche), Xho1 (Roche), HindIII (Promega) and BamH1 (New England Biolabs) 
to facilitate insertion of the fragment into the vector in a single orientation. Restriction 
buffer 2 (New England Biolabs) was used for all digests.  
Generic 20µl total volume double restriction digest reaction: 
• 2µl 10x NEB restriction buffer 2 pH 7.9 
(1x contains: 50mM NaCl, 10mM Tris/HCl, 10mM MgCl2, 1mM DTT) 
• 0.8µl enzyme 1  
• 0.8µl enzyme 2 
• 16.4µl cleaned up insert, or 0.5-1µg vector (plus dH2O to make up final volume)  
Reactions were typically incubated at 37°C for 3 hours. 
2.3.6 DEPHOSPHORYLATION 
The 5’ dephosphorylation of vectors was performed immediately after restriction 
digests by adding 2µl 1M Tris pH 9.4, 2µl 10% SDS and 0.5µl alkaline phosphatase to 
the 20µl digest reaction. The dephosphorylation reaction was then incubated at 37°C for 
30 minutes.  
2.3.7 LIGATION 
Ligation of digested PCR products into digested and de-phosphorylated vectors was 
catalysed by T4 DNA ligase (Roche). Reactions were typically prepared in a 10µl final 
volume with 1x T4 DNA ligase buffer (Roche), 1mM ATP and T4 ligase with an 
insert:vector molar ratio of 3:1 and 50ng of vector. Ligation reactions were incubated 
overnight at 16˚C.  
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2.3.8 AGAROSE GEL ELECTROPHORESIS 
For analysis of linearised vectors, 0.8% agarose gels were used, whereas 1% agarose 
gels were used for analysis of PCR products. Agarose (NBS Biologicals, NBS-AG500) 
was dissolved in 1x TAE buffer (diluted from 50x stock prepared with 12.1g Trizma 
base, 5ml 0.5M EDTA and 2.86ml glacial acetic acid made up to 50ml with dH2O. Final 
concentration of 1x TAE: 40mM Tris acetate, 1mM EDTA pH 8.0) by heating in a 
microwave. As the dissolved agarose cooled, 0.2µg/ml final concentration of ethidium 
bromide was added and mixed. The still molten agarose was poured into a gel cast and 
after setting was placed in an electrophoresis chamber and immersed in 1x TAE buffer. 
Samples in 1x DNA loading buffer (3% glycerol and approximately 0.025% each of 
bromophenol blue and xylene cyanol) and the 1kb ladder as a molecular weight marker 
were loaded and electrophoresed at 70V.  
2.3.9 DNA SEQUENCING 
Plasmids that were identified as having successfully ligated inserts were cycle 
sequenced in the PCR machine, using the BigDye® termination system (Applied 
Biosystems).  
Cycle sequencing reaction (15µl total): 
• 450ng plasmid DNA (in 9µl dH2O) 
• 3µl 5x sequencing buffer 
• 1µl 5µM primer (CMV forward for pcDNATM5 sequencing) 
• 2µl BigDye Terminator v3.1 ready reaction mix 
Cycle sequencing conditions: 
Initial Denaturation 95˚C 5 minutes 
Denaturation 95˚C 30 seconds 
Annealing  50˚C 10 seconds          30 Cycles 
Extension 72˚C 4 minutes 
Hold 4°C  Indefinitely 
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The cycle-sequenced samples were then stored at -20°C. The samples were kindly 
analysed by Charlotte Alston. 
2.3.10 DNA EXTRACTION FROM HUMAN CELL LINES 
Cultured human cells were harvested as described in 2.1.2. Cell pellets were 
resuspended in 400µl TE buffer (10mM Tris pH 8, 1mM EDTA). Final concentrations 
of 1% SDS (Sigma, L-4390) and 2mg/ml proteinase K (Roche, 25530-049) were then 
added, followed by an overnight incubation at 37°C. The samples were visually 
inspected and if the samples were not clear, they were mixed and further incubated at 
37°C until clear. Phenol/chloroform extractions were then performed as described in 
2.3.3.  The volumes of phenol and chloroform used matched the sample volume. The 
centrifugation steps were extended to two minutes and the step where both phenol and 
chloroform were added was performed twice before extracting with chloroform alone. 
Ethanol precipitation was performed as described in 2.3.3. 
2.3.11 QUANTITATIVE POLYMERASE CHAIN REACTION (qPCR) 
DNA was isolated from cells as described above (2.3.10) and the DNA concentration 
was measured using the Nano-drop (2.3.4). For each sample, 50ng of DNA was used as 
a template in the reaction and each reaction was performed in triplicate. Forward and 
reverse primers for MT-ND4 (target gene) and 18S (reference gene) are detailed in 
Table 2.3.  
Each reaction was prepared in a final volume of 20µl and comprised: 
• 1µl of 10mM forward primer 
• 1µl of 10mM reverse primer 
• 10µl FastStart Essential DNA Green Master Mix (Roche, 06402712001) 
• 2µl of 5ng/µl DNA template (10ng total) 
• 6µl sterile dH2O 
Negative controls lacked the addition of the DNA template and were therefore supplied 
with an extra 2µl of dH2O. Each reaction was prepared in polypropylene qPCR 
microtube strips, which were pulsed down prior to loading into the Lightcycler® Nano 
instrument (Roche) for performance of the qPCR.   
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Initial Denaturation 95˚C 10 minutes 
Denaturation 95˚C 10 seconds 
Annealing  59˚C 10 seconds           45 Cycles 
Extension 72˚C 15 seconds 
Final Extension 
Melting Curve 
72˚C 
60°C-95°C  
5 minutes 
0.1°C per second 
 
The Cq (quantification cycle) values for each sample were determined by the 
Lightcycler® Nano software. The analysis was performed using the normalised 
expression ratio (2-ΔΔCq) method (Livak and Schmittgen, 2001). This method is effective 
when both the target and reference genes have an approximately 100% amplification 
efficiency and are within 5% of each other. The target and reference genes were 
validated in satisfying these criteria in my host laboratory.  
ΔCq (Test) = ΔCq (Target, Test) - ΔCq (Reference, Test) 
ΔCq (Calibrator) = ΔCq (Target, Calibrator) - ΔCq (Reference, Calibrator) 
ΔΔCq = ΔCq (Test) - ΔCq (Calibrator) 
Where:  Target = MT-ND4,  
Reference = 18S, 
Test = either AURKAIP1 depletion or AURKAIP1 overexpression 
Calibrator = either non-targeting siRNA treated or uninduced cells 
 
Table 2.3: Primers for qPCR. 
Primer Name Sequence (5’ – 3’) Tm 
MT-ND4 Forward 5’-CCA TTC TCC TCC TAT CCC TCA AC 59°C 
MT-ND4 Reverse 5’-CAC AAT CTG ATG TTT TGG TTA AAC TAT ATT T 59°C 
18S Forward 5’-GTA ACC CGT TGA ACC CCA TT 59°C 
18S Reverse 5’-CCA TCC AAT CGG TAG TAG CG 59°C 
NCBI Reference Sequences: MT-ND1 = YP_003024026.1, 18S = NR_003286.2  
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2.4 RNA MANIPULATION 
All solutions for use in work with RNA were prepared using autoclaved water that had 
been previously treated with 0.1% DEPC (DEPC water).   
2.4.1 RNA EXTRACTION FROM HUMAN CELL LINES 
Harvested cells were pelleted and resuspended in 0.5ml Trizol reagent (Invitrogen) and 
left to incubate at room temperature for 5 minutes. Then, 0.1ml of chloroform was 
added to each sample followed by 15 second of vigorous shaking. After a 3-minute 
incubation at room temperature, the samples were subjected to centrifugation at 12,000g 
for 15 minutes at 4°C. The supernatant was carefully removed and transferred to a fresh 
microcentrifuge tube, before 250µl isopropanol was added. The samples were gently 
mixed and incubated at room temperature for 10 minutes. The samples were then 
centrifuged at 12,000g for 10 minutes at 4°C and the RNA pellet was briefly dried 
before being resuspended in an appropriate volume of DEPC water. Samples were 
stored at -80°C. For large cell pellets, the volumes of all reagents used were doubled.     
2.4.2 REVERSE TRANSCRIPTION 
The Superscript II Reverse Transcription kit (Invitrogen) was used to generate single 
stranded cDNA for use as a template in PCR reactions. An aliquot of 1µl of oligo dT 
primer (100mM stock) was added to 5-10ng of isolated RNA and was made up to 12µl 
total volume with DEPC treated water. The mix was incubated at 70°C for 10 minutes 
and then placed on ice whilst 1x First-Strand Reaction Buffer, dNTPs (0.5mM final 
concentration) and DTT (10mM final concentration) were added. The reaction was then 
incubated at 42°C for 5 minutes before adding 200U of Superscript II Reverse 
Transcriptase and continuing the incubation at 42°C for 50 minutes. Inactivation of the 
Superscript II Reverse Transcriptase was then achieved by heating to 70°C for 15 
minutes. The cDNA was then stored at -80°C. 
2.4.3 DENATURING AGAROSE GEL ELECTROPHORESIS 
Denaturing agarose gel electrophoresis was used to separate RNA samples for 
subsequent northern blotting. Isolated RNA was subject to phenol/chloroform extraction 
to improve purity before measuring the concentration using the Nano-drop. A total of 
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5µg of isolated RNA was prepared in an 8µl total volume of DEPC water. Samples 
were then made up to a final volume of 20µl by the addition to final concentrations of 
1x MOPS (40mM MOPS acid, 10mM NaOAc and 1mM EDTA pH 7.2), 35% 
formamide and 5.5% formaldehyde. Samples were then heated at 55°C for 15 minutes 
before adding 0.1µg/µl ethidium bromide and 1x loading dye. 
Samples were then loaded and electrophoresed through the denaturing gel (1% agarose, 
1x MOPS and 0.9% formaldehyde) in 1x MOPS buffer at 55V for 2 hours. The 
electrophoresis gel tank and all casting apparatus had been soaked with 3% H2O2 for 10 
minutes at room temperature, rinsed in DEPC H2O and subsequently air dried prior to 
gel preparation. 
The electrophoresed RNA was visualised on a UV transilluminator to assess the 
migration, quality and loading before proceeding with northern blotting. 
2.4.4 NORTHERN BLOTTING AND PROBE GENERATION 
RNA samples were electrophoresed as described above before being transferred to a 
Genescreen Plus membrane (Perkin Elmer). Transfer was carried out by capillary 
transfer in 10x SSPE (3.6M NaCl, 200mM phosphate buffer pH 7 and 20mM EDTA) 
overnight at room temperature. The membrane was then washed with 2x SSPE and 
visualised under UV light alongside the gel to confirm transfer efficiency, and rRNA 
migration. The membrane was then baked at 80°C for 2 hours in a vacuum drier. The 
membrane was blocked for 2 hours at 42°C in 10ml pre-hybridisation solution (50% 
formamide, 5x SSPE, 1% SDS and 5x Denhardt’s solution) before adding any probes. 
Various 32P-labelled DNA probes were produced to target specific desired RNA 
sequences. DNA templates used for these probes were produced by PCR. These DNA 
templates (100ng) were denatured in 9µl DEPC water at 95°C for 4 minutes before 
cooling and adding 1x random hexamer mix, 5U Klenow fragment (DNA polymerase I, 
Promega) and 2µl 32P α-dCTP (Perkin Elmer NEG513H) in a 15µl reaction. The 
reaction mix was then incubated for 1 hour at 37°C and then passed through Illustra G-
25 columns (GE Healthcare) according to manufacturer’s guidelines to remove free 
nucleotides. The activity of the final probes was then estimated using a Cerenkov 
counter and a volume equivalent to approximately 500,000cps was added to the pre-
hybridisation solution after the aforementioned membrane-blocking step. The 
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membrane was then hybridised with probe by incubation in this solution overnight at 
42°C with rotation. 
After hybridisation, the membrane was washed twice in 2x SSPE for 15 minutes at 
room temperature before a third wash in pre-warmed 2x SSPE/2% SDS and incubated 
at 65°C for 15 minutes. 
The membrane was then wrapped in saran wrap and exposed to a PhosphoImage screen 
in a cassette before visualising the signal using the Typhoon FLA 9500 and ImageQuant 
software (GE Healthcare). 
For subsequent hybridisation of probes to other targets, the membrane was washed 
twice in 2x SSPE and once with 2x SSPE/2%SDS at 65°C as described above before 
adding the next probe. If two different probes targeted RNAs with similar molecular 
weights then it was necessary to strip the membrane of the first signal before re-probing 
with the second probe. Membrane stripping was performed by washing the membrane 
twice in boiling 0.1x SSC (1x SSC: 150mM NaCl, 15mM sodium citrate) and once with 
SSC/0.1% SDS for 15 minutes. Any radioactive signal present on the membrane was 
assessed using a Geiger counter to ensure the removal of the previous signal before 
hybridising with another probe as described above. 
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2.5 PROTEIN MANIPULATION 
2.5.1 PREPARATION OF HUMAN CELL LYSATE 
Pellets of harvested cells were resuspended in approximately 50µl of lysate buffer per 
10mg of wet cell pellet.  
Lysate buffer was prepared with 50mM Tris/HCl pH 7.4, 130mM NaCl, 2mM MgCl2, 
1mM PMSF, 1% Nonidet P-40, one EDTA-free protease inhibitor tablet (Pierce) and 
was made up in a 10ml final volume before being aliquoted and stored at -20°C.   
Samples were vortexed for 30 seconds and centrifuged at 1000g for 2 minutes to 
remove nuclei and unbroken cells. The supernatant was then transferred to a fresh 
microcentrifuge tube, snap frozen in liquid nitrogen and stored at -80°C. 
Samples with small cell pellets were resuspended in 15-30µl of lysate buffer and 
vortexed, but were not subjected to centrifugation in order to prevent loss of material. 
Instead, 25U Benzonase was added to remove nucleic acids. If any sample for a 
particular experiment needed to be prepared in this way, then all of the samples were 
treated in the same manner (samples prepared in this manner will be designated whole 
cell lysate, whereas samples with nuclei removed by centrifugation will be designated 
cell lysate). Estimation of protein concentration (2.5.3) was always performed prior to 
the addition of Benzonase.   
2.5.2 MITOCHONDRIAL PREPARATION 
Mitochondria were isolated from cells grown in 300cm2 flasks. These were harvested at 
approximately 80% confluency and the resulting pellet was resuspended in 2ml ice-cold 
homogenisation buffer (0.6M mannitol, 10mM Tris pH 7.4 and 1mM EGTA) 
supplemented with 0.1% BSA and 1mM PMSF. The following steps were carried out at 
4°C. The cell suspension was transferred to a glass:Teflon Dounce homogeniser and 
subjected to 15 passes before being centrifuged at 400g for 10 minutes. The supernatant 
was retained in pre-chilled tubes, and the pellet was resuspended in a further 2ml of 
supplemented homogenisation buffer and the homogenisation and centrifugation 
process repeated. The supernatant was again retained and all supernatant tubes were 
centrifuged at 400g for 5 minutes. The supernatants were transferred to new 
microcentrifuge tubes and the mitochondria were pelleted at 11,000g for 10 minutes. 
  53 
The pellet was washed twice in homogenisation buffer lacking BSA and finally 
resuspended in 70-150µl homogenisation buffer. 
To remove cytosolic contamination 1mg of isolated mitochondria were treated with 1µg 
proteinase K on ice for 30 minutes. Digestion was then inhibited by addition of 1mM 
PMSF. 
2.5.3 ESTIMATION OF PROTEIN CONCENTRATION BY BRADFORD ASSAY 
Measurement of protein concentration was performed using the Bradford assay. 
Samples were added to a final volume of 800µl of dH2O (usually 1-2µl of cell lysate or 
mitochondrial preparation) before adding 200µl of Bradford reagent (BioRad) to either 
the lysate, or BSA standard curve samples. The samples were mixed well, then 
incubated for 5 minutes at room temperature before 200µl aliquots of each sample to a 
96 well plate. The absorbance at 595nm of samples was measured on an ELx800 
microplate reader (BioTek). The optical density was used in conjunction with the BSA 
standard curve to calculate the average protein concentration in the test samples. 
2.5.4 SDS-PAGE 
This method allows separation of denatured proteins according to their molecular 
weight. Casting and running of gels was performed using either the Hoefer Mighty 
SmallTM or Bio-Rad Mini-Protean® Tetra Cell system. Gels were cast with resolving 
phases of 12% or 14% polyacrylamide depending on the molecular weight of the 
proteins of interest (see Table 2.4 below). Addition of water above the resolving matrix 
allowed a smooth meniscus to form. This was removed after polymerisation was 
complete and a 3.75% stacking gel was added on top. Samples for SDS-PAGE analysis 
were incubated with sample dissociation buffer (final concentrations: 6.25mM Tris/HCl 
pH 6.8, 2% SDS, 10% glycerol, approximately 0.01% bromophenol blue and 100mM 
DTT) and incubated for 3 minutes at 95°C or 15 minutes at 37°C before loading. SDS-
PAGE was performed in 1x running buffer (192mM glycine, 25mM Tris and 0.1% 
SDS) at 70V through the stacking gel and 150V though the resolving gel when using the 
Hoefer system, or a stable 200V when using the Bio-Rad system. 
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Table 2.4: Reagents and Volumes for SDS-PAGE. 
 
12% resolving 
gel 
14% resolving 
gel 
3.75% stacking 
gel 
30% acryl/bisacrylamide (29:1) 2ml 2.333ml 0.625ml 
3.75M Tris/HCl pH 8.5 0.5ml 0.5ml -- 
0.5M Tris/HCl pH 6.8 -- -- 1.25ml 
dH2O 2.395ml 2.062ml 3.02ml 
10% SDS 50µl 50µl 50µl 
TEMED 5µl 5µl 5µl 
10% APS 50µl 50µl 50µl 
Final Volume 5ml 5ml 5ml 
 
2.5.5 COOMASSIE STAINING 
General Coomassie Brilliant Blue (CBB) staining was used for visualising proteins after 
SDS-PAGE. Typically gels were incubated in CBB stain (45% methanol, 10% acetic 
acid and 0.2% Coomassie Blue R250) for 8 minutes at room temperature with agitation, 
before placing in de-staining solution (45% methanol and 10% acetic acid) for 10 
minutes. The de-staining solution was then replaced with fresh de-staining solution and 
incubated at room temperature for a further 10 minutes or until the background of the 
gel was clear. 
If greater sensitivity was required (as low as 5ng can be detected), InstantBlue 
(Expedeon, ISB1L) stain was used. Gels were washed briefly with water before staining 
with Instant Blue for at least 1 hour.  
If mass spectrometry was to be performed on an excised band then the gel was washed 
3 times for 5 minutes with dH2O and stained for at least 1 hour with SimplyBlueTM 
SafeStain (Life Technologies, LC6060). 
Images of Coomassie-stained gels that had been prepared by any of the methods 
outlined above were acquired using either an Epsom EU-35 scanner or the Bio-Rad 
ChemiDocTM MP system. 
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2.5.6 WESTERN BLOTTING AND IMMUNODETECTION  
To immunodetect proteins separated by SDS-PAGE, they were transferred from the 
polyacrylamide gel to a PVDF membrane (Immobilon-P, Millipore). The gel was 
equilibrated in transfer buffer (192mM glycine, 25mM Tris, 0.02% SDS and 15% 
methanol). The PVDF membrane was activated in 100% methanol for 15 seconds 
before washing in distilled water and then transfer buffer. The gel and membrane were 
placed between double thickness 3MM Whatman filter paper and sponges in a cassette, 
which was placed in the transfer tank (TE22, Hoefer or Mini Trans-BlotTM module, Bio-
Rad). The transfer of proteins from the gel to the membrane was performed at 100V for 
2 hours at 4°C with the Hoefer system, or 100V for 1 hour at 4°C with the Bio-Rad 
system. The PVDF membrane was blocked for 1 hour at room temperature in 5% 
milk/T-TBS (Tris buffered saline with Tween-20: 50mM Tris, 150mM NaCl, 0.05% 
Tween-20), before incubation with primary antibodies. Primary antibodies were 
generally diluted (as indicated by manufacturer) in 5% milk/T-TBS (see Table 2.5 for 
specific antibody dilutions) and incubated with the membrane overnight at 4°C, with 
agitation. The membrane was then washed three times for 10 minutes in T-TBS before 
being incubated with the appropriate HRP-coupled secondary antibody (Dako 
Cytomation, Table 2.6) for 1 hour at room temperature. After a further 5 washes, each 
of 10 minutes in T-TBS, detection was carried out using either ECL+, ECL Prime (both 
GE Healthcare) or the Immun-StarTM WesternCTM kit (Bio-Rad) according to 
manufacturer’s instructions. Fluorescent signals produced by ECL+ were visualised on 
the STORM PhosphorImager (Molecular Dynamics) and analysed using ImageQuant 
software (Molecular Dynamics). Chemiluminescent signals were visualised using the 
ChemiDocTM MP system (Bio-Rad).  
Table 2.5: Primary Antibodies Used for Immunoblotting. 
Antibodies Type Dilution Company 
α-AIF Rabbit Polyclonal 1:1000 NEB (4642S) 
α-AURKAIP1 Rabbit Polyclonal 1:1000 
Produced as detailed in Chapter 3 
(Eurogentech) 
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α-AURKAIP1 
(Sigma) 
Rabbit 
Polyclonal 1:1000 
Sigma Aldrich (Prestige/Atlas) 
HPA031821 
α-β actin Mouse Monoclonal 1:10000 Sigma Aldrich (A1978) 
α-COXI Mouse  Monoclonal 1:1000 
Abcam (Mitosciences MS404) 
ab14705 
α-COXII Mouse Monoclonal 1:1000 
Abcam (Mitosciences MS405) 
ab110258 
α-DAP3 Mouse Monoclonal 1:1000 Abcam (ab11928) 
α-FLAG Mouse Monoclonal 1:2000 Sigma Aldrich (F1804) 
α-GDH Rabbit Polyclonal 1:1000 Custom antibody (Eurogentech) 
α-MRPL3 Goat Polyclonal 1:1000 Abcam (ab39268) 
α-MRPL11 Rabbit Monoclonal 1:1000 NEB (2066S) (XP, D68F2)  
α-MRPL12 Rabbit Polyclonal  1:1000 Custom antibody (Eurogentech) 
α-MRPS18B Rabbit Polyclonal 1:1000 ProteinTech (16139-1-AP) 
α-MRPS22 Rabbit Polyclonal 1:1000 ProteinTech (10984-1-AP) 
α-mtPAP 
(mouse) 
Mouse 
Monoclonal 
Co-IP 
only GeneTex (GTX70156) 
α-mtPAP (rabbit) Rabbit Polyclonal 1:1000 
Abcam (Epitomics S3295)     
ab137643 
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α-ND1 Rabbit Polyclonal 1:1000 Gift from A. Lombes 
α-NDUFA9 Mouse Monoclonal 1:1000 
Abcam (Mitosciences MS111) 
ab14713 
α-p32 (rabbit) 
(GC1qR) 
Rabbit 
Monoclonal 1:1000 Abcam (ab131284) 
α-p32 (mouse) 
(GC1qR) 
Mouse 
Monoclonal 1:1000 Abcam (ab24733) 
α-Porin 
(VDAC1) 
Mouse 
Monoclonal 1:10000 
Abcam (Mitosciences MSA03) 
ab14734 
α-Tom20 Rabbit Polyclonal 1:1000 Santa Cruz Biotechnology (Sc-17764) 
α-SDH-70 Mouse Monoclonal 1:5000 
Abcam (Mitoscience MS204)  
ab14715 
 
Table 2.6: HRP-Conjugated Secondary Antibodies Used for Immunodetection.  
Antibody Type Dilution Company 
α-Mouse secondary Rabbit Polyclonal 1:2000 Dako Cytomation P0260 
α-Rabbit secondary Swine Polyclonal 1:3000 Dako Cytomation P0339 
α-Goat secondary Rabbit Polyclonal 1:2000 Dako Cytomation P0449 
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CHAPTER 3:  
GENERATION OF ANALYTICAL TOOLS FOR 
CHARACTERISATION OF AURKAIP1 
3.1 INTRODUCTION 
In order to study the role of AURKAIP1 in human mitochondrial gene expression, 
several tools were required. The generation of the majority of the required tools will be 
described in this chapter. 
Due to a lack of available commercial antibodies, custom antibodies that would 
recognise endogenous AURKAIP1 were required. In order to produce these, 
recombinant protein corresponding to the predicted mature form of AURKAIP1 needed 
to be expressed in bacteria and then purified, to be used as an antigen.  
To achieve this goal, it was necessary to design primers to allow amplification of the 
designated sequence of the open reading frame that would correspond with the mature 
form of AURKAIP1. AURKAIP1 has three validated transcript variants that have 
different 5’ UTRs produced by alternate splicing. However, there is only one common 
open reading frame (consensus CDS: CCDS25.1), therefore all nucleotide numbers 
relating to the AURKAIP1 gene from now on will be given with reference to the start of 
the open reading frame.   
AURKAIP1 was predicted to have an N-terminal mitochondrial targeting sequence by 
the Target P 1.1 server (Emanuelsson et al., 2007; 2000). The reliability class (RC) 
value given for the prediction of an N-terminal mitochondrial targeting sequence for 
AURKAIP1 was 2 out of a classification scale of 5, with 1 being the strongest 
prediction. Therefore, this was a strong predictor, so the program was also used to 
predict if there was a cleavage site of the potential mitochondrial targeting sequence 
(Nielsen et al., 1997) or whether this was left as part of the imported protein. The 
predicted cleaved pre-sequence length (TPlen) was given as 76 amino acids, which 
suggests that the mature AURKAIP1 protein would consist of amino acids 77-199. 
However, the MitoProt II server (Claros and Vincens, 1996) predicts the cleavage site to 
be at position 55, removing 54 amino acids upon import. Despite predicting a different 
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cleavage site, the MitoProt II analysis is nevertheless strongly indicative of 
mitochondrial localisation for AURKAIP1 (probability 0.9771) (Claros and Vincens, 
1996). In addition, other localisation predictors (that do not allow cleavage site 
prediction) also suggest mitochondrial localisation e.g. Predotar (probability 0.78) 
(Small et al., 2004), pTARGET (probability 0.751) (Guda, 2006) and MultiLoc2 
(probability 0.96 low res, 0.98 high res) (Blum et al., 2009). The latter is particularly 
interesting as MultiLoc2 also gives a probability for nuclear localisation of 0.01 using 
either resolution and is claimed to outperform other prediction programs (Blum et al., 
2009). Together, the results from several localisation prediction programs strongly 
predict AURKAIP1 to be a mitochondrial, rather than nuclear protein. 
The presence of an N-terminal mitochondrial targeting sequence could be problematic 
for expressing the recombinant protein in bacteria because prokaryotes do not possess 
mitochondria, and therefore could not process the full length AURKAIP1 protein to the 
mature form by cleaving the mitochondrial targeting sequence. Thus, expressing full-
length recombinant AURKAIP1 protein would be inappropriate as the additional 
mitochondrial targeting sequence could cause misfolding relative to mature 
AURKAIP1. Additionally, the use of full length AURKAIP1 as an antigen for antibody 
production could potentially raise antibodies to antigens that would not be present in the 
mature protein in human cells. To minimise this possibility, it was important to design 
primers that would only amplify the section of the AURKAIP1 gene that would 
correspond to the mature protein.  
The prediction of the TargetP program suggests that mature AURKAIP1 would be 
missing a 76 amino acid N-terminal mitochondrial targeting sequence (Emanuelsson et 
al., 2007; Nielsen et al., 1997). This prediction suggested that the ideal primers would 
allow for amplification of nucleotides 229-600 of the AURKAIP1 open reading frame, 
which correspond to amino acids 77-199 of the protein. However, the size of the 
cleaved N-terminal targeting sequence predicted by the MitoProt II program was 54 
amino acids (Claros and Vincens, 1996). These predictions were therefore used as a 
starting point to aid primer design, but other considerations also had to be taken into 
account. For example, designing primers to amplify the DNA from position 229 
(corresponding to Target P prediction) would have been problematic since the 
nucleotide sequence immediately downstream is very G-C rich (78% for an 18 
nucleotide primer) and would therefore produce a primer with a very high melting 
  60 
temperature. G-C rich regions have been shown to be difficult to amplify and generally 
primers with 40-60% G-C content are widely used (Mitsuhashi, 1996). Therefore, the 
sequence of the AURKAIP1 open reading frame that corresponded to the region 
between the two predicted cleavage sites was studied to find a sequence that was 
suitably balanced between G-C and A-T content as to allow for the design of primers 
more likely to produce successful amplification. The final primers were designed to 
allow amplification of nucleotides 199-600 of the AURKAIP1 open reading frame, 
which corresponds to amino acids 67-199 of the protein.  
The mature version of AURKAIP1 needed to be expressed in bacteria and purified in 
order to be used as an antigen for antibody production and subsequently for affinity 
purification. The speedy 28-day protocol of antibody production offered by 
Eurogentech was selected for this purpose, as it uses a novel adjuvant that allows for 
faster antibody production. This protocol claimed to produce antibodies with 
comparable titres and affinities to the 87-day procedures using Freund’s adjuvant. The 
selected protocol was used in rabbits to produce polyclonal antibodies to the mature 
AURKAIP1 protein. Using the mature protein as an antigen would produce antibodies 
that would be more likely to recognise the endogenous protein than an antibody raised 
against a single small peptide due to the number of potential epitopes being much 
greater. This should also increase the likelihood that the polyclonal antibody would be 
appropriate for immunoprecipitation in addition to western blotting. 
Since overexpression of the mature protein in bacteria and subsequent purification of 
the mature protein was necessary for antibody production, an appropriate system needed 
to be selected to achieve this. The Glutathione S-Transferase (GST) Gene Fusion 
system (Amersham) is a versatile system for the expression and purification of protein 
produced in E. coli. There are several pGEX vectors all of which allow IPTG inducible 
expression of fusion proteins with a GST moiety at the N-terminus, and the protein of 
interest at the C-terminus. This N-terminal tag was an important factor for several 
reasons. First, the addition of the GST tag improves protein solubility, and soluble 
protein was required for both antibody production and subsequent affinity purification. 
Second, GST fusion proteins can be purified via affinity chromatography using 
immobilised glutathione, which is a gentle purification method that maximises the 
preservation of protein antigenicity. Finally, the GST coding sequence is situated 
upstream of the multiple cloning site of the pGEX vectors, which means that the 
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inserted gene must be in-frame, but does not require a start codon. As mentioned 
previously, primers were designed to allow expression of mature AURKAIP1, so they 
did not include the start codon.   
Of the available pGEX vectors, pGEX-6P-1 was selected for the additional benefits of 
the PreScission Protease site inserted between the GST coding region and the multiple 
cloning site. The PreScission protease site allows the most efficient method for 
purification as the site specific cleavage causes immobilisation of the protease on the 
column, thus the protease and GST tag are removed in the same step. The protease 
allows for elution at 4°C as it is highly active at low temperatures. This aids in 
protecting the integrity of the target protein.  
The selection of pGEX-6P-1 as a vector influenced the design of primers as it was 
vitally important to ensure that the amplified product would be in-frame once cloned 
into the vector. Primers were designed to allow incorporation of a BamHI restriction site 
upstream of the designated mature AURKAIP1 sequence and a XhoI restriction site 
downstream. The addition of these restriction sites would allow the mature AURKAIP1 
gene to be cloned into the multiple cloning site of pGEX-6P-1, which could then be 
used to subsequently transform a variety of E. coli strains. 
AURKAIP1 has previously been described as a nuclear protein in experiments using 
cell lines that overexpressed N-terminal FLAG-tagged AURKAIP1 (FLAG-
AURKAIP1) (Lim et al., 2007; Kiat, 2002). As AURKAIP1 is predicted to have a 
mitochondrial targeting sequence, it is probable that the N-terminal FLAG tag interfered 
causing mislocalisation of AURKAIP1 to the nucleus. A C-terminal FLAG tag would 
not interfere with the mitochondrial targeting sequence and therefore a cell line capable 
of expressing AURKAIP1 with a C terminal FLAG tag (AURKAIP1-FLAG) could be 
used to confirm whether or not there is mitochondrial localisation of AURKAIP1.  
To this end, primers were designed to allow amplification of the full length AURKAIP1 
open reading frame with the addition of a FLAG coding sequence at the 3’ end. The 
inducible expression vector pcDNATM5/FRT/TO was selected to clone the AURKAIP1-
FLAG insert into. The advantage of using pcDNATM5/FRT/TO is that upon transfection 
of a Flp-InTMTRexTM mammalian host cell line in tandem with the pOG44 Flp 
recombinase expression plasmid, the gene of interest is stably integrated into a defined 
site in the host genome. This integration is Flp recombinase dependent hence the 
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requirement for transient expression from the pOG44 vector. This system prevents the 
gene of interest being inserted randomly into the host genome. Random insertion can be 
problematic if for example the integration disrupts another open reading frame, 
inactivates an enhancer region, or activates an oncogene. If such integration were to 
occur, any phenotype seen in the host cell line post transfection could be wrongly 
attributed to the expression of the gene of interest. Thus the use of pcDNATM5/FRT/TO 
with a Flp-InTMTRexTM host cell line negated this potential problem. Further, the 
pcDNATM5/FRT/TO vector has a hybrid human cytomegalovirus (CMV)/TetO2 
promoter, which allows tetracycline regulated expression of the protein of interest. 
Unlike the pGEX-6P-1 vector, pcDNATM5/FRT/TO does not encode a protein tag to 
produce a fusion protein. Therefore the sequence encoding the C-Terminal FLAG tag 
was incorporated into the sequence of the reverse primer. Since this is a mammalian 
expression system, mitochondrial targeting and import would occur and so it was 
important to clone the full length AURKAIP1 open reading frame. Therefore the 
forward primer was designed to include the start codon of AURKAIP1 with an upstream 
HindIII restriction site. The reverse primer was designed to be complimentary to the 3’ 
end of the open reading frame immediately upstream of the stop codon. The stop codon 
sequence was removed to allow read-through of the inserted FLAG sequence. A stop 
codon was incorporated downstream of the FLAG sequence followed by a XhoI site. 
These restriction sites were chosen because HindIII and XhoI are present in the 
appropriate positions in the multiple cloning site of pcDNATM5/FRT/TO, facilitating 
insertion of the AURKAIP1-FLAG insert in the correct orientation.    
Generation of a stable inducible AURKAIP-FLAG expressing cell line would also 
allow the flexibility of using anti-FLAG antibodies for western blot detection or 
immunoprecipitation. Further, overexpression of AURKAIP1 would facilitate validation 
of any antibodies against endogenous anti-AURKAIP1.  
The generation of the tools described above is detailed in the next section. However, 
since this chapter is solely concerned with generation and development of tools/methods 
the results and the iterative modifications to improve the data will be presented together 
under a single heading of ‘Method Development’. 
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3.2 METHOD DEVELOPMENT 
3.2.1 PRODUCING AURKAIP1 GENE CONSTRUCTS 
3.2.1.1 PRIMERS AND PCR CONDITIONS FOR PRODUCTION OF INSERTS 
Primer pairs were designed to allow amplification of the open reading frame of 
AURKAIP1 with a C-terminal FLAG tag (henceforth designated AURKAIP1-FLAG 
insert) or to allow amplification of the open reading frame of AURKAIP1 with a 5’ 
deletion of 198 nucleotides (henceforth designated truncated AURKAIP1 insert).  
Table 3.1: Primers Used for the Generation of AURKAIP1 Constructs. 
Primer Name Sequence (5’ -> 3’) Restriction Site Tm 
AURKAIP1 
For 
(pcDNATM5) 
5’-TACTATAAGCTTCCACAGACCATGCTCCTG HindIII 58.4°C 
AURKAIP1 
Rev-FLAG 
(pcDNATM5) 
5’-
ATACTACTCGAGCTACTTATCGTCGTCATCCTTGTAA
TCTGCCCGCAGGTAGATCTTGG 
XhoI 58.4°C 
AURKAIP1 
For 
(pGEX6P1) 
5’-TACTATGGATCCAGGAAGATGTCCGTCAGC BamHI 56.3°C 
AURKAIP1 
Rev 
(pGEX6P1) 
5’-ATACTACTCGAGCGGATCACAGCAGCAACG XhoI 58.4°C 
Table shows sequences of primers used for generation of pcDNATM5/FRT/TO/AURKAIP1-FLAG and 
pGEX-6P-1/AURKAIP1 constructs. Key: bold = restriction site, green = start codon, red = stop codon, 
yellow = FLAG tag coding sequence and underline = initial annealing portion of primer. TM is the 
melting temperature of the underlined sequence. Melting temperatures were calculated using the 
OligoCalc online oligonucleotide properties calculator (Kibbe 2007). NCBI Reference Sequence: 
AURKAIP1 = NM_001127229.1. 
 
PCR was performed as described in 2.3.2. Initial attempts used cDNA from HEK293 
cells as a template, which was generated by reverse transcription (2.4.2) of RNA using 
oligo dT primers. All initial PCR reactions were performed using an annealing 
temperature of 52°C. An aliquot of 4µl of the final PCR reactions were then subjected 
to electrophoresis through a 1% agarose gel containing 0.2µg/ml ethidium bromide and 
visualised under UV light to assess the amount and purity of the products. These 
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conditions were unsuccessful in producing a product for AURKAIP1, although a 
product was produced using primers specific to a fragment of the SLMO2 gene, which 
had been used as a positive PCR control (Figure 3.1). The SLMO2 primers also acted as 
a positive control to confirm that the reverse transcription had produced amplifiable 
cDNA.  
 
Figure 3.1: Initial PCR reactions for 
AURKAIP1 inserts. PCR was carried out as 
described in Chapter 2.2.1 using an annealing 
temperature of 52°C and cDNA from HEK293 
cells as a template for both sets of AURKAIP1 
primers (lane 2=truncated AURKAIP1 primers, 
lane 4=AURKAIP1-FLAG primers). SLMO2-
FLAG primers were used as a positive control 
(lane 6). Reactions without template cDNA 
added were used as negative controls (lanes 3, 5 
and 7). * denotes size of the SLMO2-FLAG 
positive control insert. 
  
 
As mentioned, these initial PCR attempts were carried out with an annealing 
temperature of 52°C. Reducing the annealing temperature to 50°C still failed to 
generate a product for AURKAIP1. The SLMO2 primers and both sets of AURKAIP1 
primers had similar melting temperatures, so it seemed unlikely that the annealing 
temperature was the problem. However, it was possible that the reverse transcription 
had not produced enough AURKAIP1 cDNA to allow for amplification, whereas there 
was sufficient SLMO2 cDNA. This would account for the success of the positive 
control as seen in Figure 3.1. 
To address this problem, an AURKAIP1 full length I.M.A.G.E clone (IMAGE ID 
5931927/AL50 K6 (M13F)) was instead used as a template for the PCR reactions. The 
bacteria containing the AURKAIP1 I.M.A.G.E clone were cultured in 5ml LB with 
50µg/ml chloramphenicol overnight at 37°C to amplify the plasmid copy number. The 
plasmid DNA was then extracted by miniprep (2.3.1) and purified by phenol-
chloroform extraction and ethanol precipitation (2.3.3). The concentration of plasmid 
DNA was measured spectrophotometrically using the Nanodrop (2.3.4) and 
approximately 75ng of plasmid DNA was used as a template for the subsequent 
AURKAIP1 PCR reactions. These conditions did produce a product of around the 
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expected 657bp for the AURKAIP1-FLAG PCR (Figure 3.2A) and 466bp for the 
truncated AURKAIP1 PCR (Figure 3.2B). 
 
Several annealing temperatures from 45°C to 55°C were tested in order to improve the 
yield and purity of the PCR products. However, the best annealing temperature for both 
the AURKAIP1-FLAG insert and the truncated AURKAIP1 insert was found to be 
50°C. In both cases the PCR products were not clean enough to proceed with 
immediately. Though the band of the expected size was by far the most prominent in 
both cases, both PCR products had additional bands of greater size (Figure 3.2).  
Therefore the band of approximately the correct size (657bp for AURKAIP1-FLAG) 
was excised from the gel (Figure 3.2C) and the DNA was extracted from the gel using 
the QIAquick® Gel Extraction Kit (QIAGEN). Though only the gel excision of the 
AURKAIP1-FLAG insert is shown in Figure 3.2, the same procedure was carried out 
for the truncated AURKAIP1 insert. 
3.2.1.2 CONFIRMATION OF CORRECT CONSTRUCTS BY RESTRICTION DIGESTS 
The purified PCR products (AURKAIP1-FLAG insert and truncated AURKAIP1 insert) 
were then subjected to restriction digest reactions (2.3.5). As described earlier, both sets 
of primers had been designed in such a way as to incorporate restriction sites towards 
the termini of the PCR products (Table 3.1) to facilitate compatibility with the digested 
recipient vector. 
Figure 3.2: Generation of AURKAIP1 PCR Products for Insertion into pGEX-6P-1 and 
pcDNATM5/FRT/TO Vectors. A) PCR was performed as described in 2.2.1 with an annealing 
temperature of 50°C and using AURKAIP1 I.M.A.G.E clone plasmid DNA as a template. An aliquot 
of 4µl was loaded and separated through a 1% agarose gel. Lane 1 = 1kb DNA ladder, lane 2 = 
truncated AURKAIP1 PCR reaction and lane 3 = negative control reaction lacking addition of 
template. B) The same procedure as in A, but using primers designed to amplify full length AURKAIP1 
gene either with (lane 4) or without (lane 2) a C-Terminal FLAG tag. Negative control reactions that 
lacked the addition of the AURKAIP1 plasmid DNA were loaded in lanes 3 and 5 respectively. C) The 
bands corresponding to the expected size of the insert were excised from the gel in B. 
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In the case of the vectors, double restriction digests were always followed immediately 
by dephosphorylation by adding 2µl 1M Tris pH 9.4, 2µl 10% SDS and 0.5µl alkaline 
phosphatase followed by incubation at 37°C for 30 minutes. This dephosphorylation 
step is necessary to prevent the empty vector from re-ligating. The ligation reaction 
requires a 5’ phosphate and a 3’ hydroxyl group; therefore, removing the phosphate 
group from the vector encourages ligation of the insert into the vector as only the insert 
has the necessary 5’ phosphate group. After the dephosphorylation incubation, the 
volume was made up to 50µl with ddH2O and the mixture was then subjected to phenol-
chloroform extraction and ethanol precipitation (2.3.3) in order to isolate the DNA and 
remove the enzymes. 
The same phenol-chloroform extraction and ethanol precipitation was carried out on the 
truncated AURKAIP1 insert after double digestion because the BamHI restriction 
endonuclease cannot be heat inactivated and therefore must be removed before 
proceeding to ligation. However HindIII and XhoI can be heat inactivated at 80°C and 
65°C for 20 minutes respectively. Therefore the AURKAIP1-FLAG insert was 
subjected to incubation at 80°C for 20 minutes to inactivate the restriction enzymes. 
Though the pcDNATM5/FRT/TO vector was digested with the same enzymes, phenol-
chloroform extraction and ethanol precipitation was still required since alkaline 
phosphatase cannot be heat inactivated. 
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3.2.1.3 LIGATION 
Once the vectors had been digested, dephosphorylated and purified and the inserts had 
been digested and purified by gel extraction, both were ready for use in the ligation 
reaction. DNA concentrations were determined using the Nanodrop (2.3.4) and the 
following formula was used to determine the relative amounts of vector and insert to be 
used: 
             Vector (ng) x size of insert (kb) x insert:vector molar ratio = insert (ng) 
                        Size of vector (kb) 
The insert to vector molar ratio used was 3:1 and the amount of vector used per ligation 
reaction was always 50ng, therefore: 
AURKAIP1-FLAG construct:                             Truncated AURKAIP1 construct:  
50 x 0.6 x 3 = 17.6ng of insert                             50 x 0.4 x 3 = 12ng of insert  
   5.1    4.9 
The ligation reaction was performed in 10µl total volume containing 1µl 10x T4 ligase 
buffer, 0.5µl ATP, 1µl T4 ligase and the calculated volumes of vector, insert and 
ddH2O. A negative control was always included that lacked the addition of the insert to 
the reaction. This control was important to ensure the effectiveness of vector 
dephosphorylation, as no ligation should occur in the absence of a 5’ phosphate. The 
ligation reactions were incubated at 16°C overnight before being used to transform 
Bioline α-select chemically competent cells (2.2.2), which were subsequently incubated 
overnight at 37°C on LB-agar plates containing 100µg/ml ampicillin.  
If the number of colonies on the control plate was low (<4) and at least a 3-fold increase 
in colony number seen on the experimental plates, then up to 6 clones were selected for 
5ml overnight culture in LBamp media to amplify plasmid copy number. Plasmid DNA 
was then isolated (2.3.1) and DNA concentrations measured by Nanodrop (2.3.4), 
before confirming quality and quantity of isolated plasmid DNA by electrophoresis. 
Several clones were then selected to undergo double restriction digests to test whether 
the ligation had been successful. Ligation of the AURKAIP1-FLAG insert into the 
pcDNATM5/FRT/TO vector was successful (Figure 3.3B) because the vector and insert 
can both be seen when digested plasmid DNA was separated by agarose gel 
electrophoresis. 
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3.2.1.4 OVERCOMING TRUNCATED AURKAP1 PGEX-6P-1 CLONING PROBLEMS 
The previously described methodology was immediately successful for the production 
of the pcDNATM5/FRT/TO/AURKAIP1-FLAG construct (Figure 3.3B), but despite 
several attempts, these methods could not produce successful ligation of the truncated 
AURKAIP1 construct in pGEX-6P-1. Further attempts at ligation using an increased 
insert:vector molar ratio of 8:1 were still unsuccessful at producing the desired 
construct. 
To address this problem it was first important to ensure that the restriction 
endonucleases were digesting the vector and insert correctly. Digestion of the pGEX-
6P-1 vector was confirmed by subjecting double digested vector to agarose gel 
electrophoresis and visualising a single band of approximately 5kb on the gel (Figure 
3.4). This showed that the vector had been successfully linearised. However, 
linearisation could have occurred if only one of the restriction endonucleases were 
active. Since XhoI was also used in the successful generation of the 
pcDNATM5/FRT/TO/AURKAIP1-FLAG construct, it was only necessary to confirm the 
activity of the BamHI enzyme. A restriction digest reaction using only the BamHI 
Figure 3.3: Successful cloning of pcDNATM5/FRT/TO/AURKAIP1-FLAG. A) An aliquot of 
digested pcDNATM5/FRT/TO was subjected to 0.8% agaroge gel electrophoresis B) Vector from A and 
gel extracted insert (Figure 3.2C) were ligated and used to transform α-select cells. Several clones 
were selected for cells transformed with either the FLAG tagged (lanes 2 and 3) or non-FLAG-tagged 
(lanes 4 and 5) construct. Clones were cultured at 37°C in LBamp and plasmid DNA was extracted by 
miniprep. Plasmid DNA from the clones were digested with HindIII and XhoI and an aliquot was 
subjected to 0.8% agarose gel electrophoresis.    
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enzyme still resulted in successful linearisation of the vector. This proved that the 
BamHI enzyme used was active.  
 
 
 
Figure 3.4: Confirmation of pGEX-6P-1 vector 
linearisation. An aliquot of isolated pGEX-6P-1 vector 
(lane 2) or pGEX-6P-1 vector digested with BamHI and 
XhoI (lane 3) were subjected to separation through a 0.8% 
agaroge gel. 
 
 
 
Since each of the restriction enzymes were confirmed to linearise the vector, it was 
more probable that the problem was with the insert. Though there were nucleotides 
added to the primers downstream of the restriction sites in order to allow endonuclease 
activity, it was possible that they were insufficient to allow for effective digestion of the 
inserts. As described earlier, linearisation of the vector was easy to confirm via 
electrophoresis, but it was impossible to confirm digestion of the insert in the same 
manner. The few nucleotides that should have been removed from the ends of the insert 
would have been undetectable by electrophoresis. This reasoning led to the use of the 
PCR-Script Amp cloning kit (Agilent technologies), which allows any blunt ended PCR 
product to be cloned into the PCR-Script Amp SK(+) vector. Cloning the truncated 
AURKAIP1 insert into this vector may improve endonuclease activity and would allow 
visual confirmation of insert digestion by electrophoresis.  
The truncated AURKAIP1 insert was cloned into the PCR-Script Amp SK(+) vector by 
adding a 100ng aliquot of the PCR product to a 10µl ligation reaction containing 1x 
PCR Script reaction buffer, 0.5mM rATP, 10ng pre-digested PCR-Script Amp SK(+) 
vector, 0.5U/µl SrfI and 0.4U/µl T4 DNA ligase. The reaction was incubated for 1 hour 
at room temperature before heating at 65°C for 10 minutes. A 2µl aliquot of the reaction 
was then used to transform 40µl of Bioline α-select chemically competent cells (2.2.2). 
Colonies that were transformed by recombinant plasmid were selected by blue/white 
colour screening after overnight incubation at 37°C on LB-ampicillin agar plates spread 
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with 100µl of 10mM IPTG and 100µl of 2% X-gal 30 minutes prior to plating the 
transformation reaction.  
Blue/white colony screening is possible due to the presence of a lacZ’ gene in the PCR-
Script Amp SK(+) vector which encodes the α-fragment of β-galactosidase. β-
galactosidase is an enzyme that can catalyse X-GAL to 5-bromo-4-chloro-indoxyl, 
which then spontaneously dimerises and oxidises to form 5,5'-dibromo-4,4'-dichloro-
indigo, which is a blue insoluble pigment. Bacterial colonies with functional β-
galactosidase will therefore appear blue when grown on agar plates spread with X-GAL. 
Several E.coli strains (including α-select cells) express a mutated form of β-
galactosidase, which has an N-terminal deletion and is inactive. Colonies of these 
bacteria will appear white when grown on agar plates spread with X-GAL due to a lack 
of β galactosidase activity. The mutated β-galactosidase can have its function restored 
with expression of the α-fragment, therefore α-select cells transformed with the PCR-
Script Amp SK(+) vector would have active β-galactosidase activity. However, since 
the multiple cloning site of the PCR-Script Amp SK(+) vector is situated within the 
LacZ’ gene, ligation of an insert would prevent the expression of the α-fragment of β-
galactosidase. 
White colonies from the transformation were selected on the basis that they must have 
been transformed with the PCR-Script Amp SK(+) vector, as this has conferred 
ampicillin resistance, and that the PCR-Script Amp SK(+) vector must have the insert in 
the multiple cloning site because there was no β-galactosidase activity. These white 
colonies were cultured in 5ml LBamp overnight at 37°C in order to amplify the plasmid 
copy number. Plasmid DNA was then isolated from bacterial lysate (2.3.1) and digested 
with BamHI and XhoI. A 2µg aliquot of the digested construct was subjected to 
electrophoresis through a 1% agarose gel with 0.2µg/ml ethidium bromide. This 
technique confirmed that both restriction enzymes had correctly digested the insert 
because two bands were clearly visible corresponding to the size of the vector and the 
size of the insert respectively. Only one band with a size consistent with the sum of the 
sizes of vector and insert would have been seen if only one restriction enzyme had 
successfully cut the plasmid DNA. 
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Figure 3.5: Generating Correctly Digested Truncated AURKAIP1 Insert via Cloning into PCR-
Script Amp SK(+). A) Two bacterial colonies that were identified as being transformed with PCR-Script 
Amp SK(+)/truncated AURKAIP1 by blue/white colour colony screening were cultured in LB amp 
overnight at 37°C. Plasmid DNA was isolated from the bacterial lysate and subjected to double restriction 
digest with BamHI and XhoI. An aliquot of the digestion reactions from two clones were each loaded on a 
1.5% GTG low-melt agarose gel (lanes 2 and 3 respectively). B) the bands corresponding to the truncated 
AURKAIP1 insert were excised from the gel for use in subsequent ligation reactions. 
 
Correctly digested pGEX-6P-1 vector and truncated AURKAIP1 insert, as confirmed by 
electrophoresis were excised and extracted from their respective gels using the 
QIAquick® Gel Extraction Kit. Further attempts to ligate the vector and insert and 
subsequently transform α-select cells were carried out. Though some colonies grew on 
the experimental LB-ampicillin agar plates, plasmid DNA isolation and double digests 
of all colonies from several ligation and transformation attempts failed to show any 
evidence of successful construct production.  
To overcome this problem, an in-gel ligation reaction was used. The two different 
clones of the truncated AURKAIP1-PCR-Script construct were digested with BamHI 
and XhoI before a 2µg aliquot was subjected to electrophoresis through a 1.5% GTG 
low melt agarose gel (Figure 3.5A). The insert was then excised from the gel (Figure 
3.5B) and re-melted by placing at 68°C for 10 minutes. The re-melted gel was then 
placed at 37°C and an extra 10µl of dH2O was added to prevent re-formation of the gel. 
The ligation reaction was prepared in a final volume of 25µl with 9µl 10mM Tris-HCL 
pH 7.5, 2.5µl 10x T4 DNA Ligation buffer, 0.5µl vector, 0.5µl T4 DNA Ligase and 
12.5µl of re-melted agarose gel containing insert. The reaction was mixed and incubated 
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at room temperature for 3 hours. The ligation reaction was then re-melted at 68°C for 10 
minutes and a 2µl aliquot was used to transform α-select cells as described previously. 
After overnight culture at 37°C on LB-ampicillin plates there were zero colonies on the 
control plate (from ligation reaction lacking insert), three colonies from the 
transformation with the truncated AURKAIP1 clone 1 ligation and 15 colonies from the 
transformation with clone 2. Each of the 3 colonies from the clone 1 plate and 5 
colonies from the clone 2 plate were cultured in 5ml LBamp overnight at 37°C and had 
plasmid DNA isolated by miniprep (2.3.1). Plasmid DNA from each colony was then 
double digested before an aliquot of each digested plasmid was subjected to 
electrophoresis through a 1% agarose gel with 0.2µg/ml ethidium bromide (Figure 3.6). 
The results show that two truncated AURKAIP1 pGEX-6P-1 clones (clones 3 and 4 
from ligation with the insert from truncated AURKAIP1-PCR Script clone 2) were 
successfully produced (Figure 3.6, lanes 7 and 8). 
 
 
 
Figure 3.6: Successful Generation of 
pGEX-6P-1/truncated AURKAIP1 
constructs. 
 Transformed colonies from ligation 
reactions performed with digested 
pGEX-6P-1 vector and either digested 
PCR-Script/AURKAIP1 clone 1 
(Figure 3.5B lane 2) or clone 2 
(Figure 3.5B lane 3) insert were 
selected and each cultured at 37°C in 
LBamp overnight. Plasmid DNA was 
isolated from each clone and 
subjected to 1% agarose gel 
electrophoresis (lower panel). An 
aliquot of plasmid DNA from each 
clone was subjected to double 
restriction digest with BamHI and 
XhoI before separation through a 1% 
agarose gel (upper panel) 
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3.2.2 EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEIN 
FROM BACTERIA 
The purpose of generating the truncated AURKAIP1-pGEX-6P-1 construct was to 
allow expression of the mature form of the AURKAIP1 protein in bacteria for 
purification and antibody production. To this end, the plasmid construct was isolated 
from the transformed α-select cells and used to transform Rosetta cells. Rosetta is a 
strain of E.coli derived from BL21 cells. These cells include expression of additional 
tRNAs that are rare in bacteria, therefore allowing expression of mammalian proteins 
that would not usually be able to be expressed in bacteria. The AURKAIP1 gene in 
pGEX-6P-1 is under the control of a T7 promoter, which allowed IPTG induced 
expression of the GST-AURKAIP1 fusion protein. 
Rosetta cells transformed with the truncated AURKAIP1-pGEX-6P-1 construct were 
cultured overnight at 37°C with aeration in 5ml LBamp. The overnight culture was then 
added to 500ml LB with appropriate antibiotics and grown at 37°C until OD600 of 
between 0.4 and 0.6 was achieved. IPTG (1mM) was then added to induce the 
expression of the GST-AURKAIP1 fusion protein and the cultures were incubated for a 
further 4 hours at 37°C. Aliquots of 5ml were taken to represent the cells both before 
(uninduced) and after (induced) the IPTG treatment. The cells in these smaller aliquots 
were pelleted and lysed with cell lytic B (Sigma). After lysis, aliquots of uninduced and 
induced cells were saved before insoluble and soluble proteins from the induced 
samples were separated by centrifugation. Finally representative samples of uninduced, 
induced, soluble and insoluble fractions were separated on a 12% polyacrylamide gel 
and stained with Coomassie Blue to assess expression and solubility of the protein.  
Many iterations of the above protocol were used during experiments as the initial 
method failed to produce any soluble protein. Incubation at 37°C for 4 hours following 
IPTG induction produced only insoluble GST-AURKAIP1 fusion protein (Figure 3.7C). 
It is commonly found that reducing the incubation temperature post-induction can 
improve the solubility of expressed proteins in bacteria. Therefore the protocol was 
amended to incubate at 16°C for either 6 hours (Figure 3.7A) or overnight (Figure 3.7B) 
post IPTG induction. These conditions failed to produce any noticeable induction of the 
GST-AURKAIP1 fusion protein. It seemed that an incubation temperature of 16°C was 
insufficient to allow expression, but incubation at 37°C caused the packaging of the 
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expressed fusion protein into inclusion bodies. Therefore a post-IPTG induction 
temperature of 23°C was tested to try to encourage soluble expression of the fusion 
protein. However, though expression of the fusion protein was detectable, it could only 
be detected in the insoluble fraction (Figure 3.7D).     
 
Figure 3.7: Expression of GST-AURKAIP1 Fusion Protein in Rosetta Cells. Rosetta cells 
transformed with the pGEX-6P-1/truncated AURKAIP1 plasmid were cultured to an OD of 0.4-0.6 
before being induced with IPTG followed by incubation at 16°C for 6 hours (A), 16°C overnight (B), 
37°C for 4 hours (C) or 23°C overnight (D). Lysate from uninduced cells (U, lanes 1), induced cells (I, 
lanes 2), soluble fraction of induced cells (Sol, lanes 3) and the insoluble fraction of induced cells (Insol, 
lanes 4) were subjected to SDS-PAGE through 12% polyacrylamide gels and stained with Coomassie 
Blue. * Denotes position of the GST-AURKAIP1 fusion protein. 
 
Since lowering the incubation temperature failed to increase solubility of the expressed 
fusion protein, all further attempts were conducted at 37°C for 4 hours as this 
temperature allowed for induction most consistently. The next stage of method 
development led to the use of Tuner cells as host cells rather than the Rosetta cells. 
Tuner cells have the added benefit of a lac permease (LacY) mutation that allows 
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uniform entry of IPTG to the cultured cell population. This means that variations in 
IPTG concentration will affect the expression levels of the fusion protein. It was 
possible that low-level expression in this system would increase the solubility of the 
expressed GST-AURKAIP1 fusion protein. Thus, in the experiments with Tuner cells, 
IPTG concentrations were varied from 50µM to 500µM. 
Expressing the GST-AURKAIP1 fusion protein in Tuner cells improved solubility. 
Generally, there was still a greater proportion of the fusion protein in the insoluble 
fraction but in some cases the proportions were roughly equal. Lowering the IPTG 
levels resulted in a decrease in the expression of the fusion protein as expected. 
However the relative proportion of soluble to insoluble expressed protein was not 
increased. An IPTG concentration of 250µM produced an expression level equivalent to 
using 500µM IPTG but more than 100µM IPTG, therefore 250µM IPTG induction 
followed by incubation at 37°C for 4 hours became the standard protocol. Despite this, 
the expression levels and relative proportions were always slightly variable. Figure 3.8 
illustrates two examples of induction using the standard protocol in Tuner cells. 
Figure 3.8: Expression of GST-AURKAIP1 Fusion Protein in Tuner Cells. Tuner cells transformed 
with the pGEX-6P-1/truncated AURKAIP1 plasmid were cultured to an OD of 0.4-0.6 before being 
induced with 250µM IPTG followed by incubation at 37°C for 4 hours (A and B). Lysate from uninduced 
cells (U, lanes 1), induced cells (I, lanes 2), soluble fraction of induced cells (Sol, lanes 3) and the 
insoluble fraction of induced cells (Insol, lanes 4) were subjected to SDS-PAGE through 12% 
polyacrylamide gels and stained with Coomassie Blue. * Denotes position of the GST-AURKAIP1 fusion 
protein. 
 
Once conditions for producing as much soluble protein as possible had been optimised, 
the appropriately induced large  (500ml) cultures were subjected to centrifugation at 
5000RPM for 15 minutes at 4°C using a Sorvall GSA centrifuge (Rotor code 10). The 
resulting pellet of cells was frozen at -80°C for at least 2 hours before thawing and 
resuspending in 10ml PBS supplemented with 1mM PMSF, 1 protease inhibitor tablet 
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and 1µl Benzonase. The suspension was incubated on ice for 20 minutes before 
sonicating 15x for 10 seconds with intervals of 10 seconds. The suspension was 
centrifuged at 30000g and the supernatant filtered before this induced soluble fraction 
was saved for further purification. 
The next stage was purification of the soluble GST-AURKAIP1 fusion protein from the 
rest of the soluble proteins, before cleaving the mature AURKAIP1 from its GST tag. 
The induced soluble fraction was added to 0.6ml of Glutathione-Sepharose beads in a 
10ml BioRad column and incubated overnight at 4°C with agitation.  The suspension 
was then passed through the column and an aliquot of the flow through was stored. The 
beads were then washed by passing 50ml of PBS (supplemented with 1mM PMSF and 
1 protease inhibitor tablet) through the column followed by 50ml of PBS (no 
supplements). After washing, 750µl PBS with 1mM DTT, 1mM EDTA and 24µl 
PreScission protease was added to the beads, before incubating overnight at 4°C. The 
elution from the column was then saved, which contained soluble AURKAIP1 (Figure 
3.9).  
Figure 3.9: Purifying Recombinant Mature AURKAIP1. The soluble fraction was prepared from 
Tuner cells induced to express GST-AURKAIP1 with IPTG (Sol, lane 1). The soluble fraction was then 
incubated with Glutathione Sepharose beads overnight at 4°C. The flowthrough (lane 2) was collected 
before PreScission Protease was added to the beads to cleave between the GST and AURKAIP1. After 
the incubation with PreScission Protease, the AURKAIP1 was eluted in two fractions (lanes 4 and 5) and 
a sample of the remaining beads (lane 3) was also collected. Aliquots of the described samples were 
subjected to SDS-PAGE through a 12% polyacrylamide gel. * Denotes the size of the GST-AURKAIP1 
fusion protein, ** denotes the size of GST and *** denotes the size of AURKAIP1. 
 
The elution of AURKAIP1 was not completely clean and produced multiple bands. 
However there was a clear band corresponding to the size of the mature AURKAIP1 
and most of the GST was successfully removed. It was therefore decided to proceed 
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with antibody production using the eluted fraction. The additional proteins present 
should not have presented a great problem as polyclonal antibodies were to be 
produced, meaning that antibodies could be produced to several proteins. Therefore the 
presence of the additional proteins may produce a less clean antibody, but as long as the 
antibody was capable of recognising AURKAIP1 it would be useful. Additionally, the 
extra proteins were bacterial and therefore antibodies raised to them would be unlikely 
to recognise mammalian proteins, which should mean that when used on mammalian 
cell lysate, only AURKAIP1 would be recognised by the antibody. 
3.2.3 ANTIBODY PRODUCTION 
The protein concentration of the soluble AURKAIP1 elution was estimated by Bradford 
assay. Approximately 1mg of the elution was sent to Eurogentech for use in their 
speedy 28-day polyclonal antibody production protocol. The polyclonal antibodies were 
raised in rabbits. Two rabbits were used to produce the antibodies (rabbit 1349 and 
1350), both following the same procedure. The animals were immunised with 
approximately 200µg soluble AURKAIP1 on day 0, day 7, day 10 and day 18 of the 
protocol and blood was taken on day 0 just before immunisation (pre-immune serum), 
day 21 (medium bleed) and day 28 (final bleed). Serum from the pre-immune 
(approximately 2ml), medium bleed (approximately 10ml) and final bleed 
(approximately 50ml) were sent from Eurogentech to be tested and purified. 
The Pre-immune serum, medium bleed and final bleed from each rabbit was used as a 
primary antibody for immunoblotting (2.5.6). Each blot had protein loaded from the 
mature AURKAIP1 elution, HEK293 cell lysate and lysate from induced AURKAIP1-
FLAG overexpressing HEK293 cells. Pre-immune serum from each rabbit did not 
detect any cross-reacting material of the correct size. Only the final bleed from rabbit 
1349 detected a strong signal from the induced AURKAIP1-FLAG overexpressing 
HEK293 cells. However the antibody was not clean and there were several non-specific 
bands. Therefore the final bleed serum from rabbit 1349 was subjected to further 
purification.   
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3.2.4 ANTIBODY PURIFICATION 
Approximately 900µg of soluble AURKAIP1 in 1.5ml PBS buffer was added to 0.6ml 
NHS-activated Sepharose 4 fast flow beads that had been pre washed 3 times with 10ml 
cold 1mM HCL. The beads and protein were left to incubate overnight at 4°C with 
agitation. The flowthrough was saved and 0.1M Tris/HCL (pH 7.4) was added to the 
beads and left to incubate overnight at 4°C. The flowthrough was discarded and the 
beads washed 5 times with PBS. Serum from the final bleed of rabbit 1349 was 
sequentially filtered through 0.45µm and 0.2µm filters before 7ml was added to the 
beads along with 3ml PBS and left to incubate overnight at 4°C with agitation. The 
flowthrough was saved and then the beads were washed twice with 10ml PBS, once 
with 1x Tris-buffer pH 8.0 (50mM Tris/HCL pH 8.0, 0.1% Triton X-100 and 0.5M 
NaCl), once with 1x Tris-buffer pH 9.0 (50mM Tris/HCL pH 9.0, 0.1% Triton X-100 
and 0.5M NaCl) and once with 1x sodium phosphate buffer pH 6.3 (50mM sodium 
phosphate pH 6.3, 0.1% Triton X-100 and 0.5M NaCl). Adding 5ml Glycine-buffer pH 
2.5 (50mM Glycine pH 2.5, 0.1% Triton X-100 and 0.15M NaCl) then eluted the 
affinity-purified antibodies where they were immediately neutralised by collecting 
across 6 tubes with 150µl 1M Tris/HCL pH 9.0 already added. 
The collected antibodies were then pooled together and placed inside dialysis tubing. 
The tubing was sealed and the antibodies were subjected to buffer exchange in 500ml of 
PBS overnight at 4°C with stirring. This treatment was repeated a further two times by 
replacing with fresh PBS. 
After buffer exchange the antibodies, still in the dialysis tubing, were placed in 
AQUACIDE II powder (Millipore), which absorbed water through the dialysis tubing, 
thus concentrating the antibodies. The concentration procedure was monitored over 
several hours until the volume of the antibodies was approximately 1.5ml. Final 
concentrations of 10% glycerol and 0.02% sodium azide were then added before the 
final purified AURKAIP1 polyclonal antibody was aliquoted to avoid repeated freeze-
thaw cycles. 
The purified antibody was tested against the unpurified final bleed serum to test if the 
purification had been successful in reducing non-specific binding. Aliquots of 5µg and 
10µg of uninduced and induced AURKAIP1-FLAG cell lysate were loaded onto a 
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single 12% polyacrylamide gel in duplicate. After SDS-PAGE and western blot transfer 
the membrane was cut in half before blocking with 5% milk in TTBS. The two 
membrane pieces were then treated separately. One was incubated with unpurified final 
bleed serum, and the other with purified AURKAIP1 antibody. Each antibody was 
diluted 1 in 500 in 5% milk in TTBS and incubated with the membrane overnight at 
4°C. All subsequent immunoblotting steps were carried out as described in 2.5.6 and 
detected on the Storm Phosphorimager. The antibody purification (Figure 3.10B) 
significantly reduced the background and non-specific high MW binding compared to 
the unpurified serum (Figure 3.10A).   
Figure 3.10: Purification of Endogenous AURKAIP1 Antibody. Mitochondrial lysate was prepared 
from HEK293-AURKAIP1-FLAG cells that had been either induced with 1µg/ml tetracycline (I) or 
remained uninduced (U) for 3 days. Aliquots of uninduced (5µg, lanes 1 or 10µg, lanes 2) or induced 
(5µg, lanes 3 or 10µg, lanes 4) mitochondrial lysate were subjected to SDS-PAGE through a 14% 
polyacrylamide gel and immunoblotted with either unpurified (A) or purified (B) AURKAIP1 antibodies 
at a 1 in 500 dilution.  
 
The purified endogenous AURKAIP1 antibody was tested further at various dilutions to 
determine the best working dilution to use for subsequent experiments. Dilution of 1 in 
1000 produced similar results to the 1 in 500 dilution, but 1 in 2000 dilution of the 
antibody produced weaker signal. Therefore a dilution of anti-AURKAIP1 of 1 in 1000 
in T-TBS was used for immunoblotting in all subsequent experiments. 
 
 
 
  80 
3.3 DISCUSSION 
The successful generation of the endogenous AURKAIP1 antibody was vitally 
important for further experiments that will be presented throughout the remaining 
chapters. The AURKAIP1 antibody recognises overexpressed AURKAIP1-FLAG 
(Figure 3.10A and B, lanes 3 and 4), but does not appear to recognise the endogenous 
AURKAIP1 in the uninduced cells (Figure 3.10A and B, lanes 1 and 2). This could 
indicate low endogenous AURKAIP1 levels in HEK293 cells as the levels in 10µg of 
uninduced HEK293 mitochondrial lysate cannot be detected by western blot using the 
produced polyclonal AURKAIP1 antibody (Figure 3.10A and B, lanes 2). Alternatively, 
the lack of signal could indicate that endogenous AURKAIP1 is not present in the 
mitochondria. This seems unlikely because the overexpressed AURKAIP1-FLAG is 
detected in the mitochondrial lysates. These data show that the produced AURKAIP1 
antibody recognises overexpressed AURKAIP1-FLAG in human cells, showing the 
specificity of the antibody. Further, the detection of AURKAIP1-FLAG in 
mitochondrial lysates is the first indication from my own data to suggest mitochondrial 
localisation of AURKAIP1. This is in accordance with online prediction tools (TargetP 
(Emanuelsson et al., 2007), MitoProt II (Claros and Vincens, 1996), Predotar (Small et 
al., 2004), pTARGET (Guda, 2006) and MultiLoc2 (Blum et al., 2009)) that all strongly 
predict mitochondrial localisation for AURKAIP1. Therefore, assuming mitochondrial 
localisation of AURKAIP1, these data suggest endogenous levels of AURKAIP1 are 
low in HEK293 cells. 
Another observation that could indicate low endogenous levels of AURKAIP1 is that no 
PCR product could be produced when using cDNA from HEK293 cells as a template 
(Figure 3.1). However, the desired PCR products were obtained when using an 
AURKAIP1 I.M.A.G.E. clone as a template, which confirmed the primers were 
appropriate (Figure 3.2). Furthermore, PCR reactions designed to amplify another 
protein (SLMO2) were successful (Figure 3.1), when using the same cDNA from 
HEK293 cells. One explanation of these results could be that AURKAIP1 expression 
levels are very low and that there was insufficient AURKAIP1 present in the HEK293 
cDNA to allow amplification, whereas SLMO2 is expressed to higher levels and 
therefore could be amplified from the cDNA template. However, it is also possible that 
the primers designed for AURKAIP1 amplification were simply not as efficient as the 
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primers designed for SLMO2 amplification despite similar length, G-C content and 
melting temperature. 
Though the focus in this chapter was on generating tools, which were successfully 
produced, the data presented also provides initial observations that suggest that the 
endogenous levels of AURKAIP1 are low, at least in HEK293 cells. To confirm this, 
increased amounts of lysate needed to be loaded onto the gels for western blot and 
lysates from other cell types also needed to be tested. Further experiments to confirm 
these early observations and to further characterise the localisation of AURKAIP1 will 
be the focus of the following chapter.  
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CHAPTER 4: IS AURKAIP1 A 
MITOCHONDRIAL PROTEIN? 
4.1 INTRODUCTION 
The preliminary siRNA screen carried out in my host laboratory strongly suggested that 
AURKAIP1 is a protein important for mitochondrial function; since depletion of 
AURKAIP1 caused growth defects in HeLa cells, but not in 143B Rho0 cells. However, 
experimental confirmation of the mitochondrial localisation of AURKAIP1 was 
required. If AURKAIP1 were to be identified as mitochondrial then it would also be 
crucial to know which of the sub-organellar compartments it is located in. 
AURKAIP1 was originally described as a nuclear protein that interacts with Aurora A 
kinase. In these studies, however, an N-terminal FLAG-tagged protein was used (Lim et 
al., 2007), which could have resulted in mislocalisation by interfering with the predicted 
N-terminal mitochondrial targeting sequence of AURKAIP1. According to the Human 
Protein Atlas (HPA) project, AURKAIP1 has both nuclear and mitochondrial 
localisation, as determined by immunohistochemistry and fluorescence microscopy 
(Uhlen et al., 2010). However, these data are unconvincing as only one antibody was 
used and when the same antibody was used for immunodetection on HEK293 cell 
lysate, several bands were detected. This casts doubt over the localisation data as the 
antibody may be binding non-specifically.  
During the course of my PhD investigations, two more publications were released that 
partly addressed the localisation of AURKAIP1. First, a recent publication described the 
mitochondrial localisation of AURKAIP1 via expression of C-terminal GFP-tagged 
AURKAIP1 (Szklarczyk et al., 2012). The GFP-tagged AURKAIP1 was shown to co-
localise with the mitochondrial specific dye TMRM, indicating that the fusion protein 
was in, or in the vicinity of mitochondria (Szklarczyk et al., 2012). However, this gives 
no information as to the sub-localisation of AURKAIP1. A second recent publication 
suggests that bovine AURKAIP1 is a mitochondrial protein. Koc et al. found 
AURKAIP1 via capLC-MS/MS to be in preparations of bovine mitochondrial 
ribosomes (Koc et al., 2013). Since this work suggests AURKAIP1 to be a 
mitoribosomal protein (Koc et al., 2013), it would also imply localisation to the 
mitochondrial matrix. 
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However, there are no published data showing that endogenous AURKAIP1 is present 
in human mitochondria. In this chapter I will present evidence for the intra-
mitochondrial localisation of both C-terminal FLAG-tagged and endogenous 
AURKAIP1 to the matrix, the innermost compartment of the organelle, in human cells. 
4.2 METHODS 
4.2.1 STABLE TRANSFECTION OF FLP-INTM TREXTM CELLS 
Flp-InTM TRExTM cells (either HEK293 or U2OS, see 2.1.1 for cell line details) were 
transfected with pcDNATM5/FRT/TO vector (Invitrogen) containing the gene of 
interest, AURKAIP1 with an in-frame C-terminal FLAG tag (AURKAIP1-FLAG) (see 
3.2.1 for details on construct generation). Cells were seeded in a 6 well plate at 
approximately 50-60% confluency in the morning for an afternoon transfection. For 
each transfection two ratios of DNA:Superfect (QIAGEN) were used, 1:5 and 1:7.5. 
2µg of DNA (0.2µg pcDNATM5/FRT/TO/AURKAIP1-FLAG and 1.8µg pOG44) and 
either 10µg or 15µg Superfect were added to 100µl DMEM (Sigma) without 
supplements. After a ten-minute incubation at room temperature, during which time the 
spent media was aspirated from the cells, 600µl DMEM (with supplements) was added 
and the whole mix carefully transferred to the wells. After a 3 hour incubation at 37°C 
the media was replaced with fresh DMEM (with supplements). Selection was initiated 
after 2 days by supplementing medium with 100µg/ml HygromycinB (Invitrogen) and 
10µg/ml BlasticidinS (Melford). A control well of untransfected cells was always 
included in the antibiotic treatment. This was to confirm the effects of the antibiotics so 
that, when all control cells were dead, any remaining in the transfected wells would 
represent antibiotic resistant populations conferred by successful transfection. 
Cells were monitored each day and the media was changed to remove dead cells. Once 
only antibiotic resistant cells remained the plates were monitored for growth of clonally 
derived populations, which were subsequently isolated and maintained as independent 
clonal cell lines. Clonal cell lines were obtained by picking independent colonies that 
had grown from a single transfectant, and transferring to independent growth vessels. 
Clones were numbered sequentially, but some clones did not grow well after the 
selection process. A population was retained, which comprised a mix of the remaining 
transfectants that had not been clonally selected. These lines were subsequently tested 
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by subjecting 40µg of cell lysate from uninduced and induced (with 1µg/lm tetracycline 
for 3 days) cells to 12% SDS-PAGE and western blotting, before immunodetection with 
an α-FLAG antibody (Sigma). This was to confirm the inducible expression of the 
AURKAIP1-FLAG protein, which was encoded by the inserted gene. 
4.2.2 SUB-MITOCHONDRIAL LOCALISATION 
I optimised this technique through several iterations of this protocol in order to generate 
clean separation of the individual mitochondrial compartments. The following is the 
final protocol used to generate the data presented in this report. 
Mitochondria were isolated as described previously (2.5.2) and the protein 
concentration was measured by Bradford assay (2.5.3). All of the following steps were 
carried out at 4°C unless otherwise specified. An aliquot of isolated mitochondria (300 
µg) was resuspended in a total volume of 150µl homogenisation buffer. A 12.5µl 
(25µg) aliquot was taken and an equal volume of 2x dissociation buffer added to form 
the ‘total mitochondrial proteins’ fraction. A volume of 1.237ml of 5mM Tris/HCl pH 
7.4; 1mM EDTA was added to the remaining isolated mitochondria in homogenisation 
buffer, before being gently mixed and split into two equal volumes (designated as 
sample 1 and sample 2). Sample 1 was incubated with 10µg of proteinase K with 
shaking for 30 minutes at 37°C before 1mM PMSF was added to each sample (1 and 2). 
Both samples 1 and 2 were pelleted at 8000g for 10 minutes at 4°C and washed twice 
each with 1ml 5mM Tris/HCl pH 7.4; 1mM EDTA. Each pellet was resuspended in 
68.7 µl homogenisation buffer. A 12.5µl (25µg) aliquot of sample 1 was taken and an 
equal volume of 2x dissociation buffer added, which was designated as the ‘shaved 
mitoplast’ fraction. A 12.5µl (25µg) aliquot of sample 2 was taken and an equal volume 
of 2x dissociation buffer added, which was designated as the ‘mitoplast’ fraction. 
Homogenisation buffer was then added to each sample to a final volume of 687µl and 
subsequently centrifuged at 12,000g for 10 minutes at 4°C. The supernatants were 
discarded and the each of the pellets was resuspended in 1.125ml 100mM Na2CO3 and 
incubated for 30 minutes at 4°C. Both samples were pelleted in the bench Beckman 
Optima TLX ultracentrifuge at 53,000rpm (rotor code TLA 120.2) for 15 minutes at 
4°C. Each pellet was finally resuspended in 50µl homogenisation buffer. A 12.5µl 
(25µg) aliquot of each sample had an equal volume of 2x dissociation buffer added and 
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was designated the ‘Na2CO3 extracted proteins’ fraction (sample 1, PK-shaved and 
sample 2, unshaved). An aliquot of each collected fraction (10µg) was then loaded onto 
14% SDS:PAGE for subsequent western blot analysis. 
Homogenisation buffer (final concentrations) 
 0.6M Mannitol 
 10mM Tris/HCl pH7.4 
 1mM EGTA 
Filter sterilised and then stored at 4˚C for no longer than 3 months. 
4.3 RESULTS 
4.3.1 CONFIRMATION OF AURKAIP1-FLAG EXPRESSION IN FLPINTM 
TREXTM CELLS 
Clonal AURKAIP1-FLAG overexpressing cell lines were established (both U2OS-
AURKAIP1-FLAG and HEK293-AURKAIP1-FLAG lines were produced) and tested 
to confirm AURKAIP1-FLAG expression. AURKAIP1-FLAG expression was induced 
by addition of 1µg/ml tetracycline to the cell culture media for 3 days before cells were 
harvested and lysates analysed by western blotting. When probing with an anti-FLAG 
antibody, a protein migrating to approximately 15kDa was clearly present in all induced 
clonal lines tested (Figure 4.1, lanes 4, 6, 8 and 10) that was not present in the 
uninduced controls (Figure 4.1, lanes 1, 3, 5, 7 and 9). Porin was used as a loading 
control.  
Figure 4.1: Expression of AURKAIP1-FLAG in U2OS Cells. Cell lysates (40µg) from uninduced cells 
(U) and induced cells (I; grown in presence of 1µg/ml tetracycline for 3 days) were produced from 
U2OS-AURKAIP1-FLAG cell lines. Several clones (clone 2 = lanes 3 and 4, clone 3 = lanes 5 and 6, 
clone 4 = lanes 7 and 8, clone 6 = lanes 9 and 10) and the population (lanes 1 and 2) were subjected to 
12% SDS-PAGE western blotting using α-FLAG and α-porin antibodies for immunodetection.  
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The induction of the FLAG-tagged protein confirmed that the production of the stable, 
inducible cell line was successful. The observed protein size of 15kDa was considerably 
smaller than the predicted molecular weight of AURKAIP1 (22.4kDa, Figure 4.2B), 
however, this would be consistent with cleavage of a substantial mitochondrial targeting 
sequence. Supporting this, if an N-terminal pre-sequence of 76 amino acids (as 
predicted by TargetP, Figure 4.2A) was removed, the remaining mature protein would 
be predicted to have a molecular weight of 14.3kDa (Figure 4.2C), which is very close 
to the size of the observed AURKAIP1-FLAG band on the western blot. 
 
Figure 4.2: Predicted Molecular Weight of AURKAIP1. (A) TargetP prediction of mitochondrial 
localisation and N-terminal pre-sequence length. The output displays sequence length (len), Final NN 
scores (on which the final probability is based) for presence of a mitochondrial targeting peptide (mTP), 
signal peptide (SP) for secretory pathway or any other location (other). The predicted localisation (Loc) 
based on the NN scores is shown to mitochondria (M). The reliability class (RC) is a measure of the 
strength of the prediction and values range from 1-5 with 1 being the strongest predictor. The predicted 
pre-sequence length (TPlen) from the additional cleavage site prediction is also shown (Emanuelsson et 
al., 2007). (B) The full length AURKAIP1 amino acid sequence with the predicted molecular weight as 
calculated using the ProtParam online tool (Gasteiger et al., 2005). (C) The predicted amino acid 
sequence of mature AURKAIP1 with the predicted 76 amino acid N-terminal targeting sequence removed 
and the predicted molecular weight.  
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4.3.2 AURKAIP1 IS A MITOCHONDRIAL MATRIX PROTEIN 
To address the question of mitochondrial localisation of AURKAIP1, mitochondria 
were isolated from HEK293-AURKAIP1-FLAG cells following 3 days induction with 
1µg/ml tetracycline and mitochondrial lysates were analysed by immunoblotting with 
an α-FLAG antibody. The isolated mitochondria had been treated with proteinase K 
(PK) to degrade cytosolic contaminants or broken mitochondria. Western blot analysis 
showed that AURKAIP1-FLAG was present in the PK treated mitochondria (data not 
shown), however, with concomitant addition of triton X-100 added to break up the 
mitochondrial membrane, less AURKAIP1-FLAG could be detected. This preliminary 
experiment suggested AURKAIP1-FLAG was present within the mitochondria. 
To investigate the mitochondrial localisation of AURKAIP1 further, a sub-localisation 
protocol was used (illustrated in Figure 4.3A). This allowed separation of mitochondria 
into the constituent sub-fractions. Mitochondrial fractions were confirmed using 
antibodies to known markers of the outer membrane (Tom20), inner membrane 
(NDUFA9), inter membrane space (AIF), matrix (GDH) and post mitochondrial 
supernatant (S6) (Figure 4.3B). AURKAIP1-FLAG was detected in the same fractions 
(Figure 4.3B, lanes 2, 3, and 4) as GDH (glutamate dehydrogenase), which is a 
mitochondrial matrix protein. A small amount of GDH was seen in the membrane 
fractions. This was to be expected as there are several isoforms of GDH, some of which 
are membrane-bound (Rajas et al., 1996). There is no detectable signal for AURKAIP1-
FLAG in the membrane fractions (Figure 4.3B, lanes 5 and 6), suggesting AURKAIP1 
is a soluble protein present in the matrix.  
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Figure 4.3: AURKAIP1-FLAG is Present In the Mitochondrial Matrix: A) Schematic diagram of the 
mitochondrial sub-localisation procedure. IMM = inner mitochondrial membrane, OMM = outer 
mitochondrial membrane B) Mitochondria were isolated from AURKAIP1-FLAG Hek-293-Flp-InTM cell 
lines that were induced for 3 days. Samples (approximately 10µg) of post mitochondrial supernatant 
(PMS) (lane 1), and total mitochondrial proteins (lane 2) were saved before the isolated mitochondria 
were further subfractionated by hypotonic shock to form mitoplasts (lane 3) which were treated with 
proteinase k (PK) to form shaved mitoplasts (lane 4). Membrane proteins were then isolated by sodium 
carbonate extraction of PK shaved mitoplasts (lane 5) or untreated mitoplasts (lane 6). These were 
analysed by 14% SDS-PAGE and immunoblotting with antibodies against FLAG and known markers for 
the outer mitochondrial membrane (Tom20), intermembrane space (AIF), matrix (GDH) and inner 
mitochondrial membrane (NDUFA9).  
4.3.3 ENDOGENOUS AURKAIP1 
Once the localisation of the AURKAIP1-FLAG protein was established to be 
predominantly in the mitochondrial matrix, confirmation of the localisation of the 
endogenous levels of AURKAIP1 was required. The endogenous levels of AURKAIP1 
are very low and are not detectable by western blot on 40µg cell lysate from HEK 293 
or HeLa cells. To detect endogenous AURKAIP1 it was necessary to load 50µg of 
isolated mitochondria from 143B cells. Immunodetection was performed using an 
endogenous α-AURKAIP1 antibody, the production of which was described in Chapter 
3. To confirm that the detected band was indeed AURKAIP1 and was not due to non-
specific binding of the antibody, cells were depleted of AURKAIP1 via siRNA. 
AURKAIP1 siRNA was able to deplete overexpressed AURKAIP1-FLAG in HEK293 
cells (Figure 4.4A, lanes 2, 4 and 6) and endogenous AURKAIP1 in 143B cells (Figure 
4.4B, lane 3) relative to control cells transfected with non-targeting siRNA (Figure 4.4B 
lane 1). These data confirm: i) the ability of the produced AURKAIP1 antibody to 
detect endogenous AURKAIP1, ii) the specificity of the AURKAIP1 siRNA for its 
target, iii) endogenous AURKAIP1, although at low levels, is present in mitochondria. 
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Figure 4.4: AURKAIP1 siRNA can 
Deplete Both Expressed and 
Endogenous AURKAIP1 A) 
HEK293-AURKAIP1-FLAG cells 
were subjected to transfection with 
either non targeting (NT) or 
AURKAIP1 siRNA and induced with 
several concentrations of doxycycline 
(Dox) for 3 days. Cell lysate (40µg) 
was subjected to 12% SDS-PAGE and 
western blot followed by 
immunodetection with α-FLAG and 
α-NDUFA9 antibodies. B)  
Mitochondrial lysate (50µg) and post-
mitochondrial supernatant (PMS, 
50µg) from 143B cells transfected 
with either non-targeting (NT) or 
AURKAIP1 specific siRNA for 4 
days was subjected to 14% SDS-PAGE and western blotting. Immunodetection was performed using 
antibodies against AURKAIP1, NDUFA9 (mitochondrial inner membrane) and S6 (cytosolic ribosomal 
protein). 
 
Endogenous levels of AURKAIP1 in HEK293, HeLa and U2OS cells are lower than in 
143B cells and as such cannot be detected by western blotting when loading 50µg of 
mitochondrial lysate. It was important to confirm that the endogenous AURKAIP1 was 
present in the matrix, to verify the findings obtained using AURKAIP1-FLAG. Western 
blot analysis of approximately 200µg of PK-shaved mitoplasts (performed by Dr 
Hornig-Do) allowed detection of signal for AURKAIP1 (Figure 4.5C), thus confirming 
that endogenous levels of AURKAIP1 are present in the mitochondrial matrix.  
 
Figure 4.5: Endogenous AURKAIP1 is Detectable in PK Shaved Mitoplasts from HEK293 Cells. 
Approximately 200µg of Proteinase K (PK) shaved mitoplasts (PKM, lane 1) and post-mitochondrial 
supernatant (PMS, lane 3) were separated by 15% SDS-PAGE and western blotting by Dr Hornig-Do. 
(A) Dr Hornig-Do performed immunoblotting antibodies against FLAG to detect the expressed FLAG-
tagged C-terminal LARS2 fragment and (B) COXI. I then immunoblotted with the custom polyclonal α-
AURKAIP1 antibody (C). A molecular weight marker (MW) was loaded in lane 2. 
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4.4 DISCUSSION 
I have shown that AURKAIP1 is predominantly a mitochondrial matrix protein. Sub-
mitochondrial localisation experiments showed that overexpressed C-terminal FLAG-
tagged AURKAIP1 is present in the mitochondrial matrix (Figure 4.3B). Furthermore, 
endogenous AURKAIP1 is detected in PK-shaved mitoplasts of HEK293 cells (Figure 
4.5) and in mitochondrial lysates of 143B cells (Figure 4.4B). These data are in 
agreement with recent reports, published during the course of my PhD investigations 
that have also suggested the mitochondrial localisation of AURKAIP1. Szklarczyk et al. 
demonstrated that C-terminal GFP-tagged AURKAIP1 co-localises with the 
mitochondrial marker TMRM via fluorescence microscopy (Szklarczyk et al., 2012). 
Additionally, another study has suggested that AURKAIP1 is present in preparations of 
bovine mitochondrial ribosomes (Koc et al., 2013). This work implies mitochondrial 
matrix localisation as it identifies AURKAIP1 by mass spectrometry as associated with 
mitoribosomes (Koc et al., 2013). However, the work of Koc et al. was conducted in 
bovine tissue (Koc et al., 2013) and the fluorescent microscopy studies with GFP-
tagged AURKAIP1 only indicates co-localisation with mitochondria (Szklarczyk et al., 
2012). I believe, therefore, that the work presented in this chapter is the first to 
conclusively demonstrate that AURKAIP1 is present in the mitochondrial matrix of 
human cells. 
The C terminal FLAG-tagged AURKAIP1 that is detected in the mitochondrial matrix 
is considerably shorter (approximately 15 kDa, Figure 4.3B) than the predicted full 
length AURKAIP1 protein (22.4kDa, Figure 4.2B). Since the C-terminal FLAG tag 
remains intact, these data strongly suggest that the full length AURKAIP1 protein has 
an N-terminal mitochondrial targeting sequence, which is cleaved upon import into 
mitochondria. Furthermore, endogenous AURKAIP1 detected in the mitochondrial 
preparations of 143B cells and in PK-shaved mitoplasts of HEK293 cells was also 
approximately 15kDa in size (Figure 4.5C, lane 1). These data suggest that the 
endogenous protein is also cleaved upon on import into the mitochondria and indicate 
that the addition of the C-terminal FLAG tag had no significant effect on either 
localisation or size of the expressed protein.  
Therefore, these data supporting AURKAIP1 having an N-terminal mitochondrial 
targeting sequence are in agreement with bioinformatic approaches, and with the 
  91 
prediction programs, Target P (Emanuelsson et al., 2000; 2007), Predotar (Small et al., 
2004), MitoProt II (Claros and Vincens, 1996), pTARGET (Guda, 2006) and MultiLoc2 
(Blum et al., 2009), all of which predict mitochondrial localisation. MitoProt II (Claros 
and Vincens, 1996) predicts AURKAIP1 to have a 54 amino acid N-terminal targeting 
sequence. If this were correct the predicted molecular weight of mature AURKAIP1 
would be 16.8kDa (Gasteiger et al., 2005). The removal of a 76 amino acid N-terminal 
targeting sequence, as predicted by the TargetP program (Emanuelsson et al., 2007), 
would produce a mature protein with a predicted molecular weight of 14.3kDa (Figure  
4.2C). This is more similar to the observed size of AURKAIP1, as the observed size of 
AURKAIP1 on western blots is approximately 15kDa. However, the observed size of 
proteins subjected to SDS-PAGE can vary slightly, preventing accurate estimates of the 
actual molecular weight. It is, therefore, not possible from my work to predict the exact 
cleavage site with confidence, but it is probable that the N-terminal pre-sequence of 
AURKAIP1 is between 54 and 76 amino acids. This is a relatively long pre-sequence, 
especially as a proportion of the length of the protein, as typical mitochondrial targeting 
sequences usually range from 15-50 amino acids, although pre-sequence lengths up to 
~100 have been described (Chacinska et al., 2009).       
Studies by Lim et al. have described AURKAIP1 as a nuclear protein that binds to 
Aurora A kinase and promotes Aurora A degradation (Lim et al., 2007; Kiat, 2002). 
These studies describe the localisation of AURKAIP1 to be entirely nuclear, however 
overexpressed N-terminally FLAG-tagged AURKAIP1 was used. This approach has the 
potential to mislocalise the AURKAIP1 protein, as the FLAG tag at the N-terminal 
would interfere with the mitochondrial targeting sequence. Indeed, the current data 
shows that C-terminal rather than N-terminal FLAG-tagged AURKAIP1 is localised to 
mitochondria (Figure 4.3B). AURKAIP1-FLAG was not detected in the post 
mitochondrial supernatant of cells (Figure 4.3B), which comprises the cytosolic 
fraction, as it is collected after the initial centrifugation to remove nuclei and unbroken 
cells, and after the centrifugation to isolate mitochondria. This suggests there is no 
detectable expression of AURKAIP1-FLAG in the cytosol, but does not rule out nuclear 
localisation. Nuclear isolation protocols were attempted during my investigations, but I 
was unable to produce nuclear and cytosolic fractions that were free of any 
contamination with the other fraction. However, overexpressed AURKAIP1-FLAG was 
never detected in any of the nuclear fractions that were prepared, but was always 
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present in mitochondrial lysates. This indicates AURKAIP1-FLAG does not localise to 
the nucleus, which is in accordance with data from Szklarczyk et al., that did not 
identify nuclear localisation of C-terminal GFP-tagged AURKAIP1 by fluorescence 
microscopy (Szklarczyk et al., 2012). Therefore, although some nuclear localisation of 
endogenous AURKAIP1 cannot be ruled out by my investigations, all of data presented 
indicate that AURKAIP1 is predominantly a mitochondrial matrix protein. 
The majority of AURKAIP1-FLAG is present in the mitochondrial matrix (Figure 
4.3B). However, the proportions of AURKAIP1-FLAG in the PK-shaved mitoplasts 
(4.3B lane 4) relative to the total mitochondrial proteins (lane 2) were slightly lower 
than the respective proportions of the mitochondrial matrix protein GDH. This may 
have been due to a small fraction of IMS located AURKAIP1-FLAG, that was degraded 
by the PK. It is, therefore, not possible to rule out that a small amount of AURKAIP1-
FLAG may have been present in the IMS. Although, any IMS located protein could 
only account for a small percentage since there was only a slight reduction in 
AURKAIP1 signal between the untreated mitoplasts (Figure 4.3 lane 3) and the PK-
shaved mitoplasts (lane 4), whereas the IMS protein AIF was undetectable in the PK-
shaved mitoplasts. It is difficult conclude IMS localisation for AURKAIP1 from these 
data, as overexpression of AURKAIP1-FLAG was used, where there is the possibility 
that the potential IMS localisation could be explained by saturation of the matrix with 
imported AURKAIP1-FLAG. This may occur since the endogenous AURKAIP1 levels 
are very low and therefore the overexpression may represent an unusual challenge to the 
import machinery and any interacting proteins. What is clear, however, is that 
AURKAIP1-FLAG is a soluble protein as there was no signal detected in either of the 
sodium carbonate extracted fractions, which contained membrane proteins (Figure 4.3B 
lanes 5 and 6). A proportion of the signal for the matrix protein GDH was seen in the 
inner membrane fraction, which validates the stringency of the sub-localisation protocol 
because certain isoforms of GDH are tightly associated with the inner mitochondrial 
membrane (Rajas et al., 1996). Therefore AURKAIP1-FLAG can be confidently 
described as a soluble protein, predominantly located to the matrix.  
Endogenous AURKAIP1 is also present in PK-shaved mitoplasts from HEK293 cells 
(Figure 4.5), indicating mitochondrial matrix localisation. However inner membrane 
localisation cannot be completely ruled out, as mitochondrial sub-localisation studies 
were not conducted due to low endogenous levels of AURKAIP1.  
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Endogenous AURKAIP1 was detected using the custom AURKAIP1 polyclonal 
antibody (the production of which is described in Chapter 3). Depletion of AURKAIP1-
FLAG (Figure 4.4A) in HEK293-AURKAIP1-FLAG cells and endogenous 
AURKAIP1 (Figure 4.4B) in 143B cells was confirmed using this antibody. This shows 
that the antibody and siRNA used in this study were specifically targeting AURKAIP1 
and AURKAIP1-FLAG. The depletion of AURKAIP1-FLAG was more efficient than 
depletion of endogenous AURKAIP1 (Figure 4.4). This is likely to be due to the 
transfection efficiency rather than differential effects of the siRNA on the endogenous 
and FLAG-tagged AURKAIP1 transcripts. The depletion of AURKAIP1-FLAG was 
performed in 6 well plates using the standard protocol for 3 days (2.1.6) and 40µg of 
cell lysate was analysed. However, 50µg of isolated mitochondrial lysate was required 
to detect endogenous AURKAIP1, therefore, larger scale depletion experiments were 
set up (3x 75cm2 flasks) for four days to permit mitochondrial isolation. It is possible 
that the transfection efficiency was lower in the 75cm2 flasks compared to transfections 
carried out in 6 well plates. Another possibility is that AURKAIP1 depletion inhibits 
cell growth. If this were true, there would be a selection pressure favouring 
untransfected cells, thus a prolonged (extra 24-hour) incubation with siRNA would be 
expected to result in a greater proportion of cells that were not transfected with the 
siRNA. This may explain why the siRNA depletion of endogenous AURKAIP1 
depletion appeared to be less efficient than siRNA depletion of overexpressed 
AURKAIP1-FLAG. To address this issue, the effects of AURKAIP1 depletion on cell 
growth were investigated and will be presented in the following chapter.  
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CHAPTER 5: STUDYING THE 
MORPHOLOGICAL EFFECTS OF 
AURKAIP1 DEPLETION 
5.1 INTRODUCTION 
Mitochondrial gene expression encompasses a range of processes as outlined in the 
general introduction (Section 1.7). I wished to determine whether AURKAIP1 plays a 
role in any of these processes, as at the time of my investigations, there was no 
published data to suggest a functional role for AURKAIP1 in mitochondria. 
AURKAIP1 depletion could potentially affect mtDNA levels, transcription, translation, 
dynamics, protein import or several other processes, which could lead to reduced 
mitochondrial gene expression. Due to this range of possibilities, initial studies were 
conducted using imaging techniques to assess the effects of AURKAIP1 depletion on 
multiple aspects of mitochondrial morphology. These experiments allowed estimation 
of changes to mitochondrial membrane potential (Ψm), analysis of mitochondrial shape 
and visualisation of mtDNA.   
Fluorescence microscopy has long been established as a method to estimate relative 
changes in Ψm by quantifying changes in uptake of one of the several lipophilic cationic 
probes that are selectively accumulated within the mitochondria (Johnson et al., 1981). 
Fluorescent rhodamine derivatives such as rhodamine 123, tetramethylrhodamine ethyl 
ester (TMRE) and tetramethylrhodamine methyl ester (TMRM) are examples of 
cationic probes used to estimate Ψm (Scaduto and Grotyohann, 1999). TMRM, unlike 
other rhodamine derivatives, has the added benefit of not inhibiting respiration when 
used at low concentrations (Scaduto and Grotyohann, 1999). Thus, TMRM is 
commonly used to visualise mitochondria and estimate Ψm (Gerencser et al., 2012; 
Ashley and Poulton, 2009; Scaduto and Grotyohann, 1999; Nicholls and Ward, 2000; 
Szklarczyk et al., 2012; Frezza et al., 2006) including work from my host laboratory 
(Bruni et al., 2013). Under non-saturating conditions (defined as non-quench mode, see 
(Nicholls and Ward, 2000 for review), the fluorescence intensity emitted by TMRM is 
proportional to Ψm allowing relative measurements of Ψm to be made in live cells. The 
experimental measurements are always relative to controls and are presented in arbitrary 
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fluorescence units, because absolute measurements of Ψm (in mV) are not possible 
using this technique. However, a recent publication has outlined a method of absolute 
quantification of Ψm using TMRM via a combination of fluorescence imaging and 
voltage clamp (Gerencser et al., 2012). 
Inhibitors of electron transport such as antimycin A (Complex III) and rotenone 
(Complex I) diminish Ψm. Inhibition of the ATP synthase increases Ψm whilst inhibition 
of mitochondrial protein synthesis with chloramphenicol has no effect (Johnson et al., 
1981). Therefore, changes in Ψm upon AURKAIP1 depletion may indicate a role for 
AURKAIP1. 
In addition to acting as an indicator of Ψm, the accumulation of TMRM in mitochondria 
allows visualisation of the morphology of the mitochondrial network and any changes 
in the morphology to be assessed. Particularly elongated mitochondria can indicate a 
disruption of mitochondrial fission, as in cells depleted of Drp1 (Parone et al., 2008), or 
overactive fusion, as in OPA1 overexpression (Cipolat et al., 2004). If cells contain 
punctate mitochondria then this may indicate overactive fission, as in Drp1 
overexpression (Cipolat et al., 2004), or a fusion defect, as observed in OPA1 null cells 
(Song et al., 2007). Therefore, TMRM staining can be useful to indicate altered 
mitochondrial dynamics, in addition to effects on Ψm. It is worth noting that 
mitochondrial dynamics and Ψm can influence each other, for example, loss of Ψm 
promotes punctate mitochondria by causing an increase in OPA1 cleavage, thus 
impairing mitochondrial fusion (Ishihara et al., 2006; Song et al., 2007).  
PicoGreen (PiGr) is a dsDNA specific intercalating dye that has been commonly used to 
visualise mtDNA nucleoids since the technique was first established in living human 
cells (Ashley et al., 2005). PiGr staining allows nucleoid morphology to be assessed in 
addition to estimations of mtDNA depletion (Ashley et al., 2005). Furthermore, PiGr 
and TMRM can be used to co-stain live cells (Ashley and Poulton, 2009; Bruni et al., 
2013), allowing visualisation of mitochondrial morphology, estimation of mitochondrial 
membrane potential and visualisation of mtDNA nucleoids in the same cell. Therefore, 
PiGr and TMRM co-staining was selected as a method to allow the consequences of 
AURKAIP1 depletion on mitochondrial morphology to be assessed. However, it was 
necessary to first establish and confirm the most efficient and specific siRNA sequences 
with which to accomplish this.  
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As mentioned earlier, preliminary data from my host laboratory had identified potential 
involvement of AURKAIP1 in mitochondrial gene expression. This was initially 
determined through a bioinformatics approach and then preliminary laboratory data 
from siRNA mediated depletion of AURKAIP1 in HeLa and Rho0 cells. In the latter, 
there were negligible effects of AURKAIP1 depletion after 3 days. When conducting 
siRNA depletion experiments it is important to be mindful of potential off-target effects. 
To this end, the preliminary experiments were carried out using siRNAs that targeted 
three different regions of AURKAIP1 mRNA. The rationale for this is that if all three 
siRNAs have similar effects, then it is much more likely that any phenotype seen is due 
to depletion of the target protein rather than non-specific off-target effects. Cells were 
transfected with each siRNA independently and cultured for 3 days in media containing 
glucose. Cell growth was monitored to assess the effects of each AURKAIP1 siRNA. 
Three days post-transfection the cells were subjected to MTT assay (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma) to measure relative cell 
viability between AURKAIP1 depleted and non-targeting siRNA treated cells. MTT is 
reduced to an insoluble purple formazan in living cells and, as such, accumulation of 
formazan can be used as an estimation of cell growth (as measured by absorbance at 
550nm). In these preliminary experiments with HeLa cells, growth of AURKAIP1 
depleted cells treated with siRNA1, 2 and 3 was 90%, 40% and 50% respectively of the 
growth of control cells. However, the growth of Rho0 cells treated with any of the three 
AURKAIP1 siRNAs was 100% of the growth of control cells. Therefore all three 
siRNAs were causing growth retardation to different degrees in HeLa cells, but no 
growth defect was observed in the Rho0 cells. 
Since the growth retardation phenotype in AURKAIP1 depleted HeLa cells was most 
prominent when using siRNA2, it was probable that siRNA2 most efficiently depleted 
AURKAIP1 transcripts. For this reason, one of the first objectives of my investigations 
was to test the effects of each siRNA in more detail and to confirm the findings of the 
preliminary data.  
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5.2 MATERIALS AND METHODS   
General cell culture methods (2.1.1), cell counts (2.1.3) and details of siRNA depletions 
(2.1.6) are in the General Materials and Methods (Chapter 2).  
5.2.1 IMAGING THE MITOCHONDRIAL NETWORK AND NUCLEOIDS 
Cells were seeded in WillCo glass-bottomed wells (GWst 3522). Cell numbers, 
treatment and incubation time varied depending on the experiment and cell type used. 
Images were captured with an inverted fluorescent microscope (Axiovert 200 M, Carl 
Zeiss) with FITC and Texas Red filters, using the 63X magnification oil immersion 
lens. This equipment and the fluorescent lamp were switched on at least 30 minutes 
prior to image acquisition to allow the light intensity to stabilise. A 3µl PiGr aliquot 
(undiluted, Quant-iTTM, Invitrogen, cat. no. P7581 stored at -20°C and shielded from 
light) was added per ml of media and cells were incubated as normal at 37°C for 50 
minutes. TMRM (Sigma, cat. no. T5428. Stocks prepared in 100% methanol at 5µM 
concentration, stored at -20°C and shielded from light) to a final concentration of 5nM 
was then added to the media and incubated at 37°C for a further 10 minutes. Cells were 
then washed twice with 1ml KRB buffer (135mM NaCl, 5mM KCl, 0.4mM KH2PO4, 
1mM MgSO4, 20mM HEPES pH 7.4 filter sterilised and stored at 4°C,) to remove dead 
cells before adding 1ml of supplemented KRB buffer (KRB supplemented with 5.5mM 
glucose, 1.3mM Ca2+ (from 2M CaCl2 stock) and 5nM TMRM prior to each 
experiment) and shielding from light. The cells were then ready for imaging. 
Exposure times for image capture varied between different experiments, but were 
always the same for all samples within a single experiment. Signal from the PiGr dye 
was captured using the FITC channel (Excitation 495nm, emission 519nm) and signal 
from TMRM dye was captured using the Texas Red channel (excitation 589nm, 
emission 615). Each field was imaged using Z-stacks set to produce ten images with 
focal points 0.4µm apart. Each imaged field was as far apart from each other as possible 
by imaging across the whole area of the well in order to reduce photo-bleaching. 
Transmission light (bright field) images were also taken for each field to document 
cellular morphology. Transmission light images were also used to define cellular area 
when processing the images so that no user bias was introduced by selecting cells based 
on the fluorescent images.  
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5.2.2 ANALYSING NUCLEOID SIZE 
Quantification was performed on all fields imaged for each experimental condition 
using the ImageJ program (http://imajej.nih.gov/ij). The image with the most nucleoids 
in focus from the Z-stacked images from each field was selected to analyse. The 
background was subtracted using a 5-pixel rolling ball radius and then setting an 
appropriate threshold. The image was then subjected to watershed to separate any 
overlapping particles (using Euclidean distance mapping algorithms (Danielsson, 1980; 
Russ, 2011)). A representative section of each image was then subjected to particle 
analysis, which measured the area of each nucleoid. This data was then exported to 
Microsoft Excel for further analysis.  
5.2.3 ANALYSING MITOCHONDRIAL NETWORK FRAGMENTATION 
Quantification of mitochondrial network fragmentation was carried out in a similar way 
to the nucleoid size. The most in-focus Z-stack slice was selected and particles 
analysed. This analysis was kindly performed in collaboration with Dr Jorge Oliveira 
(University of Porto) whilst a visiting scholar. 
5.2.4 MEASURING MITOCHONDRIAL MEMBRANE POTENTIAL 
Cells were prepared as described in 5.2.1, but images were taken using the 10x 
objective without Z-stacks. A transmission light image was taken to ensure correct 
focus before a total of 40 fluorescent images were taken at 30-second intervals using the 
Texas Red channel. After seven images were taken, 2µM FCCP was added to abolish 
the mitochondrial membrane potential. The time-lapse images for each experimental 
condition were analysed in ImageJ. The transmission light image was used as a guide to 
draw regions of interest (ROI) around a selection of over 20 cells within the field. These 
defined ROIs were transferred to the fluorescent images. The fluorescence intensity of 
each ROI was measured and the non-mitochondrial fluorescence (intensity 
measurement from image 40) was subtracted from the total fluorescence (intensity 
measurement from image 1) to give an approximation of the mitochondrial membrane 
potential. The measurements are in arbitrary units but since all images for each 
experiment were acquired with the same exposure settings the values obtained between 
different experimental conditions can be compared to each other, therefore the average 
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membrane potential in a particular experimental condition was presented as a 
percentage of the average membrane potential of the control condition.  
5.3 RESULTS 
5.3.1 EFFECTS OF AURKAIP1 DEPLETION ON CELL GROWTH 
To ensure the preliminary data was replicable it was necessary to test the effects of each 
of the three AURKAIP1 siRNAs. HeLa cells were therefore subjected to depletion with 
each of the three siRNAs independently or with non-targeting control siRNA and cells 
counted after two, three and four days (Figure 5.1).  
Figure 5.1: The Effects of AURKAIP1 Depletion on HeLa Cell Growth. HeLa cells were transfected 
with siRNA that were non-targeting (NT, red) or targeted to AURKAIP1 (siRNA1-blue, siRNA2-green, 
siRNA3-cyan) and incubated for either 2, 3 or 4 days before cells were harvested and counted. Error bars 
show the SEM (standard error mean) of data from three independent experiments for each condition. 
Statistical significance was determined by T-tests on the raw data for each siRNA within each time point. 
* denotes p-values <0.05, ** denotes p-values <0.005, *** denotes p-values <0.0005 n=3. 
 
Two days post-transfection, there was no difference between non-targeting treated cells 
and AURKAIP1 depleted cells. After three days there was significant growth 
retardation in all AURKAIP1 depleted HeLa cells (p-values (vs. NT) - siRNA1=0.018, 
siRNA2=0.018, siRNA3=0.02). This trend continued after four days of siRNA 
treatment (p-values – siRNA1=0.037, siRNA2=0.0018, siRNA3=0.01). However, the 
growth of cells treated with siRNA2 was significantly lower than cells treated with 
either siRNA1 (p=0.0025) or siRNA3 (p=0.0045). The number of cells after four days 
of growth post-transfection with siRNA2 was lower than after 3 days, suggesting cell 
death rather than reduced growth. These data confirm that depletion using siRNA2 has 
the strongest inhibitory effect on cell growth in HeLa cells, with cell number reduced to 
30% of control NT values, compared to 70% with siRNA1 and 58% with siRNA3.  
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Therefore siRNA2 was used to deplete AURKAIP1 in HEK293 and 143B cells to 
investigate the effect on growth in other cell types and caused similar growth retardation 
to HeLa cells, with a reduced growth rate evident on day 3, and evidence of cell death 
after 4 days of depletion (Figure 5.2). 
 
Figure 5.2: AURKAIP1 Depletion Affects Cell Growth in Multiple Cell Types. HeLa, 143B and 
HEK293 cells (labelled) were transfected with either non-targeting (NT) siRNA (red) or AURKAIP1 
siRNA2 (green) and incubated for either 2, 3 or 4 days before cells were harvested and counted. Error 
bars show the SEM of data from three independent experiments for each condition. Statistical 
significance was determined using T-tests on the raw data for each siRNA within each time point. * 
denotes p-values <0.05, ** denotes p-values <0.005, *** denotes p-values <0.0005. 
 
The effects of AURKAIP1 depletion on cell growth were more severe in 143B cells 
(8% of NT after 4 days p=0.00007, 26% after 3 days p=0.0009) and HEK293 cells (8% 
of NT after 4 days p=0.01, 40% after 3 days p=0.02) compared to HeLa cells (18% of 
NT after 4 days p=0.00015, 63% after 3 days p=0.07).  
Cells depleted of AURKAIP1 were visualised by light microscopy. There was clear 
evidence of cell death after 4 days of AURKAIP1 depletion. There were many cells that 
had detached and, of those that were still attached to the culture vessel, most displayed a 
clear morphological change. These cells were more rounded compared to cells treated 
with non-targeting siRNA that had a more irregular angular shape (Figure 5.3).  
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Figure 5.3: Effects of AURKAIP1 Depletion on Cell Morphology. HeLa cells were transfected with 
either non targeting (NT) siRNA (A) or AURKAIP1 siRNA (B) and incubated for four days before being 
visualised by light microscopy. 
5.3.2 EFFECTS OF AURKAIP1 DEPLETION ON MITOCHONDRIAL AND 
NUCLEOID MORPHOLOGY 
It was clear that AURKAIP1 depletion was causing growth retardation in a range of 
different human cell lines (Figure 5.2) and the lack of an effect in Rho0 cells 
(preliminary data as described in 5.1) is suggestive of a mitochondrial role for 
AURKAIP1. Therefore, in order to assess the effects of AURKAIP1 depletion on 
mitochondria, depleted cells were treated with PiGr and TMRM to fluorescently stain 
double-stranded DNA (including mtDNA) and the mitochondrial network respectively.  
AURKAIP1 depletion with siRNA2 appeared to increase the size of mitochondrial 
nucleoids in HeLa cells compared to controls (Figure 5.4). Evidence of large nucleoids 
was clearly visible in the majority of images of AURKAIP1 depleted cells but not in 
those treated with non-targeting siRNA. However there was no difference between 
AURKAIP1 depleted and NT control cells with respect to mitochondrial morphology or 
membrane potential on the basis of TMRM staining.  
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Figure 5.4: Effects of AURKAIP1 Depletion on Mitochondrial Morphology in HeLa Cells. HeLa 
cells were transfected with either non-targeting (NT) siRNA or AURKAIP1 siRNA1 for 4 days. Cells 
were treated with TMRM to stain the mitochondrial network (red) and PicoGreen (PiGr) to stain the 
double-stranded DNA (green) and live-cell fluorescence microscopy was performed. Scale bar = 10µm. 
 
These mitochondrial imaging experiments were repeated in 143B, HEK293 and U2OS 
cells and produced similar results. Depletion with siRNA1 and siRNA3 were also 
carried out to confirm that the phenotype was not specific to siRNA2. To illustrate this, 
depletion of AURKAIP1 with siRNA1 in 143B cells is presented in Figure 5.5 and the 
same enlarged nucleoid phenotype can be seen. The same phenotype was observed with 
all 3 siRNAs, indicating that these enlarged nucleoids are likely to be a specific effect of 
AURKAIP1 depletion.  
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Figure 5.5: Effects of AURKAIP1 Depletion on Mitochondrial Morphology in 143B Cells. HeLa 
cells were transfected with non-targeting (NT) siRNA, AURKAIP1 siRNA1 or AURKAIP1 siRNA2 for 
4 days. Cells were treated with TMRM to visualise the mitochondrial network (red) and PicoGreen (PiGr) 
to stain double-stranded DNA (nucleus and mtDNA nucleoids, green) and live-cell fluorescence 
microscopy was performed. Scale bar = 10µm. 
 
Depletion of AURKAIP1 in HEK293 cells produced similar phenotypes with larger 
nucleoids than in control cells (data not shown). However, the cellular morphology of 
HEK293 cells appears to be more affected by AURKAIP1 depletion than HeLa cells or 
143B cells. Healthy HEK293 cells are more rounded and smaller than the other cell 
types used, and thus it was not possible to visualise features within the cytoplasm as 
easily. Larger and flatter cells produce better images as they have a larger proportion of 
their mitochondria in focus on a single focal plane. For this reason, quantification of the 
increased nucleoid size phenotype was performed on images of both HeLa cells and 
U2OS cells, which are also the most adherent of the cells tested. 
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As U2OS are typically the flattest of the cell type tested, the best quality data could be 
obtained using this line. Consistent with other cell lines investigated, the enlarged 
nucleoid phenotype produced by AURKAIP1 depletion was also evident in U2OS cells 
(Figure 5.6). 
 
Figure 5.6: Enlarged Nucleoids are seen in U2OS cells depleted of AURKAIP1. Representative 
images of U2OS cells that were transfected with either non-targeting (NT) siRNA (A) or AURKAIP1 
siRNA1 (B) and grown for 3 days before being stained with PicoGreen to detect double-stranded DNA 
and imaged using live-cell fluorescence microscopy. 
 
To evaluate the observation of size difference in nucleoids between control and 
AURKAIP1 depleted cells in the PiGr images, the signals detected using the FITC 
channel were subjected to processing to remove background and nuclear staining to 
leave only the signal from nucleoids. Particle analysis was then performed to measure 
the size of each nucleoid. The measurements were then plotted on a histogram to 
compare nucleoid sizes. Larger nucleoids were relatively common in U2OS cells 
depleted of AURKAIP1, but very rare in control cells (Figure 5.7A). When comparing 
the relative proportions of large nucleoids (defined as >0.4µm2) to small nucleoids 
(defined as <0.4µm2) there was a clear shift between non-targeting and AURKAIP1 
siRNA treated cells. Analysis showed that in U2OS cells depleted of AURKAIP1 42% 
of nucleoids were large compared to 22% in non-targeting treated control cells 
(p=0.0024, Figure 5.7C). Visual inspection of other cell types depleted of AURKAIP1 
suggested a similar trend towards enlarged nucleoids (Figure 5.4 and 5.5). Therefore, 
for improved scientific rigour, the phenotype was also quantified in HeLa cells (Figure 
5.7B). The results were strikingly similar between experiments performed in U2OS and 
HeLa cells. HeLa cell depleted of AURKAIP1 had 40% of nucleoids designated as 
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large (>40µm2) compared to only 17% in non-targeting controls (p=0.0003, Figure 
5.7C).   
   
Figure 5.7: Quantification of Nucleoid Size in AURKAIP1 Depleted U2OS and HeLa Cells. Images 
such as those depicted in Figure 5.6 were subjected to background removal to remove the nuclear signal. 
The areas of each remaining nucleoid were measured in images from cells treated with NT siRNA (red) 
and AURKAIP1 siRNA1 (blue) and plotted on a histogram. Results are shown from images of 
experiments performed in U2OS cells (A) and HeLa cells (B). The relative frequency of large nucleoids 
(>0.4µm2, black) to small nucleoids (0-0.4µm2, white) is depicted in (C). * denotes p-values <0.05, ** 
denotes p-values <0.005 and *** denotes p-values <0.0005. Number of nucleoids analysed (from 10 
fields of each condition): U2OS NT n=1310, U2OS AURKAIP1 n=1034, HeLa NT n=1325, HeLa 
AURKAIP1 n=595.  
 
The enlarged nucleoid phenotype upon AURKAIP1 depletion was remarkably 
consistent. Large nucleoids were seen in images of all cell types tested and with all 
siRNAs tested. However, this phenotype was not as marked using siRNA3 compared to 
siRNA1 (Figure 5.8). Although the relative percentage of large nucleoids was greater in 
AURKAIP1 siRNA3 treated cells (25%) compared to non-targeting controls (17%), this 
effect was not statistically significant (p=0.164). Large nucleoids represented 40% of 
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the total in AURKAIP1 siRNA1 treated cells, which was statistically significant 
(p=0.0003). Despite the less striking phenotype in cells treated with siRNA3, very large 
nucleoids (>1µm2) were detected in AURKAIP1 depleted cells with either siRNA (10% 
of nucleoids for siRNA1, n=595; 4% of nucleoids for siRNA3, n=1047), but not in non-
targeting siRNA treated controls (0% of nucleoids, n=1325).     
 
Figure 5.8: Comparison of Nucleoid Enlargement with Different AURKAIP1 siRNAs. Images such 
as those depicted in Figure 5.6 were subjected to background removal to remove the nuclear signal. The 
areas of each remaining nucleoid were measured in images from cells treated with NT siRNA (red), 
AURKAIP1 siRNA1 (blue) and AURKAIP1 siRNA3 (cyan) plotted on a histogram (A). The relative 
frequency of large nucleoids (>0.4µm2, black) to small nucleoids (0-0.4µm2, white) is depicted in (B). 
*** denotes p-value <0.0005. n values given in text.    
5.3.3 EFFECTS OF AURKAIP1 DEPLETION ON MITOCHONDRIAL 
MEMBRANE POTENTIAL 
TMRM is a lipophilic cationic dye that is accumulated by mitochondria due to the 
electrochemical gradient present across the mitochondrial membranes. Thus, at non-
saturating concentrations of TMRM (5nM, non-quench mode), the fluorescence 
intensity is directly proportional to Ψm.  
Initial comparisons of mitochondrial membrane potential can be gathered from the 
images taken at 63x magnification on the Texas Red channel, which detects TMRM 
fluorescence. All images of AURKAIP1 depleted and control cells were all taken with 
the exact same exposure times, to allow the intensity of TMRM signal to be compared 
between the two conditions. The analysis performed on AURKAIP1 depleted cells and 
non-targeting treated controls showed that there was no significant difference in 
membrane potential between the two conditions (Figure 5.9). However, the range of 
intensities was much greater in the AURKAIP1 depleted cells, with a population of 
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cells displaying lower membrane potential and another population displaying higher 
membrane potential than any of the non-targeting controls (Figure 5.9).  
 
 
 
Figure 5.9: Effects of AURKAIP1 Depletion 
on Mitochondrial Membrane Potential. HeLa 
cells were treated with either non-targeting (NT) 
siRNA or AURKAIP1 siRNA2 for 3 days. Cells 
were imaged and the average fluorescence 
intensity per cell was calculated using ImageJ 
software. Fluorescence intensity is presented in 
arbitrary units (A. U.).  
 
 
5.4 DISCUSSION 
The data presented in this chapter shows that AURKAIP1 depletion, with all three 
siRNAs targeting different regions of the transcript, is detrimental to all cell types 
tested. This suggests that the resulting phenotype is not an off-target effect, as it would 
be very unlikely that the same phenotype could be produced via off-target effects from 
three different siRNAs. Changes in nucleoid morphology (Figures 5.4-5.8) upon 
AURKAIP1 depletion corresponded with growth retardation (Figures 5.1 and 5.2). 
Together, these data suggest that the detrimental effects of AURKAIP1 depletion are, at 
least in part, due to effects on the mitochondria. 
Depletion of AURKAIP1 appeared to be more efficient with the use of siRNA2 since 
this showed the strongest growth retardation and caused cell death four days post-
transfection (Figure 5.1). This cell death was not evident from the growth curve data of 
cells transfected with siRNA1 and siRNA3. However, when inspecting the cells 
visually, there was evidence that cell death was occurring after siRNA1 and siRNA3 
treatment, but to a lesser degree than with siRNA2. Perhaps this lower level of depletion 
with siRNA1 or siRNA3 could be due to reduced annealing to the AURKAIP1 mRNA, 
thus resulting in less RISC-mediated degradation. Since the same reagents and 
concentration of each siRNA was used for transfection, it is unlikely that the 
discrepancy in phenotype was due to differences in siRNA uptake. It was concluded 
that siRNA2 was likely to be the most effective in binding AURKAIP1 mRNA and 
triggering RISC-mediated degradation of the transcript, with a consequent loss of 
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protein synthesis. These data, consistent with the results from the preliminary 
experiments (conducted by Dr P. M. Smith), indicated that siRNA2 was the most 
appropriate to mediate AURKAIP1 depletion.  
The efficacy of AURKAIP1 protein depletion was not readily determined by western 
blot, as the endogenous levels of AURKAIP1 are too low to allow detection in cell 
lysates, as discussed previously. Other methods to determine the efficiency of 
AURKAIP1 depletion will be discussed in the following chapter.   
Irrespective of relative differences in siRNA potency, it was clear that the increased size 
of mitochondrial nucleoids was consistent using any of the three AURKAIP1 siRNAs, 
in all of the tested cell types (Figures 5.4-5.7). This nucleoid enlargement was very 
robust and reproducible, but what it suggests about the function of AURKAIP1 is 
unclear. Similar enlarged nucleoid phenotypes have been reported with knockdown of 
TFAM (Kasashima et al., 2011), Drp1 (Ban-Ishihara et al., 2013) and REXO2 (Bruni et 
al., 2013), in addition to overexpression of POLGβ (Di Re et al., 2009) and mutant 
TWINKLE (Goffart et al., 2009).  
When drawing conclusions based on the nucleoid enlargement, it is important to 
consider that PiGr will stain any double-stranded DNA, but it will bind significantly 
less well to supercoiled DNA. This was demonstrated by a reduction in PiGr staining 
for nucleoids following ATAD3 depletion (He et al., 2007), a protein associated with 
nucleoids (Wang and Bogenhagen, 2006). The authors attribute the reduced PiGr signal 
to an increase in negative supercoiling, since the mtDNA levels were only marginally 
reduced and nucleoids could still be seen in fixed cells by immunocytochemistry using 
anti-DNA antibodies (He et al., 2007). Unpublished data from the same group showing 
an increase in PiGr staining upon relaxation of supercoiled plasmid DNA in vitro was 
cited to support the notion that PiGr staining is not necessarily an accurate measure of 
mtDNA mass (He et al., 2007).  
It is possible that the appearance of larger nucleoids in AURKAIP1 depleted cells could 
be explained by the partial or full unwinding of mtDNA. This would cause an increased 
signal from PiGr, which, at the resolution of fluorescence microscopy, may appear to 
have a greater area. This is due to ‘halo’ effects, which are common imaging artefacts 
when visualising intense signal or signals from rounded or thick cells. An unwinding of 
mtDNA would occur during replication, therefore, nucleoids containing replicating 
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mtDNA could potentially produce more intense staining. The unwinding of mtDNA is 
solely carried out by the helicase TWINKLE (Milenkovic et al., 2013). Overexpression 
of several mutated forms of TWINKLE have been shown to increase nucleoid size 
(Goffart et al., 2009). However, this increase in size is not due to TWINKLE unwinding 
DNA resulting in increased intensity of PiGr staining, as nucleoids were visualised with 
an anti-DNA antibody by immunocytochemistry in this study (Goffart et al., 2009). 
Additionally, overexpression of wild-type TWINKLE did not affect nucleoid 
morphology (Goffart et al., 2009). Instead, the replication stalling events dictated by 
mutant TWINKLE may have resulted in a failure to divide nucleoids, thus leading the 
enlarged nucleoid phenotype (Goffart et al., 2009). If this effect is also the cause of the 
enlarged nucleoids with AURKAIP1 depletion, then AURKAIP1 may be implicated in 
mtDNA replication or transcription and in the absence of AURKAIP1, there is a stalling 
of these processes, resulting in enlarged nucleoids.  
If not involved in replication stalling, AURKAIP1 may be involved in nucleoid 
dynamics. Since mitochondrial nucleoids are not static packages of mtDNA, nucleoid 
enlargement could be the result of aberrant nucleoid separation and an accumulation of 
multiple mtDNA molecules per nucleoid. This could be possible without the replication 
stalling seen with mutant TWINKLE overexpression (Goffart et al., 2009). However, 
this explanation seems unlikely, as recent data has estimated that there are only 1.4 
copies of mtDNA per nucleoid on average (Kukat et al., 2011). This study used STED 
super resolution microscopy that gives resolution down to ~50nm compared to only 
~260nm with confocal microscopy. Using this technique Kukat et al. showed that larger 
nucleoids as identified by confocal microscopy were actually clusters of discrete 
nucleoids of approximately equal size (Kukat et al., 2011), rather than a single nucleoid 
containing more copies of mtDNA.  
This could also be the case with the nucleoid distribution following AURKAIP1 
depletion, as the apparently larger nucleoids could actually be due to increased 
clustering of nucleoids. Indeed, impaired segregation of mtDNA was claimed to be the 
reason for the presence of enlarged nucleoids in TFAM depleted cells (Kasashima et al., 
2011). Furthermore, nucleoid clustering has been described in Drp1 depleted cells, 
showing that mitochondrial fission is an important factor in allowing correct nucleoid 
distribution (Ban-Ishihara et al., 2013). This is also supported by data that showed loss 
of mitochondrial fusion by OPA1 depletion prevented the formation of enlarged 
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nucleoids mediated by DNA intercalators (Ashley and Poulton, 2009). Together, these 
data may implicate a role for AURKAIP1 in mitochondrial fission. However, there was 
no evidence of overly elongated mitochondria in AURKAIP1 depleted cells on the basis 
of TMRM staining (Figures 5.4 and 5.4). 
In fact, TMRM staining did not produce any strong indicator of mitochondrial function. 
There was no clear effect on mitochondrial fission or fusion in any of the cell types 
tested. Furthermore, there was no shift in the mean mitochondrial membrane potential 
(Figure 5.9). However, this may be an oversimplification, as the range of estimated 
membrane potential readings in AURKAIP1 depleted cells was much wider than in 
non-targeting controls (Figure 5.9). There is a clear population of AURKAIP1 depleted 
cells displaying reduced membrane potential and another population displaying 
increased membrane potential relative to non-targeting controls. This could suggest a 
sequential process of increased membrane potential, as seen in ATP synthase inhibited 
cells (Johnson et al., 1981), followed by collapse, which can be caused by many insults. 
Membrane potential collapse has been shown to be linked to apoptosis (reviewed in Ly 
et al., 2003). Since cell death is apparent in AURKAIP1 depleted cells, perhaps the 
subset of cells displaying membrane potential collapse (Figure 5.9) were about to 
undergo apoptosis. Though an intriguing possibility, this is speculative and it is 
impossible to ascertain the causality of this effect from the presented data. Respiratory 
dysfunction can lead to apoptosis (reviewed in Helling et al., 2012). Therefore, since the 
preliminary data from AURKAIP1 depleted cells suggested respiratory dysfunction, 
further studies into the effects of AURKAIP1 depletion on mitochondrial gene 
expression were prioritised over estimation of apoptosis levels, due to time constraints.  
Whether the enlarged nucleoid phenotype upon AURKAIP1 depletion was due to an 
increase of mtDNA copy number within a single nucleoid, the clustering of several 
nucleoids in close proximity or the increase in signal intensity due to relaxation of 
supercoiled mtDNA needed to be addressed. If enlarged nucleoids were a result more 
replication events, AURKAIP1 depletion would be expected to lead to an increase in 
mtDNA copy number per cell. If replication stalling were the reason for observing 
enlarged nucleoids, then mtDNA levels would be expected to be reduced, as was seen in 
cells overexpressing mutant TWINKLE (Goffart et al., 2009). Disruption of nucleoid 
distribution would not be expected to alter mtDNA copy number, as was the case with 
Drp1 depletion (Ban-Ishihara et al., 2013). It was therefore important to measure the 
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mtDNA copy number, the results of which will be presented alongside further 
biochemical characterisation of the effects of AURKAIP1 depletion in the following 
chapter. 
It would be interesting to use of STED super resolution microscopy to investigate the 
effects of AURKAIP1 depletion on nucleoids. The enhanced resolution microscopy 
would allow distinction between enlarged nucleoids and clustered nucleoids (Kukat et 
al., 2011). However, due to time constraints these studies were not conducted during my 
investigations.  
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CHAPTER 6: IS AURKAIP1 REQUIRED 
FOR OXIDATIVE PHOSPHORYLATION? 
6.1 INTRODUCTION 
Thus far, my work has shown that AURKAIP1 is a mitochondrial protein (Chapter 4, 
Figure 4.3) and that depletion of AURKAIP1 impairs cell growth (Chapter 5, Figure 
5.1) and leads to an enlarged nucleoid morphology (Chapter 5, Figures 5.5-5.8). These 
data are consistent with the preliminary screen conducted in my host laboratory, which 
indicated that AURKAIP1 depletion caused growth defects in HeLa cells but not in 
Rho0 cells.  
Preliminary data from this screen further suggested a role for AURKAIP1 in 
mitochondrial gene expression as mitochondrial mRNA, protein synthesis and oxygen 
consumption were reduced after depletion of AURKAIP1. However, this preliminary 
data was generated alongside several candidate proteins in a medium/high throughput 
screen. The preliminary nature of the screen meant that estimations of mitochondrial 
mRNA levels were based on qPCR for MT-CO1 only, rather than northern blotting. 
Similarly, measurement of mitochondrial protein synthesis, via [35S] labelled 
methionine incorporation into nascent polypeptides, was estimated based on relative 
radioactivity (counts per second ratio) between AURKAIP1 siRNA treated cells and 
non-targeting siRNA treated controls, rather than visualisation of the translation 
products by SDS-PAGE. Whilst these preliminary findings were useful to implicate the 
involvement of AURKAIP1 in mitochondrial gene expression, there was a requirement 
to confirm reproducibility of these findings using more stringent methods. Therefore, 
this chapter will describe the characterisation of the biochemical phenotype resulting 
from AURKAIP1 depletion, including analysis of mtDNA levels, mt-RNA levels, 
mitochondrial protein synthesis and steady state levels of mtDNA-encoded proteins.  
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6.2 METHODS 
6.2.1 [35S]-METABOLIC LABELLING OF MITOCHONDRIAL PROTEINS 
These experiments were performed with the assistance of Dr Francesco Bruni and Dr 
Hue Tran Hornig-Do. All cells were grown in 25cm2 flasks for three days until a 
confluency of 50-60% was achieved. At this point, normal growth medium was then 
replaced with 2.5ml pre-warmed DMEM free of methionine and cysteine (Sigma, 
D0422) and incubated for 10 minutes at 37°C. Two further met/cys wash out 
incubations were performed, before the media was removed and replaced with 3ml 
methionine/cysteine free DMEM supplemented with 10% dialysed FCS (Sigma, F0392) 
and 100µg/ml emetine dihydrochloride (Sigma, E2375). Following a 10 minute 
incubation at 37°C, 20µl of [35S]-methionine/cysteine mix (Perkin-Elmer Easy Tag 
Express protein labelling mix, NEG-772, specific activity: >1000Ci(37.0TBq)/mmol) 
was added and the cells were incubated at 37°C for a further 45 minutes. Cells were 
then washed with normal growth media containing methionine, harvested in 1ml PBS-
EDTA and pelleted by centrifugation at 200g for 4 minutes. The cell pellets were 
washed three times with PBS (10ml supplemented with one protease inhibitor tablet and 
1mM PMSF) before preparing cell lysates (2.5.1). 
A 50µg aliquot from each sample was subjected to electrophoresis through a 15% SDS 
polyacrylamide gel (using the Hoefer system). The gel was stained with Coomassie for 
10 minutes and destained for 15 minutes. The stained gel was then fixed for 4 hours in 
30% methanol, 10% acetic acid and 3% glycerol and vacuum-dried for 4 hours at 70°C. 
The gel was exposed to a PhosphorImage screen for 5 days before the signal on the 
screen was visualised using the Typhoon FLA 9500 system and ImageQuant software 
(GE Healthcare). 
6.2.2 COMPLEX ACTIVITY ASSAY 
This assay was performed with the assistance of Dr Hue Tran Hornig-Do, according to 
the protocol outlined in (Rustin et al., 1994). Complex activity measurements were 
normalised using total protein concentration as determined by Bradford assay (2.5.3). 
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6.2.3 SITE DIRECTED MUTAGENESIS  
Primers were designed to allow alteration of the sequence of AURKAIP1 in the region 
that was targeted by AURKAIP1 siRNA1 (Table 6.1). Specific mutations were 
incorporated into the primers so that the third base of three consecutive codons were 
changed, but that the codons would encode the same amino acids. These silent 
mutations were incorporated into the pcDNATM5/FRT/TO/AURKAIP1-FLAG plasmid 
using the QuickChange II site directed mutagenesis kit (Agilent Technologies, 200523) 
according to manufacturer’s guidelines. Following sequence confirmation of the 
resulting plasmid, this was used to transfect HEK293 cells (as described in 4.2.1) to 
allow expression of siRNA resistant AURKAIP1-FLAG.  
Table 6.1: Primers for Site-Directed Mutagenesis. 
Name Sequence (5’-3’) 
silAURKAIP1 
siRNA1  
CGG AAG ATG AAC CAT CAT AAA TAC CGG AAG CTG GT 
silAURKAIP1 
siRNA2 
CAC CAC AAG TAC CGT AAA CTC GTG AAG AAG ACG CG 
Key: Blue highlight depicts sequence targeted by the respective siRNAs. Bold and underlined bases 
represent the altered nucleotides relative to the WT AURKAIP1 sequence. 
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6.3 RESULTS 
6.3.1 EFFECTS OF AURKAIP1 DEPLETION ON MTDNA LEVELS 
Since the nucleoid morphology of cells was altered upon AURKAIP1 depletion 
(Chapter 5, Figures 5.4-8), it was important to ascertain whether this was a consequence 
of a change in the levels of mtDNA within the cells. To investigate this, qPCR was 
carried out on DNA isolated from HeLa cells treated with either AURKAIP1 or non-
targeting siRNA for three days. The levels of MT-ND4, which is a mtDNA-encoded 
gene, were analysed relative to the nuclear-encoded gene for 18S rRNA as described in 
Section 2.3.11.  
 
 
 
Figure 6.1: The Effects of AURKAIP1 Depletion on mtDNA 
Copy Number. Graph shows data from qPCR experiments 
conducted in HeLa cells treated with non-targeting (NT) siRNA or 
AURKAIP1 siRNA1 for 4 days. DNA was extracted and qPCR 
performed using MT-ND4 and 18S primers. The relative 
quantification of mtDNA (MT-ND4) to nuclear DNA (18S) was 
calculated using the normalised expression ratio (2ΔCq) method. 
The 2ΔCq values from AURKAIP1 depleted cells were normalised 
to the data from NT controls. Statistical significance was 
determined by t-test (n=6).   
 
 
These data show that there was no significant change in mtDNA copy number in cells 
depleted of AURKAIP1 (average 95.8% relative to non-targeting control, p=0.45 n=5, 
Figure 6.1). Thus, the enlarged nucleoid phenotype seen in AURKAIP1 depleted cells 
(Figures 5.4-5.7) was unlikely to be due to increased mtDNA replication or replication 
stalling, as those conditions would be expected to lead to increased and decreased 
mtDNA copy number respectively. Consequently, it is most likely that AURKAIP1 
depletion interferes with nucleoid distribution, as nucleoid clustering would account for 
the observed phenotype, but would not be expected to affect mtDNA copy number.   
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6.3.2 EFFECTS OF AURKAIP1 DEPLETION ON MITOCHONDRIAL RNA 
LEVELS  
Since mtDNA levels were unaffected, I next wanted to assess whether AURKAIP1 
could be involved in mitochondrial transcription or RNA processing/regulation. To this 
end, the levels of mitochondrial RNA following AURKAIP1 depletion were analysed 
by northern blot. After 3 days siRNA treatment there was a slight decrease in MT-CO1 
and MT-RNR1 (12S rRNA) levels, but an increase in the levels of MT-ND1 (Figure 6.2). 
A general defect in mitochondrial transcription should affect all transcripts equally since 
mtDNA is transcribed from promoters found solely in the non-coding region and thus 
forms large polycistronic units (as discussed in 1.7.2). Therefore, these data indicated 
that AURKAIP1 depletion altered the levels of some mitochondrial RNAs, but was 
unlikely to be affecting transcription.  
 
 
Figure 6.2: Effects of AURKAIP1 Depletion on 
Mitochondrial RNA levels. HeLa cells were treated with either 
non-targeting (NT) siRNA or AURKAIP1 siRNA1 for 3 days. 
RNA was extracted and purified, before being subjected to 
northern blot analysis. The blot was analysed using probes for 
mitochondrial mRNAs MT-CO1 and MT-ND1, mitochondrial 
12S rRNA and cytosolic 18S rRNA.  
 
6.3.3 EFFECTS OF AURKAIP1 DEPLETION ON MITOCHONDRIAL 
PROTEIN SYNTHESIS 
To see whether the changes in RNA levels upon AURKAIP1 depletion corresponded to 
changes in mitochondrial protein synthesis, HeLa cells were depleted of AURKAIP1 
for three days and nascent mitochondrial proteins were radiolabelled with [35S]met. It 
was clear that the synthesis of some mtDNA-encoded proteins was reduced in 
AURKAIP1 depleted cells, most notably, COXI (Figure 6.3). However, the synthesis of 
several proteins, for example ND2, remained unchanged (Figure 6.3). Quantification 
was performed on the COXI, ND2 and cyt b signal from two independent experiments 
and analysed by T-test. COXI synthesis was reduced to 44% in cells treated with 
AURKAIP1 siRNA1 compared to controls (p=0.00063), whereas there was no 
significant change in ND2 (100% p=0.5) or cyt b (104%, p=0.36) synthesis relative to 
non-targeting controls. 
  117 
 
 
 
 
 
 
 
 
 
Figure 6.3: The Effects of AURKAIP1 
depletion on Mitochondrial Protein 
Synthesis. HeLa cells were treated with either 
non-targeting (NT, lane 1) siRNA or 
AURKAIP1 siRNA1 (lane 2) or siRNA2 
(lane3) for 3 days. Nascent mitochondrial 
polypeptides were labelled with [35S]-
methionine, subjected to 15% SDS-PAGE and 
detected using the Typhoon FLA 9500 system 
and ImageQuant software. The presented data 
is representative of two independent repeats. 
Quantification of signal intensity was 
performed using ImageQuant software and a 
trace representing this is presented with NT 
shown in black, AURKAIP1 siRNA1 shown in 
red and AURKAIP1 siRNA2 shown in blue. 
 
 
 
The phenotype produced by AURKAIP1 depletion was far from a generalised defect in 
mitochondrial translation. Unexpectedly, 3 days of AURKAIP1 depletion slightly 
reduced the synthesis of ND1 over the 45-minute time course of [35S]met incorporation, 
despite a substantial increase in mRNA levels (Figure 6.2). There was not adequate 
separation to allow distinct bands corresponding to ATP6 and COXII to be identified, 
though it was clear that there was a reduction in signal from the co-migrating band after 
AURKAIP1 depletion with either siRNA (approximately 57% and 53% of NT for 
siRNA1 and siRNA2 respectively, Figure 6.3). Whether this reduction reflects reduced 
synthesis of ATP6, COXII or both cannot be discerned. What is apparent is that 
depletion of AURKAIP1 with either siRNA1 or siRNA2 produced the same results, 
which strengthens the validity of these observations.  
6.3.4 EFFECTS OF AURKAIP1 DEPLETION ON STEADY STATE LEVELS 
OF MTDNA-ENCODED PROTEINS 
Since there was a clear effect of AURKAIP1 depletion on mitochondrial protein 
synthesis, it was important to assess the steady state levels of mtDNA-encoded proteins 
  118 
in these cells. To this end, 4-day AURKAIP1 depletion with siRNA2 was conducted in 
HeLa and 143B cells respectively. The depletion of AURKAIP1 led to reduced signal 
for COXII (Figure 6.4A) as assessed by immunoblotting. Depleting HeLa cells of 
AURKAIP1 with each of the AURKAIP1 siRNAs resulted in a reduction in steady state 
levels of COXI and COXII relative to non-targeting controls (Figure 6.4B). These data 
once again demonstrated that each siRNA was producing similar phenotypes.  
 
Figure 6.4: Effects of AURKAIP1 Depletion on Steady State Levels of mtDNA-encoded Proteins. A) 
HeLa cells (lanes 1 and 2) and 143B cells (lanes 3 and 4) were treated with either non-targeting (NT) 
siRNA (lanes 1 and 3) or AURKAIP1 siRNA2 (lanes 2 and 4) for 4 days. Cell lysates were produced and 
40µg aliquots were subjected to western blot analysis and immunoblotted with α-COXII and α-porin 
antibodies. B) HeLa cells were treated as in A, but AURKAIP1 siRNA1 (lane 2), siRNA2 (lane 3) and 
siRNA3 (lane 4) were each used for AURKAIP1 depletion and compared to treatment with NT siRNA 
(lane1). Additionally α-COXI was also used for immunoblotting. C) HeLa cells treated as in B, but 
siRNA treatment lasted 6 days and α-ND1 was also used for immunoblotting.   
 
Increasing the length of treatment with siRNA to 6 days also showed a clear reduction 
in the steady state levels of COXI, COXII and ND1 with all of the siRNAs tested 
(Figure 6.3C). However, after 6 days of AURKAIP1 depletion, the reduction of COXI 
and COXII levels was less striking. This was particularly evident in cells depleted of 
AURKAIP1 with siRNA2. This may be explained by the more severe effect of siRNA2 
on cell growth (as discussed in Chapter 5, Figure 5.1). It was likely that after 6 days of 
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depletion, most cells transfected with AURKAIP1 siRNA 2 had died. Thus, the majority 
of the remaining cells were probably those that were either not transfected or poorly 
transfected, which would account for the less severe phenotype seen.  
The data presented in Figure 6.3 are representative depictions of AURKAIP1 depletions 
after 4 and 6 days and it was consistently found that 4-day AURKAIP1 depletions using 
siRNA1 displayed the clearest reduction in mtDNA-encoded proteins and least cell 
death. For this reason, AURKAIP1 siRNA1 was predominantly used for depleting 
AURKAIP1.  
It was difficult to assess the relative effects of each siRNA on AURKAIP1 protein 
levels directly since the endogenous levels of AURKAIP1 are very low. Depletion of 
endogenous AURKAIP1 by siRNA1 was confirmed by western blot analysis of 143B 
mitochondrial lysate as discussed in Chapter 4 (Figure 4.4B). Overexpressed 
AURKAIP1-FLAG was also efficiently depleted in cells treated with AURKAIP1 
siRNA2 (Figure 4.4A). To confirm that AURKAIP1 depletion coincided with the 
reduction of steady state levels of mtDNA-encoded proteins, HEK293-AURKAIP1-
FLAG cells were simultaneously induced with 10ng/ml doxycycline to allow low levels 
of AURKAIP1-FLAG overexpression, and treated with AURKAIP1 siRNA1 for 4 
days. This allowed depletion of overexpressed AURKAIP1-FLAG, which can be seen 
in Figure 6.5. Furthermore, the COXII signal was also reduced in the AURKAIP1 
depleted cells, thus providing further evidence that the effects of AURKAIP1 siRNA 
treatment are indeed mediated by AURKAIP1 depletion and not due to off-target 
effects.  
 
Figure 6.5: AURKAIP1 siRNA can Deplete Expressed 
AURKAIP1-FLAG. HEK293-AURKAIP1-FLAG cells 
were subjected to transfection with either non-targeting 
(NT) siRNA or AURKAIP1 siRNA1. Cells were then 
induced to express AURKAIP1-FLAG at low levels by 
the addition of 10ng/ml doxycycline (Dox) to the culture 
media. The treated cells were then incubated for 4 days 
under normal growth conditions before cell lysates were 
prepared and subjected to 12% SDS-PAGE and 
immunoblotting with α-COXII, α-AURKAIP1 and α-
porin antibodies.    
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6.3.5 DOES AURKAIP1 DEPLETION AFFECT THE ACTIVITY OF 
RESPIRATORY COMPLEXES? 
Next, it was decided to see if the reduction in mtDNA-encoded protein expression 
corresponded to a reduction in activity of the respiratory complexes. COXI and COXII 
are subunits of Complex IV and ND1 is a subunit of Complex I. Since the steady state 
levels of these proteins were reduced upon AURKAIP1 depletion, it would be expected 
that AURKAIP1 depletion would inhibit the activity of these complexes. Indeed, 
AURKAIP1 siRNA1-mediated depletion led to a reduction in Complex I (Figure 6.6A) 
and Complex IV (Figure 6.6B) activity to 59% (p=0.039) and 72% (p=0.04) 
respectively. 
 
Figure 6.6: The Effects of AURKAIP1 Depletion on Respiratory Complexes. HeLa cells were treated 
with either non-targeting (NT) siRNA or AURKAIP1 siRNA1 (AUR1) for 4 days. A) Complex I (CI) and 
B) Complex IV (CIV) activity were measured spectrophotometrically as described in (Rustin et al., 
1994). These experiments were conducted with the help of Dr Hornig-Do. Data represents two 
independent experiments, error bars=SEM. * denotes p<0.05. 
6.3.6 CAN EXPRESSION OF SIRNA RESISTANT AURKAIP1 RESCUE 
THE PHENOTYPE OF AURKAIP1 DEPLETION?  
From the previous experiments it was clear that AURKAIP1 depletion was inhibiting 
mitochondrial gene expression. It has also been shown that AURKAIP1 siRNA could 
deplete both expressed AURKAIP1-FLAG (Figure 4.4A and 6.4) and the endogenous 
AURKAIP1 protein (Figure 4.4B). All three siRNAs can deplete AURKAIP1 and 
produce similar mitochondrial phenotypes such as enlarged nucleoids (Figures 5.4-5.8), 
reduced mitochondrial protein synthesis (Figure 6.3) and steady state levels of mtDNA-
encoded proteins (Figure 6.4 B and C). Together, these data suggest that these 
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phenotypes are due to AURKAIP1 depletion and not off-target effects. However, to 
conclusively demonstrate that the phenotype was due to AURKAIP1 depletion alone, it 
was important to rescue the phenotype of AURKAIP1 depletion. To this end, site 
directed mutagenesis was performed to allow expression of a modified version of 
AURKAIP1-FLAG with silent mutations (silAURKAIP1-FLAG). The silent mutations 
altered the nucleotide sequence so that the third base of three consecutive codons in the 
siRNA1-binding region of the AURKAIP1 ORF were altered. Crucially, the amino acid 
encoded by each mutated codon remained unchanged from the wild-type sequence 
(Figure 6.7A). This allowed for expression of AURKAIP1-FLAG that was resistant to 
depletion with AURKAIP1 siRNA1. The pcDNATM5/silAURKAIP1-FLAG plasmid 
was used to transfect HEK293 cells to produce stable cell lines (HEK293-
silAURKAIP1-FLAG) as described in 4.2.1. 
HEK293-silAURKAIP1-FLAG cells were treated with non-targeting siRNA or depleted 
of AURKAIP1 with siRNA1 for 48 hours before inducing the cells with 1µg/ml 
tetracycline for a further 48 hours. Since reduction of steady state protein levels of 
COXII and COXI was a consistent observation after 4 days of AURKAIP1 depletion, it 
was these parameters that were to be assessed in the ‘rescued’ cells.  
Surprisingly, steady state levels of COXI and COXII were reduced in the cells 
expressing silAURKAIP1-FLAG, regardless of AURKAIP1 depletion (Figure 6.7B). 
Strikingly, the depletion of COXI and COXII levels after overexpression was more 
severe than was seen in AURKAIP1 depleted cells (Figure 6.4). These data suggest that 
precise AURKAIP1 levels are vital for mitochondrial gene expression as AURKAIP1 
overexpression and AURKAIP1 depletion can each lead to a reduction in steady state 
levels of mtDNA-encoded proteins. 
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Figure 6.7: Expressing siRNA Resistant AURKAIP1 to attempt to Rescue the Phenotype of 
AURKAIP1 Depletion. A) Sequencing data illustrating the silent mutations made to the 
pcDNATM5/AURKAIP1-FLAG plasmid by site-directed mutagenesis. The shown sequence represents the 
siRNA1-binding region. Two C-T mutations result in change from a CAC codon to a CAT codon, both of 
which encode histidine. A further G-A mutation changes n AAG codon to an AAA codon, both of which 
encode lysine. The upper panel shows the wild-type (WT) sequence and the lower panel shows the silent 
mutated sequence. B) HEK293-silAURKAIP1-FLAG cells were transfected with either non-targeting 
(NT) siRNA (lanes 1 and 3) or AURKAIP1 siRNA1 (AUR1) for 48 hours. Cells were either left for 
another 48 hours (uninduced, lanes 1 and 2) or treated with 1µg/ml tetracycline (induced, lanes 3 and 4). 
Aliquots of cell lysate (40µg) from cells subjected to each condition were analysed by SDS-PAGE and 
western blotting. α-COXI, α-COXII, α-FLAG and α-porin antibodies were used for immunoblotting. C) 
HEK293-AURKAIP1-FLAG (WT) or HEK293-silAURKAIP1-FLAG (Silent Mutation) cells were 
subjected to combinations of siRNA treatment and tetracycline induction as in B. Cell lysate (40µg) from 
uninduced WT cells treated with NT siRNA (NT U, lane 1), induced NT treated WT cells (WT, NT I, 
lane 2), induced WT cells treated with AURKAIP1 siRNA1 (WT, AUR I, lane 3), NT treated, induced 
silent mutation cells (lane 4) or AURKAIP1 siRNA1 treated, induced silent mutation cells (lane 5) were 
subjected to SDS-PAGE and western blotting. α-FLAG and α-porin antibodies were used for 
immunoblotting. Quantification of signal intensity was performed in Image Lab.  
 
The effects of AURKAIP1 siRNA1 on expression of AURKAIP1-FLAG and 
silAURKAIP1-FLAG were assessed to ensure the silAURKAIP1-FLAG expression 
was successful. It was clear that when HEK293-AURKAIP1-FLAG cells were treated 
with AURKAIP1 siRNA1, the expression of AURKAIP1-FLAG was greatly 
diminished (approximately 19% compared to uninduced controls). In contrast, 
HEK293-silAURKAIP1-FLAG cells treated with AURKAIP1 siRNA1 expressed 
silAURKAIP1-FLAG to similar levels as cells treated with non-targeting siRNA 
(approximately 82% of uninduced controls) (Figure 6.7C).  
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6.4 DISCUSSION 
The data presented in this chapter clearly show that AURKAIP1 depletion negatively 
affects mitochondrial gene expression. The effects are not due to reduction in the 
mtDNA itself, as qPCR analysis did not show a change in mtDNA copy number after 
AURKAIP1 depletion (Figure 6.1). Coupled with the enlarged nucleoid phenotype seen 
in AURKAIP1 depleted cells (Figures 5.4-5.8), these data may indicate that 
AURKAIP1 plays a role in nucleoid distribution. TFAM depleted cells show similar 
nucleoid enlargement, which was attributed to a role for TFAM in nucleoid distribution 
between daughter cells during mitosis (Kasashima et al., 2011). In addition, depletion of 
the mitochondrial AAA protease ClpX produces a similar nucleoid enlargement 
phenotype (Kasashima et al., 2012). This effect was dependent on TFAM and ClpX was 
hypothesised to function as a chaperone rather than a protease to maintain nucleoid 
distribution through TFAM (Kasashima et al., 2012). Mitochondrial fission has also 
been implicated in nucleoid distribution as depletion of Drp1 also results in enlarged 
nucleoids, without any change in mtDNA copy number (Ban-Ishihara et al., 2013). It is 
difficult to say whether effects on nucleoid distribution are a primary effect of depletion 
of these proteins, or a consequence of another effect. Very little is currently understood 
regarding nucleoid distribution and its importance for mitochondrial gene expression. 
Nonetheless, a potential role for AURKAIP1 in the process will be an interesting topic 
for future investigations. 
Though the levels of mtDNA remain unchanged, there were effects on the steady state 
levels of mitochondrial RNAs after AURKAIP1 depletion. This may implicate 
AURKAIP1 as a modulator of transcription or in an RNA processing or maturation 
process. Levels of MT-CO1 and 12S rRNA (MT-RNR1) were slightly reduced in 
AURKAIP1 depleted cells, but MT-ND1 levels were increased (Figure 6.1). These data 
suggest AURKAIP1 is unlikely to play a role in mitochondrial transcription as there 
was not a generalised reduction in mitochondrial RNA levels as would be expected if 
transcription was inhibited. Perhaps AURKAIP1 has a role in stabilising MT-CO1 
mRNA. This could explain the reduction in MT-CO1 mRNA relative to MT-ND1 
mRNA. AURKAIP1 shares a conserved DUF1713 domain (conserved domain search 
for AURKAIP1 was carried out using the Conserved Domain Database (Marchler-
Bauer et al., 2011) with the yeast Cox24 protein, which is expressed in 
Schizosaccharomyces pombe (Wood et al., 2002) and Saccharomyces cerevisiae (Huh 
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et al., 2003). Cox24 has been shown to be involved in COXI mRNA splicing in 
S.cerevisiae (Barros et al., 2006). This shared DUF1713 domain also led to AURKAIP1 
appearing on a bioinformatic screen searching for Complex IV assembly factors 
(Szklarczyk et al., 2012). However, there are no introns in the human mitochondrial 
genome, unlike in yeast mtDNA. Therefore, MT-CO1 mRNA does not require splicing, 
unlike COXI mRNA in yeast (Barros et al., 2006). A notable difference between yeast 
Cox24 and AURKAIP1 is that Cox24 is a mitochondrial inner membrane protein 
(Barros et al., 2006), whereas I have shown AURKAIP1 to be a matrix protein (Figure 
4.3B). Nevertheless, this conservation of domains was of interest and was pursued 
during the course of my investigations, however, no RNA binding activity was seen 
with AURKAIP1-FLAG using CLIP (cross-linking and immunoprecipitation, as 
described in (Ule et al., 2005) (data not shown).  
The importance of AURKAIP1 for mitochondrial translation was determined by [35S] 
labelling of nascent polypeptides (Figure 6.2). The synthesis of some mitochondrial 
proteins (most notably COXI) was significantly reduced, though the synthesis of most 
proteins (such as ND2 and cyt b) was similar to non-targeting controls. Since there was 
not a general effect on the synthesis of all mtDNA-encoded protein, these data suggest 
that AURKAIP1 is not involved in critical translation processes such as elongation. 
However, there may be a modulatory role for AURKAIP1, perhaps as a translational 
activator for COXI. It may also be possible that AURKAIP1 associates with a subset for 
mitoribosomes and affects which mRNAs are loaded. Alternatively, the reduction in 
protein synthesis for COXI could simply be due to the reduced mRNA levels of MT-
CO1. This is unlikely because the effect on COXI synthesis was more profound than the 
reduction of MT-CO1 mRNA. Moreover, synthesis of ND1 was reduced in AURKAIP1 
depleted cells (Figure 6.3), whereas MT-ND1 mRNA levels were increased (Figure 6.2), 
suggesting the effects on mitochondrial translation cannot be explained by altered 
mRNA levels alone. The discrepancy between MT-ND1 mRNA levels and protein 
synthesis of ND1 is interesting, but this effect is not unique. Other data from my host 
laboratory has also shown an increase in MT-ND1 mRNA, with an accompanying 
reduction of ND1 protein levels in patient cell lines harbouring a mutation in mtPAP 
(Dr W. C. Wilson personal communication). The mechanisms underlying this 
phenotype remain unclear. 
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Steady state levels of mtDNA-encoded proteins are in accordance with the observed 
effects on protein synthesis in AURKAIP1 depleted cells. For example, COX1 and ND1 
protein levels are both reduced in cells lacking AURKAIP1 (Figure 6.3C). The steady 
state levels of COXII are also reduced. This may suggest that a reduction in COXII 
protein synthesis. From the [35S] labelling of nascent proteins, it was difficult to 
determine the effects of AURKAIP1 depletion on COXII synthesis as COXII and ATP6 
were not separated by the 15% polyacrylamide gel. There was a clear decrease in the 
intensity of the co-migrating band, but from the presented data alone it was impossible 
to suggest whether reduced synthesis of COXII, ATP6 or both was the cause of this 
observation. Since steady state levels of COXII are dramatically reduced after 
AURKAIP1 depletion, it is more likely that COXII synthesis was impaired. Although, 
low COXI levels would affect Complex IV stability, potentially leading subsequent 
COXII degradation, which could also explain for the observed reduction in steady state 
COXII levels. 
The most surprising observation presented in this chapter is the dramatic reduction in 
steady state levels of COXI and COXII after overexpression of silAURKAIP1-FLAG 
(Figure 6.7B). Far from rescuing the phenotype of AURKAIP1 depletion, 
overexpression of silAURKAIP1-FLAG resulted in a more pronounced reduction of 
COXI and COXII steady state levels. Moreover, AURKAIP1 depletion did not reduce 
the mtDNA-encoded protein levels in HEK293-silAURKAIP1-FLAG cells (Figure 
6.6B lane 2). The most likely explanation for this is ‘leaky’ expression of 
silAURKAIP1-FLAG in the uninduced cells. The FlpInTMTRExTM system relies on 
expression of the tet-repressor to prevent expression of the inserted gene in the absence 
of tetracycline. However, there is almost always a very small amount of ‘leaky’ 
expression of the inserted gene in the absence of tetracycline (Prof R. N. Lightowlers, 
unpublished observation, personal communication). Therefore, it is probable that there 
was low-level expression of silAURKAIP1-FLAG in the uninduced cells that was not 
detectable on the western blot (Figure 6.7B lanes 1 and 2). Since the endogenous levels 
of AURKAIP1 in 40µg of cell lysate are also undetectable by western blot, and that 
silAURKAIP1-FLAG is resistant to AURKAIP1 siRNA1 treatment (Figure 6.7C), it is 
possible that the ‘leaky’ expression of silAURKAIP1-FLAG is sufficient to prevent the 
conditions of AURKAIP1 depletion. This explanation is consistent with data showing 
that AURKAIP1 depletion led to a reduction in COXII protein levels in HEK293-
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AURKAIP1-FLAG cells (Figure 6.5, lane 2), but not in HEK293-silAURKAIP1-FLAG 
cells (Figure 6.7B, lane 2), as the wild-type AURKAIP1-FLAG was depleted by the 
siRNA (Figure 6.5, lane 2), but silAURKAIP1-FLAG was resistant to depletion (Figure 
6.7C, lane 5).  
The ‘leaky’ expression of silAURKAIP1-FLAG cannot be said with certainty to 
account for the apparent rescue of the effects of AURKAIP1 siRNA treatment, as the 
potential ‘leaky’ expression could not be detected by western blot. However, this 
hypothesis best explains the observed data and would suggest that AURKAIP1 siRNA 
mediates its effects by specific AURKAIP1 depletion rather than off-target effects. The 
fact that AURKAIP1 depletion with each siRNA produces very similar phenotypes in 
terms of morphology changes (Chapter 5), and impairment of mitochondrial gene 
expression (this Chapter), further supports this conclusion.  
The most striking aspect of the AURKAIP1 overexpression phenotype is that it is 
similar to the AURKAIP1 depletion phenotype in that COXI and COXII protein levels 
are reduced by each condition. This creates a conundrum as to how excessively high or 
extremely low levels of a single protein can exhibit similar, rather than opposite effects. 
To address this issue, further characterisation of the AURKAIP1 overexpression 
phenotype will be the focus of the following chapter.  
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CHAPTER 7: STUDYING AURKAIP1 
OVEREXPRESSION 
7.1 INTRODUCTION 
In the preceding chapter I showed that AURKAIP1 overexpression, as well as 
AURKAIP1 depletion, disrupted mitochondrial gene expression as measured by COXI 
and COXII steady state protein levels (Figure 6.6B). Therefore, it was important to 
further investigate the effects of AURKAIP1 overexpression on mitochondrial gene 
expression. To this end, studies were conducted to characterise the effects of 
AURKAIP1 overexpression on cell and mitochondrial morphology, mtDNA levels, 
mitochondrial RNA levels and mitochondrial protein synthesis. Of particular interest 
was determining the similarities and differences between the phenotypes exhibited by 
AURKAIP1 overexpression and AURKAIP1 depletion. In this way, AURKAIP1 
overexpression was used as an additional tool to allow further investigation of the 
function of AURKAIP1 in human mitochondria. 
The role of AURKAIP1 may be hinted by identifying binding partners. Towards this 
goal, immunoprecipitation studies were conducted. Co-immunoprecipitation (Co-IP) is 
the method of precipitating a known protein, along with any proteins that are bound to 
it, out of a solution using an antibody that specifically binds the known protein. The 
precipitated protein complex can then be eluted and analysed by various methods 
including western blot analysis and mass spectrometry. Western blot analysis should be 
used when testing for specific interactions, and requires antibodies to each protein that 
is to be assessed. Mass spectrometry analysis, on the other hand, allows identification of 
unknown proteins based on the mass-charge ratio of their constituent molecules. Since 
there were no published data regarding binding partners of AURKAIP1 at the time of 
my investigations, mass spectrometry was a useful technique to use. There are many 
types of mass spectrometry, but of particular relevance to my work is MALDI-TOF 
(matrix-assisted laser desorption/ionisation with time of flight), which coupled with 
peptide mass fingerprinting is commonly used for identification of proteins. MALDI 
refers to the method of breaking up and charging the analyte and TOF refers to the 
method of detection (Vorm et al., 1994). Put simply, when used to analyse peptides, the 
analyte is charged by MALDI, before the application of a voltage causes acceleration of 
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the constituent molecules based on their charge. The molecules then pass though a 
defined space to a detector, with the time of flight being proportional to the mass of the 
molecule (Wollnik, 1993). Peptide mass fingerprinting involves the protein being 
cleaved into smaller peptides, the masses of which are determined by MALDI-TOF. 
The resulting masses are compared to those produced by known proteins in a large 
database. The best match is determined statistically and the identified protein can then 
be confirmed using western blotting.  
AURKAIP1 overexpression allowed Co-IP studies to be conducted via the FLAG 
moiety. For this reason, Co-IP experiments will be presented in this chapter alongside 
the biochemical characterisation of the effects of AURKAIP1 overexpression.  
7.2 METHODS 
7.2.1 ISOKINETIC SUCROSE GRADIENT 
Before harvesting cells, gradient buffer was prepared (50mM Tris/HCl pH 7.2, 10mM 
MgOAc, 40mM NH4Cl, 100mM KCl, 1mM PMSF and 50µg/ml chloramphenicol), 
filter sterilised and left on ice. A total of 0.5g and 1.5g of sucrose was added to 5ml 
gradient buffer to produce 10% and 30% sucrose solutions respectively. An aliquot of 
500µl of the 10% sucrose solution was added to a Beckman Ultracentrifuge tube 
(Beckman Coulter, 343778). Then, using a 1ml syringe and needle, 500µl of the 30% 
sucrose solution was carefully injected under the 10% solution, so as to produce two 
distinct layers. The tubes were sealed with a rubber plug and placed onto the Biocomp 
Gradient Maker 107 instrument. A linear gradient was produced by running the TL55 
program (short sucrose, 10-30% S1/1 0:55/85.0/22) and then incubating at 4°C on a flat 
surface for 1 hour.  
Cells were harvested and lysed in Sigma lysate buffer (as for immunoprecipitation 
described below, 7.2.2) and incubated at 4°C for 30 minutes with rotation. The lysates 
were centrifuged at 12,000g for 10 minutes before the supernatant was collected and 
protein concentration measured by Bradford assay (2.5.3). An aliquot of 800µg (in a 
100µl volume) of lysate was carefully loaded onto the gradient so as not to disturb the 
gradient. The loaded gradient(s) were then centrifuged at 100,000g for 2 hours 15 
minutes at 4°C (Beckman Optima TLX ultracentrifuge, acceleration-1, deceleration-4). 
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The gradient(s) were carefully removed from the ultracentrifuge and eleven 100µl 
fractions were sequentially taken, removing the uppermost layer of the remaining 
gradient each time. The first fraction taken from the top of the gradient was designated 
fraction 1 and all subsequent fractions named sequentially, until finally fraction 11 was 
taken. The gradient fractions were either snap frozen in liquid nitrogen and stored at -
80°C or aliquots of 10µl (with the addition of 2.5µl 5x SB) were subjected to SDS-
PAGE.    
7.2.2 CO-IMMUNOPRECIPITATION VIA THE FLAG MOIETY 
Co-Immunoprecipitaiton (Co-IP) via the FLAG moiety was carried out on 
mitochondrial preparations from HEK293-AURKAIP1-FLAG or U2OS-AURKAIP1-
FLAG cells that had been grown in 300cm2 flasks and induced with tetracycline for 3 
days. Mitochondrial pellets were resuspended in homogenisation buffer (2.5.2) and the 
protein concentration was measured by Bradford assay (2.5.3). A known quantity 
(varied between experiments depending on amount of material available, generally 0.5-
1mg) of mitochondria were once again pelleted at 11,000g for 10 minutes at 4°C before 
the supernatant was discarded and the mitochondrial pellet was lysed by the addition of 
500µl Sigma lysis buffer (50mM Tris/HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% 
Triton X-100 and supplemented with 10mM MgCl2 and 1mM PMSF) and incubating at 
4°C for 30 minutes with rotation.  
The Co-IP was carried put using the FLAG® immunoprecipitation kit (Sigma, 
FLAGIPT-1). A 40µl aliquot of the ANTI-FLAG® affinity gel, which equates to 
approximately 20µl volume of packed gel resin, was centrifuged at 5000g for 30 
seconds in a hydrophobic microcentrifuge tube. The supernatant was discarded and the 
packed gel washed 3 times with 1ml of 1x wash buffer (50mM Tris/HCl pH 7.4 and 
150mM NaCl supplemented with 10mM MgCl2, 1x protease inhibitor cocktail and 
1mM PMSF). Wash buffer was removed without discarding any resin. 
After the 30-minute incubation, the mitochondrial lysate was centrifuged at 12,000g for 
10 minutes at 4°C before removing the supernatant into a new tube and performing a 
Bradford assay (2.5.3). Typically, 800µg of mitochondrial proteins in 500µl Sigma 
lysate buffer was added to the washed resin and incubated at 4°C for 3 hours with 
rotation. The resin was pelleted by centrifugation at 5000g for 30 seconds and the 
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supernatant (flowthrough fraction) was saved. The resin was then washed 3 times with 
supplemented wash buffer. To elute, the resin was resuspended in 100µl supplemented 
wash buffer with 250ng/µl final concentration of 3x FLAG® peptide and incubated at 
4°C for 45 minutes with rotation. The resin was pelleted by centrifugation at 5000g for 
30 seconds and the supernatant (elution fraction) saved for analysis by SDS-PAGE and 
either western blotting (2.5.6) or InstantBlue Coomassie staining (2.5.5). 
7.2.3 CO-IMMUNOPRECIPITATION VIA ANTIBODIES TO ENDOGENOUS 
PROTEINS 
Typically 20µl of magnetic beads (Dynabeads Protein G, Life Technologies, 10003D) 
were used per Co-IP reaction. The beads were prepared by washing 3 times with 1ml 
100mM sodium phosphate buffer pH 8.1 (Na-P) and pelleted after each wash by placing 
in a magnetic rack. The beads were resuspended in a final volume of 100µl antibody 
mix (10µl for commercial antibodies (mtPAP, MNK1, p32) and 30µl for in-house 
generated antibodies (AURKAIP1 and MRPL12) made up to 100µl with Na-P) and 
incubated for 1 hour at room temperature with rotation. This allowed the formation of a 
Protein G-antibody complex, which was subsequently washed 3 times with 1ml chilled 
Sigma lysate buffer before the addition of the lysed mitochondrial fraction (prepared in 
the same manner as for α-FLAG Co-IP, see 7.2.2 above). The reaction was incubated 
for 3 hours at 4°C with rotation. The beads (now complexed with antibody and antigen) 
were once again pelleted in a magnetic rack and washed 5 times with chilled lysate 
buffer. The antigens were eluted from the beads by the addition of 25µl Sigma lysate 
buffer and 6.25µl 5x sample loading buffer (as for western blotting, 2.5.6) and heating 
at 95°C for 3 minutes with 1000rpm shaking in an Eppendorf Thermomixer. The beads 
were pelleted in a magnetic rack and the elution (supernatant) transferred to a fresh tube 
and either stored at -80°C or immediately subjected to SDS-PAGE (2.5.4).  
When performing Co-IP using the endogenous AURKAIP1 antibody, 800µg of 
proteinase K shaved mitoplasts were used rather than crude mitochondrial lysate. 
Preparation of the mitoplast fraction was performed as for the mitochondrial sub-
localisation protocol (4.2.2).  
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7.2.4 MASS SPECTROMETRY ANALYSIS 
Approximately half of the α-FLAG Co-IP elution from HEK293-AURKAIP1-FLAG 
isolated mitochondria was subjected to SDS-PAGE (2.5.4) and stained using 
SimplyBlueTM SafeStain (2.5.5). Bands were excised using a sterile scalpel and sent to 
Pinnacle (Newcastle University) for MALDI-TOF mass spectrometry analysis. 
7.3 RESULTS 
7.3.1 DOES AURKAIP1 OVEREXPRESSION AFFECT MITOCHONDRIAL 
MORPHOLOGY? 
AURKAIP1-FLAG overexpression did not produce a striking growth retardation or cell 
morphology change even after 7 days of treatment (Figure 7.1). This observation 
contrasts with the effects of AURKAIP1 depletion, where treated cells exhibited clear 
growth retardation (Figure 5.3).  
 
There was a distinctive enlarged nucleoid phenotype in AURKAIP1 depleted cells as 
discussed in Chapter 5. This is likely due to improper nucleoid distribution. To see if 
AURKAIP1 overexpression had the opposite effect, fluorescence microscopy was 
performed on AURKAIP1-FLAG overexpressing cells. Since HEK293 cells do not 
provide good images, U2OS-AURKAIP1-FLAG cells were used for imaging. 
Figure 7.1: Effects of AURKAIP1 Overexpression on Cell Morphology. Equal 
numbers of U2OS-AURKAIP1-FLAG cells were seeded in Wilco glass bottomed 
dishes and cultured as normal (uninduced, A) or with 1µg/ml tetracycline (induced, 
B) for 7 days and visualised by light microscopy. 
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Surprisingly, cells overexpressing AURKAIP1-FLAG also displayed an enlarged 
nucleoid phenotype (Figure 7.2). However this effect differs from AURKAIP1 depleted 
cells in that and there were very few nucleoids, almost all of which were enlarged. 
 
Figure 7.2: Effects of AURKAIP1 Overexpression on Mitochondrial Morphology. U2OS-
AURKAIP1-FLAG cells either grown as normal (uninduced) or treated with 1µg/ml tetracycline 
(induced) for 4 days. Cells were stained with TMRM to visualise the mitochondrial network (red) and 
PicoGreen (PiGr) to stain double-stranded DNA (nucleus and mtDNA nucleoids, green) and live-cell 
fluorescence microscopy was performed. Scale bar = 10µm. 
 
The mitochondria, as visualised by TMRM staining and fluorescent microscopy, 
appeared more punctate in AURKAIP1-FLAG overexpressing cells, with fewer 
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elongated mitochondria. This could indicate an increase in mitochondrial fission, or 
impaired mitochondrial fusion in AURKAIP1-FLAG overexpressing cells. 
Quantification of this phenotype showed on average fragmented mitochondria (defined 
as <1µm particles with a circularity between 0.5 and 1) accounted for 25% of the total 
mitochondrial mass in AURKAIP1-FLAG overexpressing cells, which was significantly 
more than in uninduced controls (13.6%, p=0.0221, n=7 fields, further details in the 
following chapter, Figure 8.6A).  
7.3.2 EFFECTS OF AURKAIP1 OVEREXPRESSION ON MITOCHONDRIAL 
GENE EXPRESSION 
The data presented in the preceding chapter clearly showed a strong reduction of COXI 
and COXII after AURKAIP1-FLAG overexpression (Figure 6.7B). It was crucial to 
ensure that this effect was not simply due to the addition of tetracycline. To this end, 
several clones of HEK293-AURKAIP1-FLAG cells were induced with tetracycline 
alongside untransfected HEK293 cells. These data showed that tetracycline did not 
deplete the steady state levels of COXII in wild-type HEK293 cells (Figure 7.3A, lane 
2), but that all HEK293-AURKAIP1-FLAG clones exhibited reduced COXII levels 
upon tetracycline-mediated induction (Figure 7.3A, lanes 4, 6 and 8). Additionally, 
AURKAIP1-FLAG overexpression produced the same phenotype in U2OS-
AURKAIP1-FLAG cells (Figure 7.3B), which showed that these effects were not cell 
type dependent. It is also worth noting that depletion of mtDNA-encoded proteins was 
not seen with the induction of any other overexpressed protein within our laboratory 
using the same FlpInTMTRExTM (HEK293) system (data from other lab members not 
shown). Together, these data strongly suggest that it is the overexpression of 
AURKAIP1-FLAG that is causing the reduction in COXI and COXII levels. 
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As was the case when studying the effects of AURKAIP1 depletion, it was important to 
test mtDNA copy number to see if there was an effect that may allow explanation of the 
enlarged nucleoid phenotype. There was a small, but statistically significant reduction in 
mtDNA copy number after 3 days of AURKAIP1-FLAG overexpression (85.3% of NT 
controls, p=0.012, n=6, Figure 7.4). 
 
 
Figure 7.4: The Effects of AURKAIP1 Overexpression on mtDNA 
Levels. Graph shows data from qPCR experiments conducted in 
U2OS-AURKAIP1-FLAG cells. Uninduced cells or cells treated with 
1µg/ml tetracycline (induced) were grown for three days. DNA was 
extracted and qPCR performed using MT-ND4 and 18S primers. The 
relative quantification of mtDNA (MT-ND4) to nuclear DNA (18S) was 
measured using the normalised expression ratio (2ΔCq) method. The 2ΔCq 
values for the induced samples were normalised to be expressed as a 
percentage of the uninduced controls. Statistical significance was 
determined by t-test (p=0.012, n=6). * denotes p<0.05. Error bars 
indicate SEM. 
 
 
Again, these data showed similarities between the effects of AURKAIP1 depletion and 
AURKAIP1-FLAG overexpression in that only modest reduction in mtDNA levels was 
seen (95.8% and 85.3% respectively). However, the results were only statistically 
significant with AURKAIP1-FLAG overexpression. 
Next, the effects of AURKAIP1-FLAG overexpression on mitochondrial RNA levels 
were assessed by northern blot. The levels of MT-CO1 and 12S rRNA (MT-RNR1) were 
clearly reduced with AURKAIP1-FLAG overexpression, but the levels of MT-ND1 
Figure 7.3: AURKAIP1 Overexpression Causes Depletion of COXI and COXII. (A) Untransfected 
HEK293 cells (lanes 1 and 2), and three independent HEK293-AURKAIP1-FLAG clones (lanes 3-8) 
were either grown as normal (uninduced) or with 1µg/ml tetracycline (induced) as indicated for 3 days. 
Cell lysate (40µg) from each sample was subjected to SDS-PAGE and western blotting. (B) U2OS-
AURKAIP1-FLAG cells were treated as described in A. α-COXI, α-COXII, α-porin and α-FLAG 
antibodies were used for immunoblotting. 
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mRNA remained unchanged (Figure 7.5). Once again, this is consistent with 
AURKAIP1-FLAG overexpression providing a more severe biochemical phenotype 
compared to AURKAIP1 depletion.  
 
 
 
Figure 7.5: The Effects of AURKAIP1 Overexpression on 
Mitochondrial RNA levels. HEK293-AURKAIP1-FLAG 
cells were either grown as normal (uninduced) or treated with 
1µg/ml tetracycline (induced) for three days. RNA was 
extracted and purified, before being subjected to northern blot 
analysis. The blot was analysed using probes for 
mitochondrial mRNAs (MT-CO1 and MT-ND1), 
mitochondrial 12S rRNA (MT-RNR1) and cytosolic 18S 
rRNA as a loading control. 
 
 
In keeping with previous observations of AURKAIP1-FLAG overexpression causing a 
more dramatic biochemical phenotype than AURKAIP1 depletion; a more severe 
reduction of Complex I and Complex IV activity was seen in AURKAIP1-FLAG 
overexpressing cells (Figure 7.6). Average Complex I and Complex IV activities were 
reduced (to 49.7% and 47.8% respectively) in AURKAIP1-FLAG overexpressing cells 
compared to uninduced controls.  
 
Figure 7.6: The Effects of AURKAIP1 Overexpression on Respiratory Chain Complexes. HEK293-
AURKAIP1-FLAG cells were either grown as normal (uninduced) or treated with 1µg/ml tetracycline 
(induced) for 4 days. A) Complex I (CI) and B) Complex IV (CIV) activities were measured 
spectrophotometrically as described in (Rustin et al., 1994). These experiments were conducted with the 
assistance of Dr Hornig-Do. * denotes p<0.05. Statistics were performed on data from two independent 
repeats using T-test. CI – p=0.044. CIV – p=0.013. 
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Next, it was important see if the effects of AURKAIP1-FLAG overexpression on steady 
state levels of mtDNA-encoded proteins and RNA were consistent with an impairment 
of mitochondrial protein synthesis. To this end, [35S] labelled methionine incorporation 
studies were conducted as described in Section 6.2.1. As expected, protein synthesis 
was more severely impaired with AURKAIP1-FLAG overexpression compared to 
AURKAIP1 depletion (Figure 7.7). Notably, AURKAIP1-FLAG overexpression 
severely reduced the synthesis of all mtDNA-encoded proteins (Figure 7.7, lane 4), 
whereas AURKAIP1 depletion only reduced the synthesis of COXI (46% of NT 
control) and COXII (60% of NT control) clearly (Figure 7.7 lane 2, Chapter 6), 
suggesting that AURKAIP1 depletion and overexpression mediate their effects by 
different mechanisms. 
 
Figure 7.7: The Effects of AURKAIP1 Depletion and Overexpression on Mitochondrial Protein 
Synthesis. (A) HeLa cells were treated with non-targeting (NT, lane 1) or AURKAIP1 siRNA1 (lane 2) 
for 3 days. Nascent mitochondrial polypeptides were labelled with [35S] methionine and subjected to 
SDS-PAGE (15-20% polyacrylamide gel) and detected using the Typhoon FLA 9500 system and 
ImageQuant software. Graphical representation of NT = black and AURKAIP1 siRNA1 = blue. (B) Same 
technique performed In parallel with A, but using HEK293-AURKAIP1-FLAG cells either grown as 
normal (uninduced, U, lane 1, black trace) or treated with 1µg/ml tetracycline (induced, I, lane 2, blue 
trace) for 3 days. ([35S] radiolabeling and SDS-PAGE were performed in collaboration with Dr Francesco 
Bruni). Designation of which mtDNA-encoded protein corresponded to each signal was determined with 
reference to (Chomyn, 1996). After detection of the radioactive signal, the gel was rehydrated and stained 
with Coomassie Brilliant Blue (CBB) to ensure equal loading.    
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7.3.3 ARE MTDNA-ENCODED PROTEINS ACTIVELY DEGRADED UPON 
AURKAIP1 OVEREXPRESSION? 
AURKAIP1-FLAG overexpression led to depletion of COXI and COXII steady state 
protein levels after just 3 days (Figure 7.3). In contrast, depletion of AURKAIP1 was 
required for at least 4 days before changes in COXI and COXII levels were detectable. 
Both COXI and COXII are highly hydrophobic integral membrane components of 
Complex IV and, as such, are fairly stable. Indeed, the half life of COXI has been 
shown to be 5 days in liver tissue (Ip et al., 1974). If this were the case in cultured cells, 
inhibition of translation would not dramatically affect the levels of COXI after 3 days, 
as the mature protein would not degrade rapidly.  
Since I have already shown that AURKAIP1-FLAG overexpression inhibits 
mitochondrial protein synthesis (Figure 7.7), I wanted to investigate whether inhibition 
of translation alone could account for the rapid and severe depletion of COXI and 
COXII seen in the induced AURKAIP1-FLAG expressing cell lines, or whether these 
proteins were being actively degraded, perhaps as a consequence of Complex IV 
disassembly. Towards this goal, the effects of AURKAIP1-FLAG overexpression via 
induction with tetracycline were investigated alongside the effects of chloramphenicol-
mediated inhibition of translation. The stocks of chloramphenicol and tetracycline were 
each dissolved in ethanol. Therefore, uninduced control cells were treated with equal 
volumes of ethanol to exclude any potential contribution to the phenotype. Cells 
incubated with each treatment were harvested after 2, 3, 4, 5 and 6 days and cell lysates 
were analysed by western blotting and immunodetection (Figure 7.8). 
 
Figure 7.8: Is COXI and COXII Depletion Upon AURKAIP1 Overexpression More Rapid than is 
Possible by Inhibiting Mitochondrial Translation Alone? HEK293-AURKAIP1-FLAG cells were 
treated with 1µl 100% ethanol, 50µg/ml chloramphenicol or 1µg/ml tetracycline for 2, 3, 4, 5 and 6 days. 
Cell lysate was prepared from cells subjected to each treatment at each time point and also cells harvested 
before any treatment (Day 0). Aliquots (40µg) of the cell lysates were subjected to SDS-PAGE and 
western blotting. Antibodies to mtDNA-encoded Complex IV subunits (COXI and COXII), nuclear-
encoded Complex I subunit (NDUFA9) and porin (loading control) were used for immunoblotting.  
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It was clear that COXI and COXII protein levels were reduced after only 2 days of 
translation inhibition via chloramphenicol treatment (Figure 7.8, lanes 8-12). The same 
effect was seen after tetracycline-mediated AURKAIP1-FLAG overexpression (Figure 
7.8, lanes 14-18), but not in ethanol treated control cells (lanes 1-6). These data indicate 
that the reduction in the steady state levels of COXI and COXII in AURKAIP1-FLAG 
overexpressing cells can be explained by inhibition of mitochondrial protein synthesis 
alone. Furthermore, NDUFA9 (a nuclear-encoded subunit of Complex I) levels are 
neither affected by mitochondrial translation inhibition via chloramphenicol treatment 
nor AURKAIP1-FLAG overexpression, thus suggesting that AURKAIP1-FLAG 
overexpression may specifically deplete only mtDNA-encoded protein levels. Together, 
these data are consistent with AURKAIP1-FLAG overexpression inhibiting 
mitochondrial protein synthesis.   
7.3.4 DOES AURKAIP1 INTERACT WITH THE MITORIBOSOME? 
Since AURKAIP1-FLAG overexpression impaired mitochondrial protein synthesis 
(Figure 7.7), it was important to see if these effects were mediated by interfering with 
the assembly of the mitoribosome. To investigate this possibility, sucrose gradient 
studies were conducted to investigate the potential of AURKAIP1 to interact with the 
mitoribosome and assess whether AURKAIP1-FLAG overexpression alters ribosome 
assembly (Figure 7.9).  
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Figure 7.9: Does AURKAIP1 Overexpression Affect the Mitoribosome? Aliquots (800µg) of cell 
lysate from uninduced (A) or induced (with 1µg/ml tetracycline for 3 days (B)) HEK293-AURKAIP1-
FLAG cells were separated on 10-30% sucrose gradients. Fractions of equal (100µl) volume were 
collected from the top of the gradient (fraction 1) sequentially to the bottom (fraction 11). An aliquot of 
10% of each fraction was subjected to SDS-PAGE and western blotting was performed. The displayed 
images are compiled from two blots per condition, loaded with the same amount of material from the 
same sucrose gradient fractions. (C) An aliquot of 40µg of cell lysate from the same uninduced (lane 1) 
or induced (lane 2) cells prior to sucrose gradient centrifugation were subjected to SDS-PAGE and 
western blotting The displayed images are a compilation of signals from several blots each loaded with 
equal amounts of lysate from the same preparation. Antibodies to DAP3, MRPS18B, MRPL3, MRPL11, 
MRPL12, COXII, AURKAIP1 (A only), FLAG (B and C) and porin were used for immunoblotting. 
 
AURKAIP1-FLAG was predominantly found in the least dense fractions of the sucrose 
gradient (Figure 7.9B fractions 1 and 2), whereas MRPL3 was present in fractions 6 and 
7 and DAP3 predominantly detected in fraction 5, indicating the expected positions of 
the mitoribosomal 39S LSU and 28S SSU respectively. These data suggest that 
AURKAIP1-FLAG does not associate with the mitoribosome and implies that 
AURKAIP1-FLAG is mostly ‘free’ with a small proportion present in aggregates in the 
densest fraction (Figure 7.9B fraction 11).  
Mitoribosomal proteins (MRPs) were affected by AURKAIP1-FLAG overexpression. 
MRPL12 is present in the large subunit of the mitoribosome and, in uninduced cells, 
was found in fractions 6 and 7 (Figure 7.9A). However, it is known that there is a pool 
of ‘free’ MRPL12 in cells (Surovtseva et al., 2011), which was seen in the least dense 
gradient fractions (Figure 7.9A fractions 1 and 2). AURKAIP1-FLAG overexpression 
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caused the relative amounts of MRPL12 to shift dramatically toward the less dense 
fractions, indicating a reduction in LSU-associated MRPL12 (Figure 7.9B) compared to 
uninduced controls (Figure 7.9A). The relative levels of LSU-associated MRPL3 
(fractions 6 and 7) were also lower in AURKAIP1-FLAG overexpressing cells, 
however, the position of MRPL3 shifted toward the most dense fractions (fraction 11). 
MRPL3 also appeared to be present at lower levels in the induced cells (Figure 7.9B). 
To assess the steady state levels of MRPs after AURKAIP1-FLAG overexpression more 
stringently, 40µg of cell lysate from uninduced and induced HEK293-AURKAIP1-
FLAG cells (without sucrose gradient separation) were analysed by immunoblotting. 
These data showed that steady state levels of MRPL3, MRPL11, MRPS18B and DAP3 
were all reduced after AURKAIP1-FLAG overexpression. The only MRP tested that 
was not reduced was MRPL12. This is probably due to the fact that a certain amount of 
MRPL12 is ‘free’ (Surovtseva et al., 2011), indicating stability when separate from the 
mitoribosome. Other MRPs may not be as stable as MRPL12 and perhaps they are 
degraded when not bound to the mitoribosome. If this is true, then the data presented in 
Figure 7.9C may be explained by AURKAIP1-FLAG overexpression causing 
disassembly of the mitoribosomes and that MRPs are subsequently degraded.  
The reduction of MRP levels upon AURKAIP1-FLAG overexpression was intriguing. 
To see if ribosome stalling protected the MRPs from degradation, HEK293-
AURKAIP1-FLAG cells were pre-treated for 24 hours with 50µg/ml chloramphenicol 
to stall mitoribosomes before inducing the cells with 1µg/ml tetracycline for a further 3 
days (still in the presence of chloramphenicol). In ethanol treated control cells, 
AURKAIP1-FLAG overexpression lead to reduced MRP levels (Figure 7.10, lane 2). 
However, the results showed that chloramphenicol-mediated ribosome stalling reduced 
AURKAIP1-FLAG-mediated MRP depletion (Figure 7.10, lane 4). These data may 
indicate that an actively translating ribosome is required for AURKAIP1-FLAG 
overexpression to mediate its effects. 
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Figure 7.10: Can Mitoribosome Stalling Protect 
MRPs from AURKAIP1-FLAG Overexpression 
Mediated Depletion? HEK293-AURKAIP1-FLAG 
cells were either treated with chloramphenicol 
(50µg/ml) or an equivalent volume of ethanol for 24 
hours. After this incubation an aliquot of ethanol 
treated cells remained uninduced (U, lane 1) and 
another aliquot induced (I) with 1µg/ml tetracycline 
for further 3 days (lane 2). Chloramphenicol treated 
cells were also either left uninduced (lane 3) or 
tetracycline induced (lane 4), with chloramphenicol 
treatment persisting for the further 3 days. Cell lysate 
(40µg) from each treatment was subjected to SDS-
PAGE and western blotting. The displayed images 
were compiled from two independent western blots 
carried out in an identical fashion with the same 
material. Antibodies to MRPL3, MRPL11, 
MRPS18B, COXII, FLAG and β-actin were used for 
immunoblotting. Signal for MRPL11 and β-actin is 
shown from each blot. 
 
 
A recent study has been published proposing that AURKAIP1 is a small subunit MRP 
and should be renamed MRPS38 (Koc et al., 2013). My data strongly indicated that this 
is not the case as AURKAIP1 levels are too low to have 1:1 stoichiometry with 
mitoribosomes. Furthermore, AURKAIP1-FLAG was not detected in sucrose gradient 
fractions corresponding to the SSU (Figure 7.9B, fraction 5) and overexpression 
resulted in reduced steady state levels of MRPs (Figure 7.9C). These data do not 
support the notion of AURKAIP1 being a bona fide MRP. To address this issue, a 
commercial antibody to AURKAIP1 that was used in the study by Koc et al. was 
purchased (Sigma α-AURKAIP1). Immunoblotting with Sigma α-AURKAIP1 did not 
allow detection of signal from endogenous AURKAIP1 at the correct size 
(approximately 15kDa) in the uninduced sucrose gradient fractions (Figure 7.11A). This 
was to be expected due to low endogenous AURKAIP1 levels. Figure 7.11A shows 
signal from an entire blot containing the sucrose gradient fractions from uninduced cells 
in order to show all of the signal from the Sigma α-AURKAIP1 antibody, which was 
the first primary antibody incubated with this blot. These data show that although no 
signal of the correct size was detectable, a non-specific band of approximately 25kDa 
was seen in fraction 4, which would correspond to the small subunit of the 
mitoribosome (Figure 7.10A). This signal does not correspond with the size of 
AURKAIP1-FLAG detected in cell lysate (Figure 7.10B).  
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Figure 7.11: Does Endogenous AURKAIP1 Bind to the Mitoribosome? Sucrose gradient analysis was 
performed as in Figure 7.9. (A) shows an entire blot from sucrose gradient western blot analysis of 
uninduced HEK293-AURKAIP1-FLAG cell lysate after immunoblotting with Sigma α-AURKAIP1 
only. (B) Shows an entire blot from western blot analysis of 40µg cell lysate from uninduced (U) or 
tetracycline induced (I) cells after only immunoblotting with the Sigma α-AURKAIP1 antibody with 
different exposure settings.   
 
The Sigma α-AURKAIP1 antibody has a degree of non-specific binding, as does the in-
house produced α-AURKAIP1 antibody. However, the Sigma antibody does bind to 
AURKAIP1 as it produced similar signal as the in-house produced α-AURKAIP1 
antibody or α-FLAG antibody (Figure 7.9C) when tested on induced cell lysate from 
HEK293-AURKAIP1-FLAG cells (two different exposures shown in Figure 7.11B). 
In summary, the data presented in this section do not support the notion of AURKAIP1 
being a small subunit MRP as no evidence of endogenous or overexpressed AURKAIP1 
associating with the mitoribosome was detected (Figures 7.9A, 7.9B and 7.11A). 
However, this does not exclude the possibility that AURKAIP1 transiently associates 
with some MRPs, which may account for the identification of AURKAIP1 by mass 
spectrometry in bovine mitoribosomal preparations (Koc et al., 2013). For this reason, 
immunoprecipitation studies were carried out to assess any AURKAIP1 binding 
partners (including MRPs) with more stringency, which I will outline below. 
7.3.5 IDENTIFYING BINDING PARTNERS OF AURKAIP1 
As another tool to understand the role of AURKAIP1 in mitochondrial gene expression 
it was important to identify proteins that interact with AURKAIP1. Co-IP studies were 
performed in HEK293-AURKAIP1-FLAG cells, overexpressing AURKAIP1-FLAG, 
using α-FLAG antibodies (α-FLAG Co-IP). Only two clear bands were detectable by 
SimplyBlueTM SafeStain of the α-FLAG Co-IP elution, one of which corresponded to 
the AURKAIP1-FLAG protein (Figure 7.12A).  
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Figure 7.12: Identification a Novel Interaction Between AURKAIP1 and p32. (A) α-FLAG Co-IP 
was performed on 500µg of mitochondrial lysate from HEK293-AURKAIP1-FLAG cells induced for 3 
days with 1µg/ml tetracycline. Half of the elution was analysed alongside 25µg of total mitochondrial 
lysate by SDS-PAGE and staining with SimplyBlueTM SafeStain. The higher molecular weight band was 
excised and identified as p32 by mass spectrometry analysis (MALDI-TOF Pinnacle, Newcastle 
University). (B) An aliquot of 25% of the elution described in A (lane 4), 35µg of post mitochondrial 
supernatant (PMS, lane 2) and flowthrough (lane 3) from the same experiment were loaded alongside 
10µg of mitochondrial lysate from 143B cells (lane 1) and subjected to SDS-PAGE and western blotting. 
(C) The same α-FLAG Co-IP procedure was carried out (as in A) on mitochondrial lysate from U2OS-
AURKAIP1-FLAG cells. Aliquots of total mitochondrial proteins (mitos, 25µg, lane 1), flowthrough 
(25µg, lane 2) and elution (50% of total, lane 3) fractions were subjected to SDS-PAGE and western 
blotting. Antibodies to p32 (rabbit), FLAG and COXII were used for immunoblotting where indicated.  
 
The unidentified band was excised from the gel and sent for mass spectrometry analysis 
(MALDI-TOF conducted by Pinnacle, Newcastle University). The protein was 
identified as p32, a protein that has several aliases, which will be described in detail in 
the following chapter. Western blotting and immunodetection using α-p32 antibodies 
allowed confirmation that p32 was immunoprecipitated with AURKAIP1-FLAG as the 
elution fraction contained strong signal for p32 when α-FLAG Co-IP was performed in 
either HEK293-AURKAIP1-FLAG (Figure 7.12B) or U2OS-AURKAIP1-FLAG cells 
(Figure 7.12C). 
Further confirmation of the interaction between AURKAIP1 and p32 was sought by 
performing Co-IP using α-p32 antibodies. Initial attempts at α-p32 Co-IP using a α-p32 
antibody raised in rabbit (α-p32 (rabbit), see Table 2.6 for antibody details) failed to 
immunoprecipitate p32 (data not shown). Therefore, another α-p32 antibody (mouse) 
was used. Co-IP using α-p32 (mouse) did pull down some p32 as detected by western 
blot using α-p32 (rabbit) (Figure 7.13). However, the levels of immunoprecipitated p32 
were very low relative to the amount of p32 detected in the mitochondrial fraction 
  144 
(Figure 7.13). Even with this small amount of p32, AURKAIP1-FLAG was also 
detected in the α-p32 (mouse) Co-IP elution (Figure 7.13), further implicating a strong 
interaction between AURKAIP1 and p32. 
Figure 7.13: Endogenous p32 Immunoprecipitation. 
Mitochondrial lysates were prepared from tetracycline-induced 
HEK293-AURKAIP1-FLAG cells and incubated with α-p32 
(mouse) antibodies. Aliquots of the mitochondrial lysate before 
Co-IP (25µg, mitos), the flowthrough (25µg, flow) and the 
fraction eluted from the antibody (50% of total, elution) were 
subjected to SDS-PAGE. α-p32 (rabbit) and α-AURKAIP1 
antibodies were used for immunoblotting. 
  
Since the α-p32 Co-IP was very inefficient, care must be taken when interpreting these 
results. To ensure that the problems with α-p32 Co-IPs were due to the antibodies used 
and not the Co-IP procedure itself, α-MRPL12 Co-IPs were performed. The α-MRPL12 
antibody has been shown to successfully Co-IP other MRP proteins (work from Agata 
Rozanska in my host laboratory, see Serre et al., 2013). Thus, α-MRPL12 Co-IP would 
allow confirmation of the validity of the Co-IP procedure. 
The α-MRPL12 Co-IP was successful in pulling down MRPL3 and DAP3 as expected 
(Figure 7.14A, lanes 3 and 6). Surprisingly, the α-MRPL12 Co-IP also pulled down 
AURKAIP1-FLAG in the induced cells (Figure 7.14A, lane 6). Very small amounts of 
p32 were also co-immunoprecipitated with α-MRPL12 antibodies, which may account 
for the presence of AURKAIP1-FLAG in the elution (Figure 7.14B). 
 
Figure 7.14: Does AURKAIP1 Interact with MRPL12? (A) Endogenous α-MRPL12 Co-IPs were 
carried out on mitochondrial lysates from HEK293-AURKAIP1-FLAG cells either grown as normal 
(uninduced) or with 1µg/ml tetracycline (induced). Total mitochondrial lysate (input/mitos), flowthrough 
and elution fractions were subjected to SDS-PAGE and western blotting. (B) Repeat of α-MRPL12 Co-IP 
described in A on induced mitochondrial lysate. Antibodies to DAP3, MRPL3, p32 (mouse) and FLAG 
were used for immunodetection. 
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It was important to ensure that AURKAIP1-FLAG was not binding non-specifically to 
the beads rather than to the antibodies used for Co-IP. To this end, α-mtPAP Co-IP 
experiments were conducted. The α-mtPAP has been used successfully for Co-IP and 
did not pull down MRPs (work conducted in my host laboratory by Dr W. C. Wilson, 
personal communication). This is consistent with data presented in Figure 7.15A, which 
showed that MRPL3 and MRPL12 were not immunoprecipitated by α-mtPAP Co-IP 
(lane 3). Importantly, AURKAIP1-FLAG was also not present in the elution of α-
mtPAP Co-IP (Figure 7.15A, lane 3). This result confirmed that AURKAIP1-FLAG 
was not binding non-specifically to every antibody or binding the beads used for 
antibody immobilisation during the Co-IP procedure. Co-IP studies with α-FLAG 
showed that certain quantities of MRPL3 and MRPL12 were present in the α-FLAG 
Co-IP elution (7.15B, lane 3), which, coupled with the results from α-MRPL12 Co-IP 
(Figure 7.14), may suggest a transient association between AURKAIP1 and the 
mitoribosome.  
 
Figure 7.15: Is the Interaction Between AURKAIP1 and MRPL12 Specific? (A) α-mtPAP Co-IP 
experiments were carried out on mitochondrial lysates from induced HEK293-AURKAIP1-FLAG cells. 
Total mitochondrial lysate (mitos), flowthrough (flow) and elution fractions were subjected to SDS-
PAGE and western blotting. (B) α-FLAG Co-IP was performed on the same mitochondrial lysate 
described in A. Antibodies to MRPL3, MRPL12, mtPAP, Tom20 and AURKAIP1 were used for 
immunodetection. 
 
Despite identifying a novel interaction between AURKAIP1-FLAG and p32 by Co-IP 
experiments, it was imperative to show that p32 and AURKAIP1 could interact at 
endogenous levels. This was required in order to rule out the possibility that the 
interaction observed thus far was mediated by the FLAG tag or by the presence of much 
higher AURKAIP1 levels in the induced HEK293-AURKAIP1-FLAG cells. Validation 
of an endogenous interaction between AURKAIP1 and p32 was attempted in several 
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different ways and proved difficult for several reasons: i) as mentioned, endogenous p32 
Co-IP was very inefficient ii) endogenous AURKAIP1 levels are very low and iii) both 
antibodies to AURKAIP1 produce additional non-specific signal on western blots of 
cell lysate. To overcome these obstacles, the following observations were considered. 
First, 143B cells express detectable levels of endogenous AURKAIP1 in mitochondrial 
lysate (as previously shown in Figure 4.4B). Second, the non-specific signal from the α-
AURKAIP1 antibody is predominantly seen in cell lysate and is greatly reduced in 
mitochondrial lysate. Finally, AURKAIP1 is present in the mitochondrial matrix (as 
shown in Figure 4.3B and 4.5C). For these reasons, endogenous α-AURKAIP1 Co-IP 
was conducted in proteinase K-shaved mitoplasts from 143B cells, in order to confirm 
an endogenous interaction between p32 and AURKAIP1 within the mitochondrial 
matrix (Figure 7.16). Further, to ensure that p32 was not binding non-specifically, Co-
IP was also carried out with control IgG (antibody to cytosolic protein MNK1) as a 
negative control.  
 
Figure 7.16: Endogenous AURKAIP1 Interacts 
with p32. A and B represent independent repeats of 
the same experiment. Mitoplasts were isolated from 
143B cells and treated with proteinase K. The 
proteinase K-shaved mitoplasts (PKM) were lysed 
and used as the input for endogenous α-
AURKAIP1 Co-IP. Lysates were also subjected to 
the Co-IP protocol with control IgG (antibody to 
cytosolic protein MNK1). Aliquots of input PKM 
(lane 1), flowthrough (lane 2) and elution (lane 3) 
for control Co-IP and flowthrough (lane 4) and 
elution (lane 5) from α-AURKAIP1 Co-IP samples 
were subjected to SDS-PAGE and western blotting. 
Antibodies to p32 (mouse), ClpX and AURKAIP1 
were used for immunodetection. * denotes signal 
from the heavy chain of the AURKAIP1 antibody. 
 
It was clear that α-AURKAIP1 Co-IP pulled down p32 (Figure 7.16 A and B, lane 5), 
but that control IgG did not (lane 3). These data showed that endogenous levels of 
AURKAIP1 interact with p32, thus increasing confidence in data obtained using 
AURKAIP1-FLAG.  
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7.4 DISCUSSION 
The work presented in this chapter has focused on investigating the role of AURKAIP1 
using AURKAIP1-FLAG overexpressing cell lines. The overexpression of AURKAIP1-
FLAG is interesting as it leads to a severe reduction in mitochondrial gene expression. 
This presents a fascinating dilemma because, as discussed in the previous chapter, 
AURKAIP1 depletion also inhibits mitochondrial gene expression. Quite how depletion 
and overexpression of AURKAIP1 can each lead to defects in mitochondrial gene 
expression remains unclear at this stage. 
One of the distinguishing features of AURKAIP1 depletion was nucleoid enlargement 
without a change in mtDNA copy number (Figures 5.8 and 6.1). As discussed earlier, 
these apparently larger nucleoids, as visualised by fluorescent microscopy, are most 
likely clusters of similar sized nucleoids that arise as a consequence of aberrant nucleoid 
distribution. If this were true, it would have been reasonable to assume that AURKAIP1 
overexpression would have the opposite effect. This was clearly not the case, however, 
as AURKAIP1-FLAG overexpression also led to an apparent enlargement of nucleoid 
size. Potential mechanisms to explain the observed nucleoid enlargement have been 
discussed in detail in Chapter 5. Nucleoid enlargement has been seen in cells depleted 
of several proteins with very different functions including the transcription factor 
TFAM (Kasashima et al., 2011), fission protein Drp1 (Ban-Ishihara et al., 2013), AAA 
protease ClpX (Kasashima et al., 2012) and exonuclease REXO2 (Bruni et al., 2013). 
Thus, it is impossible to attribute a function to AURKAIP1 based on the enlarged 
nucleoid phenotype alone. 
Similarities were observed between AURKAIP1 depletion and AURKAIP1-FLAG 
overexpression regarding mitochondrial RNA levels. Each condition led to a reduction 
in MT-CO1 and MT-RNR1 levels compared to the respective control cells, but MT-ND1 
levels were not reduced. The clearest distinction between AURKAIP1 depletion and 
AURKAIP1-FLAG overexpression lies in the respective effects on mitochondrial 
protein synthesis. AURKAIP1-FLAG overexpression has a more dramatic inhibitory 
effect on translation than AURKAIP1 depletion. This was illustrated by AURKAIP1-
FLAG overexpression inhibiting the synthesis of all mtDNA-encoded proteins (Figure 
7.7, lane 4), whereas AURKAIP1 depletion only affected the synthesis of a subset of 
mtDNA-encoded proteins (Figure 7.7, lane 2). Synthesis of COXII was confirmed to be 
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decreased by AURKAIP1 depletion (Figure 7.7 lane 2), which had been uncertain due 
to co-migration with ATP6 when analysed using a 15% SDS polyacrylamide gel 
(Figure 6.3). The improved resolution achieved using 15-20% SDS polyacrylamide 
gradient gel allowed separation of COXII and ATP6 and showed that synthesis of 
COXII was reduced (to 60% of the NT controls), whereas synthesis of ATP6 was 
increased in AURKAIP1 depleted cells (Figure 7.7, lane 2).  
The difficulty in directly assessing the relative effects of AURKAIP1 depletion and 
AURKAIP1-FLAG overexpression on mitochondrial protein synthesis was partly due to 
the enforced use of different cell types for siRNA depletions and overexpression. 
Initially only HEK293-AURKAIP1-FLAG stable cell lines were available, which 
limited AURKAIP1-FLAG overexpression studies to HEK293 cells. However, 
HEK293 cells are not as robust as HeLa cells, thus depletion studies were carried out in 
HeLa cells. HeLa cells and other cell types (for example 143B) are known to have 
slightly different patterns of segregation when analysed by SDS-PAGE (Chomyn, 
1996). Thus, more direct comparisons could be made if expressing and depleting 
AURKAIP1 was possible in a single cell type. This was one of the reasons that U2OS-
AURKAIP1-FLAG cells were produced. However, these cells were not available until 
my investigations were nearing an end. Thus, repeats of the [35S]-methionine studies in 
U2OS-AURKAIP1-FLAG cells were not conducted within the timeframe of my 
investigations, as there simply was not sufficient time to repeat all of the work in these 
cells. Imaging studies using the U2OS-AURKAIP1-FLAG cells were prioritised to 
assess mitochondrial morphology with AURKAIP1-FLAG overexpression, as these 
studies were not possible with the HEK293-AURKAIP1-FLAG cells. These studies 
showed a significant increase in mitochondrial fragmentation with AURKAIP1-FLAG 
overexpression, which will be discussed in the following chapter. 
Another interesting observation with AURKAIP1-FLAG overexpression was the 
depletion of MRP levels. Interestingly, this depletion of MRP levels occurred after just 
three days of overexpression. As described earlier, mitochondrial protein synthesis and 
steady state levels of COXI and COXII are also greatly reduced within this time frame. 
These effects occur more rapidly than would be expected by simply blocking ribosome 
biogenesis, as the mitoribosome is very stable. For example, ERAL1 is important for 
the assembly of 28S small subunit of the mitoribosome, but 3 days of ERAL1 depletion 
does not impair mitochondrial protein synthesis, nor MRPL3 levels in HEK293 or HeLa 
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cells, implying that the ribosomes already assembled are stable and able to maintain 
their levels of protein synthesis (Dennerlein et al., 2010). Recently C7orf30 has been 
suggested to have a role in biogenesis of the 39S large subunit of the mitoribosome 
(Rorbach et al., 2012). After 6 days of C7orf30 depletion there was no reduction in the 
steady state level of MRPL3 (Rorbach et al., 2012), which also implies the stability of 
the already formed MRPL3. Overexpression of mutated C7orf30 also caused a shift of 
MRPL3 toward less dense fractions after 3 days, but there was no report of MRPL3 
levels being reduced at steady state (Rorbach et al., 2012). Together the data from 
ERAL1 and C7orf30 suggest that inhibition of ribosome biogenesis is not sufficient to 
dramatically reduce levels of MRPL3. AURKAIP1-FLAG overexpression reduces 
MRPL3 steady state levels after 3 days Figure 7.9C), which suggests that AURKAIP1 
overexpression causes disassembly of mitoribosomes and subsequent degradation of 
MRPs, which is sufficient to impair mitochondrial protein synthesis. This hypothesis is 
consistent with the observed data, which showed reduced levels of many MRPs 
including MRPL3, MRPL11, MRPS18B and DAP3 (Figure 7.9C). MRPL12 is a 
notable exception, as steady state levels of this MRP were not significantly reduced. 
However, as mentioned earlier, there is a pool of ‘free’ MRPL12 present in normal 
cells, thus, disassembled MRPL12 may be tolerated without degradation. 
Reduced steady state levels of mtDNA-encoded proteins upon AURKAIP1-FLAG 
overexpression can be explained solely by a translation defect rather than active 
degradation since inhibiting mitochondrial protein synthesis with chloramphenicol 
reduces the levels of mtDNA-encoded proteins within the same time frame (2 days) 
(Figure 7.8). Recent data has shown that 48 hours of chloramphenicol treatment reduced 
COXI levels to almost undetectable levels (Richter et al., 2013), which is consistent 
with my observations. Moreover, this publication shows that the antibiotic actinonin has 
a profound effect on MRP levels after 16 hours, which can be prevented with co-
treatment with chloramphenicol (Richter et al., 2013). This is strikingly similar to the 
data shown with AURKAIP1-FLAG overexpression (Figures 7.9C and 7.10). Actinonin 
treatment of MEFs led to a severe block of cell proliferation (Richter et al., 2013), 
however, which was not a feature of AURKAIP1-FLAG overexpression (Figure 7.1). 
Perhaps the effects of both overexpression and depletion of AURKAIP1 on 
mitochondrial protein synthesis can be explained by a role for AURKAIP1 in rescuing 
stalled ribosomes. If a subset of mtDNA-encoded transcripts i.e. MT-CO1 and MT-CO2 
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have a tendency to stall mitoribosomes during elongation, the usual release factor, 
mtRF1a (Soleimanpour-Lichaei et al., 2007) would not be able to resolve the stalling 
event. If AURKAIP1 could allow the recycling of these transcripts and mitoribosomes, 
then normal protein synthesis could be maintained. Perhaps in the absence of 
AURKAIP1 these stall events are not resolved, preventing translation of a subset of 
mtDNA-encoded proteins. If this hypothesis was correct then it would be possible that 
overexpression of AURKAIP1 could lead to a loss of specificity and thus disassemble 
non-stalled mitoribosomes, which may account for subsequent degradation of MRPs 
and general inhibition of translation. The lack of an in vitro mitochondrial translation 
system prevents the direct assessment of this hypothesis at this time, as each transcripts 
propensity to stall mitoribosomes during elongation cannot be determined. However, 
optimisation of ribosome profiling techniques may allow insights into this possibility. If 
a higher percentage of mitoribosomes were stalled with RNA sequences matching MT-
CO1 or MT-CO2 in AURKAIP1 depleted cells, then this hypothesis would be 
supported. Thus, ribosome profiling could be an interesting area for further research.    
During the course of my investigations, a study was published that identified 
AURKAIP1 as a protein associated with the mitoribosome (Koc et al., 2013). 
Moreover, the authors suggested that AURKAIP1 was a SSU MRP and sought to 
rename the protein MRPS38 (Koc et al., 2013). As discussed earlier, the results of my 
investigations contrast with this view. I have shown that the majority of AURKAIP1-
FLAG does not associate with the mitoribosome (Figure 7.9B) and that no endogenous 
AURKAIP1 signal corresponding to the correct size was observed in ribosome 
associated fractions with either of the α-AURKAIP1 antibodies tested (Figures 7.9 and 
7.11). However, a transient interaction between AURKAIP1 and the mitoribosome 
seems likely. Indeed, AURKAIP1-FLAG was immunoprecipitated with α-MRPL12 
antibodies (Figure 7.14). Additionally the fact that AURKAIP1-FLAG overexpression 
caused depletion of MRPs is consistent with AURKAIP1 interacting with the subunits 
of the mitoribosome, perhaps to actively disassemble the ribosome or target some MRPs 
for degradation. The exact mechanisms to explain the effects of AURKAIP1-FLAG 
overexpression are currently unknown, but it is probable that there is some interaction 
with the mitoribosome, either directly or indirectly. This would be consistent with the 
Co-IP data presented in this chapter and with the identification of AURKAIP1 in 
preparations of bovine mitoribosomes (Koc et al., 2013). 
  151 
What is clear is that any potential interaction of AURKAIP1-FLAG with the 
mitoribosome is weaker or more transient than the interaction between AURKAIP1 and 
p32. This is apparent since p32 was the only protein to be co-immunoprecipitated with 
AURKAIP1-FLAG in high enough quantities to be seen via SimplyBlueTM SafeStain 
(Figure 7.12A). It is even possible that the weak or transient interaction seen between 
AURKAIP1 and MRPL12 could be mediated through the stronger interaction between 
AURKAIP1 and p32. Indeed, p32 has been shown to interact with many mitoribosomal 
proteins (Yagi et al., 2012), including MRPL12, as will be discussed in the following 
chapter. The particular focus of the following chapter will be to address the possibility 
that overexpression of AURKAIP1-FLAG causes its phenotype via effects on p32. 
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CHAPTER 8: ARE THE EFFECTS OF 
AURKAIP1 OVEREXPRESSION MEDIATED 
VIA EFFECTS ON P32? 
8.1 INTRODUCTION 
As described in the previous chapter, I have demonstrated a novel interaction between 
AURKAIP1 and the protein p32. Human p32 is a multifunctional protein that has been 
known by many aliases. First, p32 was identified as splicing-factor 2 associated protein 
(Krainer et al., 1991), but p32 itself did not show any splicing activity in vitro. Second, 
p32 was identified as a processed form of TAP (tat associated protein), which consisted 
of amino acids 71-279 of TAP (Yu et al., 1995). Full length TAP binds HIV-1 tat and 
possesses a transcriptional activation domain (Yu et al., 1995). The identification of p32 
in the two cases described suggest nuclear localisation of p32 (Yu et al., 1995; Krainer 
et al., 1991), but p32 has also been described as an extracellular protein on the outer 
surface of the plasma membrane (Deb and Datta, 1996). This study identified a 
homodimer of p32 as HABP1 (hyaluronic acid-binding protein) (Deb and Datta, 1996). 
Also, p32 was further reported to be a membrane protein based on an interaction with 
the globular heads of C1q (complement component 1 q) (Lim et al., 1996; Ghebrehiwet 
et al., 1996), leading to the aliases C1QBP (complement component 1 Q subcomponent 
binding protein) and gC1qR (globular C1q receptor). 
Functional roles of p32 were not identified through these various interactions and p32 
was subsequently shown to be predominantly localised to the mitochondrial matrix and 
to be required for respiratory function (Muta et al., 1997). Furthermore, recent p32 
knockout studies conducted in mice showed that p32 is a vital protein as knockout mice 
exhibited embryonic lethality (Yagi et al., 2012). This study also isolated mouse 
embryonic fibroblasts (MEFs) from the p32 knockout embryos and observed a severe 
impairment in mitochondrial protein synthesis (Yagi et al., 2012). Another recent study 
suggested that p32 binds to RNaseH1 (important for hydrolysing DNA/RNA hybrids) 
and MRPP1 (a subunit of RNaseP, involved in 5’ tRNA processing in mitochondria) 
and suggests a role for p32 in mitochondrial pre-RNA processing (Wu et al., 2013). Wu 
et al. propose that these interactions are mediated by DNA or RNA binding rather than 
protein-protein interactions (Wu et al., 2013). The RNA binding ability of p32 has been 
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described before (Ponamarev et al., 2005; Yagi et al., 2012). Co-IP studies of 
overexpressed HA tagged p32 showed that p32 interacts with many MRPs, RNA 
binding proteins, transcription factors and proteases within mitochondria (Yagi et al., 
2012). 
Accumulating evidence indicates that the major functional role of p32 takes place in the 
mitochondria (Muta et al., 1997; Yagi et al., 2012). This is supported by currently 
unpublished data from my host laboratory that has identified a pathological mutation in 
p32, via exome sequencing, in a patient with severe mitochondrial disease (Dr M. 
Olahova, Prof R. W. Taylor, personal communication). The patient had compound 
heterozygous mutations, each of which caused amino acid substitutions in highly 
conserved residues (c.557G>C predicting p.Cys186Ser and c.612C>G predicting 
p.Phe204Leu, see supplementary Figure S1). The patient presented with failure to 
thrive, cardiomyopathy and severe lactic acidosis and died at a few weeks of age. 
Respiratory chain complex activities (I, III and IV) were markedly decreased in patient 
muscle. The identification of possible pathogenic mutations in p32 strongly indicates 
that the major role of p32 is in mitochondrial gene expression. In addition, p32 was one 
of the proteins included in the initial siRNA screen that led to the study of AURKAIP1. 
However, p32 was only included in the growth rate screen in HeLa and Rho0 cells, as 
only one of the three p32 siRNAs caused a growth defect in HeLa cells. Only proteins 
that, when depleted with two or more of the siRNAs, impaired HeLa cell growth were 
investigated further in the initial screen (Section 1.9). Therefore, it was important to test 
the specificity of the p32 siRNA that did cause a growth defect in HeLa cells by western 
blot, which was possible as several commercial antibodies to p32 were available.  
So far, my work has identified p32 as the major binding partner of AURKAIP1 and that 
AURKAIP1-FLAG overexpression causes a profound reduction in mitochondrial 
translation. Since a similarly severe effects on mitochondrial protein synthesis were 
seen in p32 knockout MEFs (Yagi et al., 2012), this chapter will focus on elucidating 
the functional relevance of the interaction between p32 and AURKAIP1. 
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8.2 RESULTS 
8.2.1 ARE P32 STEADY STATE PROTEIN LEVELS AFFECTED BY 
AURKAIP1 DEPLETION OR OVEREXPRESSION? 
I have already demonstrated that AURKAIP1-FLAG overexpression impairs 
mitochondrial protein synthesis and that AURKAIP1 interacts with p32. Since p32 
knockout has also been shown to impair mitochondrial translation (Yagi et al., 2012), it 
was important to see if the overexpression of AURKAIP1-FLAG caused depletion of 
p32, as this may account for the observed translation defect mediated by AURKAIP1-
FLAG overexpression. Additionally, it was of interest to determine whether 
AURKAIP1 depletion altered p32 protein levels as an increase in p32 levels may 
indicate that AURKAIP1 acts as a negative regulator of p32. 
 
These results showed that 4-day siRNA depletion of AURKAIP1 (siRNA1) did not 
affect p32 levels (Figure 8.1A, lane 2), although, the p32 siRNA was specific and 
depleted p32 protein levels after 4 days (Figure 8.1A, lane 3). Overexpressing 
AURKAIP1-FLAG for 3 days did not alter the levels of p32 in HEK293-AURKAIP1-
FLAG cells (Figure 8.1B). Together, these data suggest that AURKAIP1 does not 
Figure 8.1: Steady State Levels of p32 are not Affected by Changes in AURKAIP1 
Protein Levels. (A) U2OS cells were treated for 4 days with non-targeting (NT, lane 1), 
AURKAIP1 siRNA1 (lane 2) or p32 siRNA (lane 3). Cell lysates (40µg) from cells 
subjected to each treatment were analysed by SDS-PAGE and western blotting. (B) Cell 
lysates were collected from two independent clones of HEK293-AURKAIP1-FLAG 
cells that were either uninduced (U) or induced with 1µg/ml tetracycline (I) for 3 days. 
Each 40µg aliquot of cell lysate was subjected to SDS-PAGE and western blotting. α-
COXI, α-COXII, α-p32 (rabbit), α-porin, α-SDH-70 and α-FLAG antibodies were 
used for immunoblotting.    
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regulate the protein levels of p32. However, this does not rule out the possibility that 
AURKAIP1 functionally impacts p32. Perhaps, when overexpressed, AURKAIP1 
sequesters p32 from performing its regular function without modulating the expression 
or degradation of p32 protein levels. Since the exact function of p32 is unknown, this 
was difficult to ascertain, but assessing the similarities between the effects of p32 
depletion and AURKAIP1-FLAG overexpression was used as a starting point to 
investigate this hypothesis. 
8.2.3 EFFECTS OF P32 DEPLETION, IS THE PHENOTYPE SIMILAR TO 
THAT OF AURKAIP1 OVEREXPRESSION? 
First, p32 depletions were carried out in HeLa cells for 3 and 6 days respectively. 
Reduction in steady state levels of mtDNA-encoded proteins COXI and COXII was 
seen after 6 days of depletion, but not after 3 days (Figure 8.2). Depletion of COXI and 
COXII was also seen after 4-day p32 depletions in U2OS cells (Figure 8.1A, lane 3).  
 
 
Figure 8.2: Testing the Efficiency and Effects of 
p32 siRNA Depletion: HeLa cells were treated with 
either non-targeting (NT) or p32 siRNA for either 3 
days or 6 days. Cell lysate (40µg) from cells 
subjected to each condition were analysed by SDS-
PAGE and western blotting. α-COXI, α-COXII, α-
p32 (rabbit) and α-Tom20 antibodies were used for 
immunodetection. 
 
 
 
 
The most striking phenotype of AURKAIP1-FLAG overexpression was the depletion of 
MRPs. Therefore, HeLa cells were depleted of p32 and levels of MRPs were analysed 
by immunoblotting (Figure 8.3). The results showed that p32 depletion lead to a 
reduction in the steady state levels of MRPL3 and MRPL11 (Figure 8.3A, lanes 2,4 and 
6). Similar reductions in MRPL3 levels were observed in AURKAIP1-FLAG 
overexpressing (Figure 8.3B, lane 2) and p32 depleted (Figure 8.3B, lane 4) cells 
respectively. However, the levels of DAP3 were not depleted in cells lacking p32, 
whereas they were slightly reduced by AURKAIP1-FLAG overexpression (Figure 
8.3B). 
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Figure 8.3: The Effects of p32 Depletion on MRP Levels. (A) HeLa cells were treated with 33nM non-
targeting (NT, lanes 1,3,5) or p32 siRNA (lanes 2,4,6) for 6 days. Cell lysate (40µg) was subjected to 
12% SDS-PAGE and western blotting. Blot shows results from 3 independent experiments (B) 
Uninduced (U, lane 1) HEK293-AURKAIP1-FLAG cells, or those induced with 1µg/ml tetracycline (I, 
lane 2) were harvested and cell lysates prepared after 3 days. HeLa cells were treated with either non-
targeting (NT, lane 3) or p32 siRNA (lane 4) for 6 days. Cell lysates (40µg) from each condition were 
subjected to 12% SDS-PAGE and western blotting. Immunodetection was performed using α-MRPL3, α-
MRPL11, α-p32, αDAP3, α-AURKAIP1 and α-porin antibodies.  
     
Another feature of p32 depletion was poor cell growth and viability. Changes in cellular 
morphology and growth retardation were clearly visible by light microscopy in HeLa 
and U2OS cells (Figure 8.4). This was in contrast to the effects of AURKAIP1-FLAG 
overexpression, which did not noticeably affect the morphology of U2OS cells (as 
discussed earlier, Figure 7.1). 
Figure 8.4: 
Depletion of p32 
Inhibits Growth 
and Alters Cell 
Morphology. In all 
cases 30,000 cells 
were seeded and 
subjected to siRNA 
transfection for 6 
days, before being 
visualised by light 
microscopy. Panels 
show representative 
images for: (A) 
HeLa cells treated 
with non-targeting 
(NT) siRNA, (B) 
HeLa cells treated 
with p32 siRNA, 
(C) U2OS cells 
treated with NT 
siRNA and (D) 
U2OS cells treated 
with p32 siRNA. 
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As shown in the previous chapter, AURKAIP1-FLAG overexpression lead to a greater 
proportion of punctate, rather than tubular, mitochondria as visualised by TMRM 
(Figure 7.2). Depletion of p32 has also been shown to increase the proportion of cells 
with punctate mitochondria (Hu et al., 2013). Therefore, the respective effects of p32 
depletion and AURKAIP1-FLAG overexpression with relation to mitochondrial 
dynamics were compared. 
 
Figure 8.5: Effects of p32 Depletion on Mitochondrial Dynamics. Upper panel shows TMRM stained 
U2OS cells treated with either non-targeting siRNA (A) or p32 siRNA (B) and visualised by fluorescent 
microscopy. Lower panel shows the same field after the image was processed and subjected to 
thresholding to visualise the shape of the mitochondria without any change in intensity. These are 
representative images of those used for quantification (Figure 8.6). 
 
Mitochondrial morphology was assessed in p32-depleted cells by TMRM staining. It 
was clear that p32 depleted cells contained far more punctate and fragmented 
mitochondria (Figure 8.5B) compared to the normal tubular morphology seen in non-
targeting siRNA treated controls (Figure 8.5A). To compare the effects of p32 depletion 
to the effects of AURKAIP1-FLAG overexpression, the fragmented mitochondria 
phenotype was quantified (Figure 8.6).  
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Figure 8.6: Quantification of the Effects of p32 Depletion and AURKAIP1-FLAG Overexpression 
on Mitochondrial Fragmentation. To allow quantification, images were subjected to thresholding to 
eliminate changes in intensity (examples seen in Figure 8.5, lower panel). Particle analysis was then 
performed to quantify fragmented mitochondria, which were defined as small particles (<1µm in 
diameter) with a circularity value of between 0.5 and 1.0. The total fragmented mitochondrial area was 
expressed as a percentage of the total mitochondrial area to allow comparisons of approximate 
mitochondrial fragmentation levels to be made between cells. The proportion of fragmented mitochondria 
in U2OS-AURKAIP1-FLAG cells that were uninduced or induced with 1µg/ml tetracycline for 3 days is 
shown in (A). The equivalent data from images of U2OS cells either treated with non-targeting (NT) 
siRNA or p32 siRNA for 3 days is shown in (B). Each point denotes the percentage of fragmented 
mitochondria per field. Analysis was performed in collaboration with Dr J. M. A. Oliveira. * denotes 
p<0.05 (two-tailed Mann-Whitney U test). 
 
The percentage of mitochondria that were fragmented in uninduced U2OS-AURKAIP1-
FLAG cells on average was 13.6%. In cells overexpressing AURKAIP1-FLAG, 
fragmented mitochondria comprised 25% of the total mitochondrial mass, which was 
significantly more than in the uninduced controls (p=0.0221 n=7). Similarly, p32 
depletion led to a significant increase in the relative proportion of fragmented 
mitochondria to an average of 35.8% compared to 14% in non-targeting controls 
(p=0.0317 n=5).   
8.3 DISCUSSION 
The main focus of this chapter was to investigate whether the effects of AURKAIP1-
FLAG overexpression could be explained by negatively regulating p32. The data 
presented in this chapter can neither conclusively confirm nor deny this possibility. It is 
clear that AURKAIP1 does not regulate the steady state levels of p32, as there was no 
evidence of a change in p32 levels with either depletion (Figure 8.1A) or 
overexpression (Figure 8.1B) of AURKAIP1.  
It remains possible that AURKAIP1-FLAG overexpression either sequesters or 
functionally impairs p32 since there is a strong interaction between the two proteins (as 
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discussed in the previous chapter). Additionally, the phenotype of AURKAIP1-FLAG 
overexpression has some striking similarities to the phenotype of p32 depletion. For 
example, the levels of MRPL3 and MRPL11 are reduced in cells overexpressing 
AURKAIP1-FLAG and in cells depleted of p32 (Figure 8.3). Furthermore, in p32 
knockout MEFs, the synthesis of all mtDNA-encoded proteins is inhibited (Yagi et al., 
2012), which was also shown in AURKAIP1-FLAG overexpressing cells (Figure 7.7, 
lane 4). Other similarities include the respective effects of AURKAIP1-FLAG 
overexpression and p32 depletion on mitochondrial dynamics. Each condition led to a 
significant increase in fragmented mitochondria (Figure 8.6). Mitochondrial 
fragmentation in p32 depleted cells has been demonstrated in a recent publication (Hu et 
al., 2013) and the authors attributed the effects of p32 depletion to a decrease in 
mitochondrial fusion as the steady state levels of fusion proteins Mfn1 and Mfn2 were 
reduced in p32 depleted cells (Hu et al., 2013).  
On-going work within my research group aims to study the physiological function of 
p32 in the mitochondria by studying tissue and cell lines from a patient with 
mitochondrial disease caused by pathogenic mutations in p32 (all work regarding the 
p32 patient was conducted by Dr Monika Olahova and is presented, with permission, as 
supplemental material for reference). The specific mutations in the C1QBP gene 
identified in the p32 patient are shown in Figure S.1 (personal communication M.O.). 
Steady state levels of p32 are reduced in patient fibroblasts (Figure S.2A M.O.) and 
virtually absent in muscle tissue (Figure S.2B M.O.). Consistent with a role for p32 in 
mitochondrial gene expression, COX1 steady state levels are reduced in patient muscle 
tissue (Figure S.3B M.O.). However, the biochemical defect is not seen in patient 
fibroblasts (Figure S.3A M.O.). This is likely due to the higher steady state levels of p32 
in the patient fibroblasts compared to skeletal muscle (Figure S.2 M.O.). Western blot 
analysis of patient muscle tissue showed a reduction in Mfn2 levels compared to 
controls (Figure S.4B M.O.), which is in accordance with the effects of p32 depletion 
(Hu et al., 2013). Since AURKAIP1-FLAG overexpression led to mitochondrial 
fragmentation (Figure 8.6A) it is likely that Mfn levels are be reduced in these cells, 
though this awaits confirmation. 
The similarities between the effects of p32 depletion and AURKAIP1-FLAG 
overexpression fit with the hypothesis that AURKAIP1-FLAG may elicit a phenotype 
via sequestration of p32. That being said, there were distinctions between the effects of 
  160 
AURKAIP1-FLAG overexpression and p32 depletion. For example, cells treated for 3 
days with p32 siRNA had comparable COXI and COXII steady state protein levels to 
non-targeting controls (Figure 8.2, lane 2), however, 3 days of AURKAIP1-FLAG 
overexpression consistently reduced COXI and COXII levels (Figure 7.3). This was 
likely due to the time scale and efficiency of p32 depletion. It takes time for siRNA 
treatment to deplete the target protein levels, as only further expression of the protein is 
prevented. The mature protein that is present at the time of siRNA transfection may be 
sufficient for activity for a period of time before it is degraded. This could explain why 
COXI and COXII steady state protein levels were unaffected after only 3 days of p32 
depletion, but were reduced after 4 days (Figure 8.1A, lane 3) and 6 days (Figure 8.2, 
lane 4) of depletion. Consistent with these data, p32 knockout MEFs have been shown 
to have undetectable steady state levels of COXI and COXII (Yagi et al., 2012) and 
analysis of skeletal muscle from the p32 patient also shows marked reduction in COXI 
levels (Figure S.3B M.O.), suggesting that loss of p32 does impair expression of 
mtDNA-encoded proteins. Perhaps the more rapid reduction in COXI and COXII levels 
upon AURKAIP1-FLAG overexpression can be explained by the expressed protein 
functionally inhibiting or sequestering p32, thus effectively subjecting the cell to the 
effects of p32 loss, without the lag time associated with siRNA-mediated p32 
degradation. 
Depletion of p32 led to a change in cellular growth and morphology (Figure 8.4), 
whereas AURKAIP1-FLAG overexpression did not (Figure 7.1). There are several 
reports linking p32 to apoptosis (Sunayama et al., 2004; Itahana and Zhang, 2008; Hu et 
al., 2013), but the role of p32 remains somewhat unclear as p32 depletion has been 
shown to protect against cell death and to cause increased cell death under different 
stress conditions (Hu et al., 2013). The presence of mitochondrial p32 has been shown 
to be important for apoptosis mediated via Hrk (Sunayama et al., 2004) and ARF 
(Itahana and Zhang, 2008). Therefore, depletion of p32 should inhibit apoptosis via 
these mechanisms. However, p32 depletion causes mitochondrial fragmentation 
(Figures 8.5-8.6 and (Hu et al., 2013)), which is linked to apoptosis (reviewed in 
Cleland and Youle, 2011) and as such, the role of p32 in apoptosis remains unclear.  
It is likely that p32 has multiple functions within the cell as many interactions have been 
described, both inside (Hu et al., 2013; Yagi et al., 2012; Itahana and Zhang, 2008) and 
outside (Krainer et al., 1991; Yu et al., 1995; Deb and Datta, 1996; Lim et al., 1996; 
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Ghebrehiwet et al., 1996) the mitochondria. It is therefore probable that the proposed 
sequestering and/or inhibition of p32 in AURKAIP1-FLAG overexpressing cells would 
inhibit a subset of these functions, whereas p32 depletion would presumably inhibit all 
p32 mediated functions. This may account for some of the differences in cell growth 
between the phenotypes caused by AURKAIP1-FLAG overexpression and p32 
depletion. 
Consistent with data presented in this chapter, p32 knockout MEFs show a decrease in 
mitoribosomes (Yagi et al., 2012). However, steady state levels of MRPs, including 
MRPL3 were not reduced (Yagi et al., 2012). In HeLa cells, p32 depletion caused a 
reduction in the steady state levels of MRPL3 (Figure 8.3), A potential role for p32 in 
mitoribosome maintenance is an attractive hypothesis given the data presented in this 
chapter. Interestingly, p32 has recently been implicated in pre-ribosome processing in 
conjunction with fibrillarin and Nop52 in the nucleolus (Yoshikawa et al., 2011). The 
authors of this study suggest p32 is important for early processing of pre-rRNAs, thus 
playing a role in ribosome biogenesis. Perhaps p32 has a similar role within 
mitochondria. Indeed, the RNA binding capacity of p32 has been suggested to be 
important (Yagi et al., 2012). Furthermore, p32 has recently been shown to interact with 
RNaseH1 and depletion of p32 led to an increase in pre-12S/16S rRNA levels (Wu et 
al., 2013). The authors attribute the increase in pre-12S/16S rRNA to reduced 
processing by the RNaseP complex in p32 depleted cells (Wu et al., 2013). If this 
hypothesis were correct, then presumably mature rRNA levels would be reduced, 
potentially accounting for the observed depletion of mitoribosomes in my 
investigations. Strangely, levels of mature mitochondrial rRNAs were not shown in this 
study (Wu et al., 2013). Further, the levels of neither mature mitochondrial rRNAs nor 
any mature mitochondrial mRNA were reduced in p32 knockout MEFs (Yagi et al., 
2012). Quite how translation could be inhibited by accumulation of pre-rRNA without 
any effect on the mature rRNAs is difficult to fathom. 
Further study is clearly required to elucidate the functional role of p32 in human 
mitochondria. Due to time constraints, the levels of mitochondrial RNA levels were not 
analysed by northern blot after p32 depletion. However, after AURKAIP1-FLAG 
overexpression the levels of 12S rRNA and MTCO1 mRNA were reduced (Figure 7.5). 
As discussed earlier, the decrease in 12S and MTCO1 are unlikely to be due to reduced 
transcription, as MTND1 levels are not depleted. Perhaps inhibition of p32 mediated 
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pre-rRNA processing could account for the reduction in 12S rRNA levels. This seems 
unlikely, as I did not observe any increase in pre-rRNA levels. An alternative 
explanation is that the effects on mitochondrial RNA levels are secondary to the effects 
on mitochondrial protein synthesis. Perhaps disassembly of the mitoribosome and 
subsequent degradation of MRPs is the primary effect of AURKAIP1-FLAG 
overexpression and p32 depletion. If this hypothesis were correct then mitochondrial 
RNA levels may be degraded more rapidly due to the presence of fewer mitoribosomes 
to protect them. This hypothesis is interesting as it suggests p32 may have a role in 
mitoribosomal maintenance rather than biogenesis. Support for this notion comes from 
data showing that depletion of proteins such as ERAL1 (Dennerlein et al., 2010) and 
C7orf30 (Rorbach et al., 2012), which are involved in biogenesis of the SSU and LSU 
respectively, do not show decreased MRP levels after 3 days and 6 days respectively. 
Together, these data suggest that the half-life of mature mitoribosomes is too long for 
inhibition of ribosome biogenesis to show an effect on MRP levels after 6 days. I have 
shown that p32 depletion leads to a significant reduction in MRPL3 levels after 6 days, 
which may imply that mature ribosomes become disassembled.  
If AURKAIP1-FLAG overexpression and p32 depletion cause disassembly of the 
mitoribosome, then the question of what causes the subsequent degradation of MRPs 
must be asked. One possibility that is being currently investigated in my host laboratory 
is that AURKAIP1 may bind p32 activating a latent protease activity, which may lead to 
MRP degradation. The crystal structure of p32 shows that the protein forms a doughnut-
shaped trimer with a pore large enough to allow proteins to pass through (Jiang et al., 
1999), indicating protease activity may be feasible. However, the depletion of MRPs in 
the absence of p32 does not support this hypothesis. Another avenue for future work 
would be to deplete known matrix proteases, such as ClpP, ClpX, AFG3L2, SPG7 and 
LonP1 independently before overexpressing AURKAIP1-FLAG. If depletion of any of 
these proteases could protect MRPs from AURKAIP1-FLAG mediated degradation, 
then that protease would be implicated MRP degradation. A recent publication showed 
that actinonin treatment leads to degradation of mitoribosomes (Richter et al., 2013). 
The authors propose that this degradation is a consequence of actinonin causing 
mitoribosome stalling, possibly by binding to mitochondrial Pdf (peptide deformylase) 
and causing Pdfs usually transient binding to the mitoribosome to become permanent 
(Richter et al., 2013). This could lead to activation of ribosome quality control pathways 
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being activated (reviewed in Shoemaker and Green, 2012), although these pathways are 
poorly understood in mitochondria. If these stalled ribosomes cannot be resolved to 
allow recycling of the assembled SSU and LSU respectively then they may be degraded 
by the proteasome, as is the case in the cytosol (Shoemaker and Green, 2012). Perhaps 
AURKAIP1 is involved in a similar pathway and that overexpressed AURKAIP1 binds 
to p32 causing a change in formation that results in binding and stalling the 
mitoribosome.  
Another avenue being pursued in my host laboratory is the ability of AURKAIP1 to 
regulate the amount of p32 that exists as trimer. From my investigations it was clear that 
the steady state protein levels of p32 are not affected by changes in AURKAIP1 levels, 
however, it is possible that AURKAIP1 may facilitate a change in oligomerisation of 
p32. It is known that the majority of p32 exists in trimeric form, but that a small 
proportion is hexameric (Jha et al., 2002). The hexameric form is formed by 
dimerisation of two trimers via disulphide bond formation (Jha et al., 2002). Perhaps 
AURKAIP1 facilitates the dimerisation of the p32 trimers. It has been reported that 
trimeric and hexameric p32 have distinct binding capabilities and possibly independent 
functions in the extracellular matrix (Jha et al., 2002). If this is also the case in the 
mitochondria, then the regulation of the two oligomeric forms may allow explanation of 
why AURKAIP1 depletion and overexpression cause distinct phenotypes. Perhaps 
depletion of AURKAIP1 prevents the production of hexameric p32, whereas 
overexpression depletes the required pool of p32 trimer. If evidence for this hypothesis 
can be gathered using blue native PAGE, then future work will focus on establishing the 
respective functions of the distinct p32 oligomers. 
It is evident from this discussion that there are many more avenues left to explore in 
order to elucidate the functions of p32 an AURKAIP1 in mitochondria. 
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CHAPTER 9: GENERAL CONCLUSIONS AND 
DISCUSSION   
The data presented in this thesis has mainly focused on the characterisation of 
AURKAIP1, a protein about which very little data had been published at the beginning 
of my investigations. My aims at the outset and the progress I made towards achieving 
these aims are described below: 
• To express and purify recombinant AURKAIP1 to use as an antigen for antibody 
production 
I successfully overexpressed and purified sufficient recombinant mature 
AURKAIP1 to allow the production of custom made antisera. I affinity purified 
the antisera to reduce non-specific binding and characterised that the α-
AURKAIP1 antibody was specific to AURKAIP1. Using this tool, I determined 
that the levels of endogenous AURKAIP1 were too low to be detected in 40µg 
of cell lysate, but could be identified in 50µg of isolated mitochondrial lysate 
from 143B cells. 
• To produce stable human cell lines capable of expressing C-terminal FLAG-
tagged AURKAIP1  
I produced HEK293 cell lines that could inducibly overexpress AURKAIP1 with 
a C-terminal FLAG tag. I later identified that U2OS cells tolerated siRNA 
mediated AURKAIP1 depletion better and allowed improved visualisation of 
mitochondrial morphology by fluorescence microscopy compared to HEK293 
cells. For these reasons, I also established U2OS lines capable of inducible 
AURKAIP1-FLAG expression.  
• To use these tools to determine whether AURKAIP1 is mitochondrial, and if so, 
the sub-mitochondrial localisation 
The α-AURKAIP1 antibody and AURKAIP1-FLAG expressing cell lines were 
used to show that AURKAIP1 is present in human mitochondria and is 
predominantly localised to the mitochondrial matrix. 
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• To characterise the phenotype of AURKAIP1 depletion, with a view to 
identifying any critical role of AURKAIP1 in mitochondrial gene expression 
I have shown that AURKAIP1 is an essential protein required for cell viability 
and normal mitochondrial gene expression, as depletion of the protein causes 
mitochondrial translation defects. 
• To identify binding partners of AURKAIP1 via immunoprecipitation to elucidate 
the potential functions of AURKAIP1 
I have demonstrated a strong novel interaction between AURKAIP1 and p32 
using Co-IP techniques. Weaker or more transient interactions were observed 
between AURKAIP1 and MRPs (MRPL12 and MRPL3), although further 
investigation would be required to demonstrate that these interactions were 
direct, rather than mediated by binding of each protein to p32.  
Despite extensive study towards my original aims, the precise functional role of 
AURKAIP1 in human mitochondria remained elusive. One of the difficulties in 
determining the role of AURKAIP1 lies in the effects resulting from over or under-
representational levels of AURKAIP1 protein. This was made apparent by the 
unexpected observation that AURKAIP1-FLAG overexpression as well as depletion led 
to an impairment of mitochondrial gene expression. AURKAIP1 depletion and 
AURKAIP1 overexpression each led to cellular phenotypes that included enlarged 
nucleoid morphology, reduced steady state levels of 12S rRNA, MT-CO1 mRNA and 
also of mtDNA-encoded proteins. Not all the changes were identical, a number of 
distinctions existed. AURKAIP1-FLAG overexpression caused a generalised defect in 
mitochondrial translation, whereas depletion of AURKAIP1 reduced the synthesis of 
only a specific subset of mtDNA-encoded proteins. Only AURKAIP1-FLAG 
overexpression led to a reduction in steady state levels of mitoribosomal subunits. This 
strongly suggests that separate signalling pathways underlie the mechanisms that cause 
the altered cellular phenotype following AURKAIP1 depletion or overexpression. The 
combination of overlapping and distinct differences in presentation mean that it is 
difficult to propose a hypothesis to explain all of the observed data at this stage.  
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It is not possible to say with certainty which of the observed effects following changes 
in steady state levels of AURKAIP1, are primary and which are secondary. The most 
striking effect of AURKAIP1-FLAG overexpression was the reduction in MRP levels. 
This was likely the result of disassembly of mitoribosomes since MRP levels were not 
reduced upon inhibition of mitoribosome biogenesis, over similar time frames 
(Dennerlein et al., 2010). The hypothesis that disassembly of the mitoribosome is the 
primary effect of AURKAIP1-FLAG overexpression offers the best explanation of the 
observed data, as this could lead to secondary effects of MRP degradation by the 
proteasome and subsequent impairment of mitochondrial protein synthesis due to the 
resulting lack of active mitoribosomes. In addition, the reduction in mitochondrial RNA 
levels may be explained by this hypothesis, as without the MRPs to protect the mRNA 
transcripts and rRNA, it is possible that they would be more rapidly degraded. Since my 
data shows that p32 depletion also reduces MRPL3 protein levels and published data 
has shown that loss of p32 causes a mitochondrial protein synthesis defect (Yagi et al., 
2012), an attractive hypothesis is that AURKAIP1 acts to sequester p32 from its 
function. This may imply that p32 is involved in mitoribosome maintenance. That being 
said, p32 depletion and AURKAIP1-FLAG overexpression do not have identical 
phenotypes. This may be explained by p32 being a multifunctional protein. One 
explanation might be that AURKAIP1-FLAG overexpression blocks only one specific 
interaction of p32, leading to the impairment of protein synthesis, but other functions of 
p32 remain unaffected. In contrast p32 depletion would deprive the cells of all p32-
mediated functions. 
There are several other hypotheses, which may explain the data generated thus far, but 
further work is required to assess their likelihood. Of particular interest is assessing the 
nature of the interaction between AURKAIP1 and p32. Studies are currently on-going 
in my host laboratory, primarily focusing on determining: 
• Whether AURKAIP1 can effect the relative amounts of p32 present as a trimer 
or hexamer and investigating the functional role of each  
• Whether p32 and AURKAIP1 can form a complex that has protease activity 
• The crystal structure of AURKAIP1 both alone and in complex with p32. 
 
  167 
The original aim of these investigations was to study the role of AURKAIP1 in 
mitochondrial gene expression. Unfortunately, the data described in this thesis is 
insufficient to conclusively elucidate this. If the effects of AURKAIP1-FLAG 
overexpression are found not to be mediated by p32, then perhaps studying AURKAIP1 
depletion further may be appropriate. The most striking observation upon AURKAIP1 
depletion is that synthesis of only a subset of mtDNA-encoded proteins is impaired. 
Perhaps AURKAIP1 acts to recruit specific mRNAs to the mitoribosome. Alternatively, 
certain transcripts may have a propensity to stall the mitoribosome during the 
elongation phase of translation and as such will not be recognised by mtRF1a and 
subsequently resolved. AURKAIP1 may act to rescue these stalled mitoribosomes, 
liberating the transcript allowing it to participate in another round of translation. If this 
were the case, then in AURKAIP1 depleted cells the mitoribosomes may remain stalled 
on this subset of specific transcripts, resulting in reduced synthesis of the encoded 
proteins. This hypothesis may also be able to account for the phenotype resulting from 
overexpression, as high levels of AURKAIP1 may result in a loss of 
specificity/selectivity and thus disassemble non-stalled mitoribosomes. These ideas are 
speculative and targeted experiments would be required to test the hypothesis. One 
approach that could be used to determine if there is a change in the stall profile is 
ribosome profiling. By performing this technique on mitoribosomes from AURKAIP1 
depleted cells, any change in amount or position on transcripts of stall events could be 
detected and provide data that would challenge or substantiate the hypothesis. 
Although the molecular mechanism by which AURKAIP1 contributes to mitochondrial 
gene expression is not yet clear, my studies have made a contribution to the increasing 
amounts of data concerning AURKAIP1. Since I have shown that both AURKAIP1 
depletion and overexpression affect mitochondrial protein synthesis, I propose that 
AURKAIP1 plays a role in the regulation mitochondrial translation, potentially 
mediated though a titrated interaction with p32, however further work is required to 
confirm this. The identification of pathogenic mutations in p32, the precise function of 
which is also unknown, leading to mitochondrial disease (M.O. unpublished, personal 
communication) serves to highlight the importance of understanding the fundamental 
aspects of mitochondrial biology. Better comprehension of mitochondrial processes, in 
turn provides enhanced understanding of mitochondrial dysfunction, which could lead 
to advances in treatment strategies for patients suffering from mitochondrial disease.  
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Figure S.1: Genotype For Patient with Compound Heterozygous Mutation in C1QBP. 
Sequencing chromatograms displaying mutations present in the patient. Both allelic variants exhibit base 
transversions resulting in an amino acid substitution in a conserved residue denoted by *. 
 
 
 
 
 
Figure S.2: Reduction of p32 Levels in Patient Derived Fibroblasts and Skeletal Muscle. (A) Cell 
lysate from control (C, lane 1) and patient (P, lane 2) fibroblasts were subjected to SDS-PAGE and 
analysed by immunoblotting. (B) Lysate from skeletal muscle from patient (P, lane 2) and controls (C1 
and C2, lanes 1 and 3) were subjected to SDS-PAGE and western blotting. α-p32 and α-β actin 
antibodies were used for immunodetection. 
 
  190 
 
Figure S.3: Effects of p32 Mutation on Steady State Levels of mtDNA-Encoded Proteins in Patient 
Derived Fibroblasts and Skeletal Muscle Tissue. (A) Cell lysate from control (C, lane 1) and patient (P, 
lane 2) fibroblasts were subjected to SDS-PAGE and analysed by immunoblotting. (B) Lysate from 
skeletal muscle from patient (P, lane 2) and two controls (C1 and C2, lanes 1 and 3) were subjected to 
SDS-PAGE and western blotting. α-COXI, α-porin, α-COXII, α-Tom20 and α-β-actin antibodies were 
used for immunodetection. 
 
 
 
Figure S.4: Effects of p32 Mutation on Mitochondrial Fusion Proteins. (A) Cell lysate from control 
(C, lane 1) and patient (P, lane 2) fibroblasts were subjected to SDS-PAGE and analysed by 
immunoblotting. (B and C) Lysate from control (C, lane 1) and patient (P, lane 2) skeletal muscle were 
subjected to SDS-PAGE and western blotting. α-p32, α-porin, α-Mfn2, α-Core2, α-OPA1 and α-ATPB 
antibodies were used for immunodetection. 
